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SUMMARY 
 
 
Chronic pain may be defined as pain which persists in a patient for a prolonged period of time. 
Although this period of time may range from 3-12 months, it is most commonly described as pain 
which extends beyond the time required for healing. Chronic pain may also be classified into two 
different categories depending on the cause. The first category is nociceptive, which is chronic pain 
caused by activation of nociceptors. This may be due to several factors such as trauma or 
temperature. The second category is neuropathic chronic pain. These are chronic pains which are not 
necessarily caused by trauma, but more likely due to the malfunction of the nervous system. For this 
study, our aim is to develop a patient-controlled, externally actuated hydrogel system which is capable 
of ‘ON-OFF’ drug release. The model drug which was incorporated into the SAPD was a Non-
Steroidal Anti-Inflammatory Drugs (NSAID), and thus our drug release system would be beneficial 
primarily for nociceptive chronic pain. This subcutaneously implanted SAPD is produced with an 
electroactive polymer which allows drug release in the presence of electrical stimulation. This would 
result in direct availability of drug at the site of actuation with reduced side-effects and increased drug 
bio-availability. 
The SAPD was formed by crosslinking polyvinyl alcohol (PVA) with diethyl acetamidomalate (DAA). 
The result was a hydrogel which was capable of swelling while remaining insoluble when placed in 
various solvents. After the hydrogel was synthesized, indomethacin was incorporated as the model 
drug. Indomethacin exhibited superior Drug Entrapment Efficiency (DEE) (±70-90%) and responsive 
release in the presence of an electrical stimulus. Finally, polyaniline (PANi) was used as the 
electroactive polymer in order to enhance the conductivity and allow sufficient release of the drug.  
Optimization of the SAPD was undertaken with a 3-factor Box-Behnken Design which measured the 
rate of erosion, drug release and DEE. The optimized SAPD was synthesized using PVA (0.8g) 
crosslinked with DAA (0.0689g) and a concentration of 1.3418%w/w PANi. Indomethacin was used and 
the DEE achieved was 76.32±10.46% (target 80.5381%). The drug release profile was 
1.622%±0.1857% (target 1.7%) per release cycle and erosion rate was 5.73±1.26% (target 6.3201%) 
when actuated with a potential difference of 1V for a duration of 1 minute. 
Chemometric modelling performed on the SAPD showed that drug release may be attributed to 
erosion of the SAPD in the presence of an electrical stimulus. The polymeric strands usually rest as a 
coiled state within the SAPD. This coiled state may be the reason the hydrogel remained intact in the 
absence of electrical stimulation. However, external electrical fields may adduct to form a coil rather 
than an extended chain resulting in the formation of a globular aniline-vinyl complex. This formation 
thus leads to a weakened form of the hydrogel structure, resulting in breakdown and ultimately 
erosion. This erosive phenomenon ceased once the electrical stimulation was removed. The end 
result of this hydrogel erosion is the liberation of the entrapped indomethacin. 
In vivo animal studies on the SAPD indicated an ‘ON-OFF’ drug release profile. The drug release was 
consistent and drug quantity of ±0.15mg per release cycle in the Sprague-Dawley rat model. The 
SAPD was implanted subcutaneously under the left flank and an electrical stimulation was triggered 
with the use of a 2-in-1 galvano/potentiostat in order to ensure the electrical stimulus was constant. 
The potential difference used was 1V over a period of 1 minute. The rats were assessed for signs of 
illness or swelling after the implantation procedure to determine the biocompatibility of the SAPD. The 
rats were monitored for 10 days and weighed daily. Results have shown that the rats did not 
experience any considerable swelling and the weights of each rat were steady, thus indicating 
biocompatibility of the SAPD. Histopatholgical samples indicated mild inflammation around the site of 
implantation 10 days after implantation. This may have been due to minor surgery at site of 
implantation. The biocompatibility of the SAPD was generally good and there were no signs of tumour 
or long term tissue inflammation. Future application of the SAPD may include an external actuation 
device to be worn as a watch which allows actuation of the SAPD when required by the patient. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1. Introduction 
 
The management of chronic pain has always proved to be challenging for both clinicians and 
patients. Pain is caused due to the activation of nociceptors, which conveys signals to the 
brain and is interpreted as pain (Semenchuk, 2000). This activation may be caused by injury 
and in most cases, complete pain relief is rare and difficult. The World Health Organisation 
(WHO) has set up a three-step ladder algorithm as a guide for the treatment of the chronic 
pain (Barakzoy, 2006). This ladder aimed to treat pain by using a combination of non-opioid 
analgesics and opioid analgesics which proved to be effective for 80-90% of cases. 
However, treatment with such analgesics and opioids often resulted in significant side-
effects. Patients may feel severe chronic nausea, vomiting, itching, constipation or 
drowsiness (Raghavan, 2011 and Palos, 2004). In severe cases, patient dependence and 
addiction may occur, leading to treatment complications. 
 
Conventional treatment of chronic pain included patient-controlled pump administration of 
oral tablets and drugs which relied on patient compliance and often induces gastric side-
effects. Long-term use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause 
gastric ulceration, increased risk of cardiovascular disease, fluid retention and interactions 
with anti-coagulants (Prasad, 2008). Oral drugs tend to have limited dissolution or be 
strongly ionized which decreases absorption through the intestine (Pleuvry, 2006). 
Traditional oral or parenteral drugs may have inadequate therapeutic effects and further 
metabolism and inactivation of the drug which may result in even lower systemic levels of 
the drug (Pleuvry, 2006). 
 
To date, research on Electro-Active Polymers (EAPs) have shown that EAPs can be 
employed for various applications (Palmre, 2011; Sheika, 2004; Pernaut, 2000 and Bar-
Cohen, 1999). Researchers have envisaged that EAPs may one day be used as artificial 
muscle and implanted into patients who have suffered from muscular injuries. Robotic 
scientists have managed to create robotic arms with grippers by using EAPs. The use of 
EAP for drug delivery is also currently a novel area of research (Prakash, 2008). In 2000, a 
company called Creganna (Pty) Ltd. (Marlborough, Massachusetts, USA) designed an EAP-
based substance delivery system called Micro-muscle® using EAPs which allowed a 
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substance to be released when the system was exposed to an external electric current. 
EAPs may be the center of current drug delivery system, however, other possible stimuli can 
also be considered for the purpose of drug delivery. These include polymers such as such 
as polylactic acid (PLA), polyglycolides (PGA) and polylactide-co-glycolides (PLGA) which 
are biodegradable and biocompatible polymers that can be implanted without the need to be 
removed once the drug-load is depleted from the device. 
 
The use of a patient-controlled targeted drug delivery device may thus prove to be efficient in 
the treatment of chronic pain. Targeted delivery would remit drug directly at the site of pain, 
eliminate the problem of first pass metabolism and systemic circulation which occurred with 
a conventional oral tablet. This may be achieved by implantation of the device directly at the 
site of pain. In order to allow the patients’ control over the device, the device should be 
capable of an “On-Off” mechanism via an external stimulus. The external stimulus should 
result in drug release from the device directly to the target site. Once therapeutic dose was 
achieved, the external stimulus may be removed and drug release would cease.  
 
Research in the sector of EAP is considered as one of the most popular topics. To date, 
researches on EAPs have shown that EAPs can be employed for a wide variety of 
applications (Pernaut, 2000; Bar-Cohen, 1999; Chiba 1999). One of these applications 
included the use of EAPs as an artificial muscle and implants in patients who have suffered 
from muscular injuries (Sheika, 2004). Robotic scientists have managed to create robotic 
arms with grippers by the use of an EAP. EAPs used for drug delivery is, however, currently 
a less explored area of research (Prakash, 2008). 
 
EAPs have gained increased attention from scientists across various fields, starting as early 
as the 1970’s. The EAP’s unique ability to undergo redox reactions upon the activation of an 
electric current has distinguished itself from other polymers. Recently, researchers have 
been looking at these polymers for the possible use of substance delivery in humans. A few 
novel EAPs have fulfilled these criteria, however, there are still possibilities of synthesizing 
new EAPs in the future.  
 
A polymer is chemical specie with a very high molecular weight and comprised of repeating 
units of low molecular weight. The units that made up the polymer are called monomers. 
Polymers were initially discovered in 1909 in the form of resin used in adhesives and paints. 
Since then, chemists have continued to formulate new polymers. Polymers may be classified 
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as addition polymers or condensation polymers depending on the reaction that was used to 
form it (Ebbing, 1996). 
Recently, a new method of polymerization has been extensively used for the synthesis of an 
EAP. This method is known as electropolymerization. Electropolymerization is one of the 
most powerful tools that can be used for the development of modified electrodes. The end 
result of an electropolymerized material is usually one that possesses unique properties than 
that of its monomer (Karyakin, 1998). EAPs are capable of exhibiting diverse electrical 
properties. The imposition of an electric charge upon a polymer will cause a redistribution of 
any charge of that polymer, provided that it is mobile enough to respond to the charge. In 
summary, the response of a polymer to an electric field can be summarized into two 
parameters, and each parameter can be divided further into two subparameters: 
Dielectric properties: 
• Dielectric constants which represents polarization  
• Tangent of dielectric loss angle which represents the relaxation phenomena.  
Bulk conductive properties: 
• Dielectric strength, which represents the breakdown phenomena  
• Conductivity which represents electrical conduction 
In addition to these two fundamental sub-parameters, there were other electrical properties 
which were sought after. New materials have been developed and other special electrical 
properties include piezoelectric, pyroelectric, ferroelectric, triboelectric, photovoltaic and 
photoconducting materials (Ku, 1987). 
 
It is generally accepted that during the oxidation or reduction of an EAP, electrochemical 
charge is transported through the polymer by an electron hopping mechanism. The rate of 
reduction or oxidation within a polymer film can be expressed in terms of a diffusion 
coefficient (DE). This coefficient described the efficiency of charge percolation through the 
polymer which can be determined by the use of cyclic voltammetry, chronoamperometry or 
chronocoulometry (Lyons, 1990). These properties are important as the response time in 
which the EAPs react toward the stimuli is directly related to these properties. 
 
A few drugs that were considered for incorporation into a proposed EAP included those in 
the groups of opioids and NSAIDs or selective COX II inhibitors. Table 1.1 provided a list of 
possible water-soluble opioids which may be used in this drug delivery device. 
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Table 1.1. Other possible model drugs that could be incorporated into the SAPD. 
Opioids which may 
be incorporated 
Therapeutic 
advantage 
Water solubility Properties 
Morphine (Bijur, 
2005; Masako, 2003; 
Podczeck, 1996;  
Hasselström, 1990) 
By delivering drug 
directly to the blood 
stream, a decreased 
dosage is required 
and thus less chance 
of side-effects 
Morphine is soluble in 
water and is 
administered as an 
injection. Therefore, 
morphine may be 
incorporated as a 
water soluble base in 
an EAP matrix 
system 
pKa 7.8. Side-effects 
include respiratory 
depression, itching, 
mouth dryness and 
nausea. Mean 
terminal elimination 
half life is 4.2 hours. 
Standard dose is 
0.1mg/kg 
intravenous injection. 
 
Hydromorphone HCl 
(Golembiewski, 
2005; Hong, 2008 
and Gupta, 2007) 
By delivering drug 
directly to the blood 
stream, a decreased 
dosage is required 
and thus less chance 
of side-effects 
By incorporating 
hydromorphone HCl, 
the water solubility is 
increased to 1:3 
hydromorphone:water 
solubility. This will 
also allow it to be 
incorporated as a 
water soluble water 
pKa 8.1. Side-effects 
include miosis, 
constipation, 
respiratory 
depression and 
nausea. Mean 
termination half life is 
2.6 hours. Dosage 
0.2-0.4mg initially, 
then 0.1-0.2mg 
every 5-10min 
 
Methadone HCl 
(Han, 2008; 
Sadovsky, 2000 and 
LoVecchio, 2007) 
 
 
 
 
 
 
 
 
 
Indomethacin (de 
Jong, 2008) 
 
 
 
 
 
 
 
 
 
 
 
 
By delivering drug 
directly to the blood 
stream, a decreased 
dosage is required 
and thus less chance 
of side-effects 
 
 
 
 
 
 
 
NSAIDs may be 
released directly at 
the target site to 
achieve anti-
inflammatory effect 
 
 
 
 
 
 
 
 
 
Methadone, when 
incorporated with a 
HCl salt, is freely 
soluble in water and 
can thus be 
incorporated as a 
water soluble base 
 
 
 
 
 
 
Indomethacin is 
poorly soluble in 
water and solubility 
increases under basic 
pH 
 
 
 
 
 
 
 
 
 
pKa 8.7 in water at 
20ºC. Side-effects 
include respiratory 
depression, 
constipation, miosis, 
nausea and 
hypotension. 
Terminal half life 
ranges from 8-59 
hours. Initial dosing 
is 2.5mg to 10mg i.v. 
every 8-12 hourly. 
 
pKa 4.5. Side effects 
include constipation, 
diarrhoea, dizziness, 
drowsiness, 
headache, 
heartburn, nausea 
and stomach upset. 
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Diclofenac sodium 
(Kearney, 2006; 
Brater 2002) 
NSAIDs may be 
released directly at 
the target site to 
achieve anti-
inflammatory effect 
Diclofenac alone is 
poorly soluble in 
water, but 
incorporation of a 
sodium salt increases 
the water solubility 
pKa 4.0. Side effects 
include increased 
risk of thrombotic 
event, myocardial 
infarction, gastric 
ulceration and renal 
toxicity. 
 
 
Therefore, when formulating a stimulus-responsive drug delivery device using an EAP, it 
was important to bear in mind these unique characteristics in order to obtain optimal and 
efficient release of drug from the device.  
 
The aim of this study was to develop an SAPD that is capable of controlled drug release 
upon the application of an external electrical stimulus. This would require the patient to carry 
an external device that would allow them to actuate the SAPD at the patient’s own choosing. 
This system may eliminate the challenges that were encountered in patients who were 
taking long-term analgesics, had a risk of dependence, tolerance and were susceptible to 
significant side-effects due to unnecessarily increased doses over prolonged periods of time. 
The use of this patient-controlled system would also enable prospective drugs to be used in 
the future by using the concept developed in this study. Furthermore, the development of 
this SAPD would improve the application of the EAP in a biocompatible setting. 
In order to achieve this goal, the following objectives were outlined: 
1.   Develop a SAPD that allowed drug release at the desired time and quantity.  
2. Characterization of the EAP’s physicochemical and physicomechanical properties. 
3. To develop a novel drug delivery system by using the EAP as a platform for the SAPD. 
4. To develop a device that would be compatible with the intended drug to be used and 
subcutaneous site of implantation. 
5. To perform in vitro studies to determine the amount of drugs released when exposed to a 
stimulus such as electric current.  
6. To investigate of other factors which may affect the release of drug and the operating of 
the system as a whole, such as temperature, pH etc. 
7. To perform in vivo animal studies in order to assess the established pharmacokinetic 
parameters of the device in a suitable model such as the Sprague Dawley rat  
8. To compile a preliminary histomorphological report using the in vivo data obtained from 
animal studies 
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1.2. Approach to this study 
 
The aim was to develop a subcutaneous implantable system which could be implanted at the 
site of the chronic pain. This implantable system would release drug, in response to an 
external stimulus such as electric current, directly to the target site. The external stimulus of 
the electric current would have to be generated via an external device. This could reduce the 
gastric side effects that were caused by chronic use of NSAIDs and reduce the dosage 
required due to its high protein binding. 
 
This approach relied on the use of a hydrogel or a polyelectrolyte hydrogel, into which, 
analgesic drugs would be incorporated. The drug may be physically blended into the 
hydrogel while it was in its liquid state, or it may be dissolved in a solvent. The hydrogel may 
also be placed into the solvent where the drug would be absorbed. The amount of drug 
absorbed may be calculated by measuring the difference in drug concentration before and 
after the incorporation of the hydrogel.  
 
Another approach was to form a hydrogel with an inter-penetrating network (IPN) of EAP, 
through which electricity would be conducted. Once the electric current was flowing through 
the hydrogel via the EAP, the drug would move out of the hydrogel through mechanisms 
such as electrophoresis or repulsion of an anionic drug against the electric current. This 
phenomenon would stop once the electric current was ceased, thus resulting in termination 
of drug delivery to the target site.  
 
Once the drug was depleted in the hydrogel, the implant would have to be removed, in the 
case of a non-biodegradable implant, and replaced with a new implant. The implant was 
aimed to last for a period of two months while delivering standard analgesic dose of the drug 
which it contained. Therefore, the use of a more potent anionic drug was preferred for the 
design of this system.  
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1.3. Overview of this dissertation 
 
Chapter 1 investigated the background and possible challenges to the current development 
of the SAPD. Electro-behaviour of the EAPs was examined and possible drugs which may 
be incorporated were discussed. The understanding of these factors was important as these 
factors would greatly affect the design of the SAPD. 
Chapter 2 provided a comprehensive literature review on current research into the stimuli-
actuated polymers and hydrogel systems. This provided us with various approaches taken 
by other researches and possible challenges which still remained in the field of stimuli-
actuated drug release systems. 
Chapter 3 was the pre-design and formulation of the SAPD. This chapter highlighted the 
various designs which were used and the efficacy of such design. In the light of a design not 
producing satisfactory results, the reason of this result was investigated and further designs 
were made to improve the results. Light microscopy was used to assess the surface 
morphology coupled with Fourier Transform Infra-Red in order to assess the chemical 
compositions of the SAPD. 
Chapter 4 described the development of a non-soluble hydrogel based on the results 
obtained in Chapter 3. The formulation of this hydrogel was followed by incorporation of an 
EAP and a drug which would then be further assessed. The actuation was achieved by the 
use of a PGSTAT instrument and drug release was ascertained with the use of an UV/visible 
spectroscopy. 
Chapter 5 focused on the optimization and characterization of the developed SAPD. The 
design of the SAPD in Chapter 4 was initially optimized with a Box-Behnken Design. Once 
the SAPD was optimized, external factors such as actuation voltage and storage 
temperature were optimized. The release mechanism was investigated with the use of 
chemometric modelling to determine the mechanism of the erosion at a molecular level. 
Chapter 6 investigated the in vivo drug release profile of the SAPD as well as its 
biocompatibility. SAPD was implanted for a period of 30 days and actuated periodically. 
Blood samples were taken and analyzed with both HPLC and UPLC to ascertain the 
presence of drug in the blood sample. Histological samples were taken at the end of the 30 
day period to determine the biocompatibility of the SAPD. 
Chapter 7 provided the conclusion, recommendations and future developments for further 
studies. 
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CHAPTER 2 
DESIGN, ADVANCES AND APPLICATIONS OF ELECTROACTIVE POLYMERIC 
SYSTEMS AS A RESPONSIVE DRUG DELIVERY STRATEGY 
 
 
2.1. Introduction 
 
A hydrogel is comprised of a 3-dimensional hydrophilic network structure which is capable of 
absorbing water and remains insoluble in water due to its crosslinked, entanglement or 
crystalline structure (Peppas, 2006). By incorporating an EAP into the hydrogel, the EAP not 
only renders the hydrogel responsive, but offered other advantages as well. In order to 
overcome this drawback, there were three ways in which the EAPs may be prepared in order 
to enhance its physical property and its uses. The first technique was physical blending of 
the EAP with an insulating material. The second technique involved electro-chemical or 
chemical oxidative polymerization of the EAP into another matrix system, and the third 
technique involved creation of a composite via co-deposition of the EAP and the insulating 
polymer (Brahim, 2004). The blending of an EAP into a hydrogel was an example of the 
second technique. This blending may also render the hydrogel responsive towards electrical 
stimulation. The responsive behaviour that would be exhibited from the hydrogel may be due 
to conformational changes. The resultant change may be actuation, catalytic, signalling 
event, movements or interactions with other species (Ehrick, 2005). A responsive hydrogel 
may respond to stimuli such as pH, temperature, electric fields, saccharides or even 
antigens (Miyata, 1999). Table 2.1 demonstrated the various stimuli which have been 
discovered for the actuation of a responsive-hydrogel. 
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Table 2.1. Various mechanisms which cause the actuation of responsive hydrogel (Kim, 
1996). 
Stimulus 
 
Hydrogel 
 
Mechanism 
 
Thermal 
 
Thermal responsive hydrogel 
such as poly-N-isopropyl-
acrylamide. 
 
Change in temperature 
would cause polymer-
polymer and water-polymer 
interaction. This may lead to 
swelling and drug release. 
 
Magnetic 
 
Magnetic particle dispersed 
in alginate microsphere. 
 
When magnetic field was 
present, a change in porosity 
may lead to drug release. 
 
Ultra-sound irradiation 
 
Ethylene-vinyl alcohol 
hydrogel. 
 
Upon ultra-sound irradiation, 
the temperature of the 
hydrogel may increase, 
which could result in drug 
release. 
 
pH 
 
Acidic or basic hydrogel. 
 
Change in pH may lead to 
swelling and therefore drug 
release.  
 
Ionic Strength 
 
Ionic hydrogel. 
 
Change in ionic strength 
which caused changes in 
concentration of ions inside 
the gel. This may lead to 
change in swelling and thus 
drug release. 
 
Chemical species 
 
Hydrogel containing electron-
accepting groups. 
 
Electron-donating 
compounds may interact with 
the hydrogel to form 
charge/transfer complex. 
This caused swelling of the 
hyrdogel and possible 
release of drug. 
 
Enzyme substrate 
 
Hydrogel containing 
immobilized enzyme. 
 
When substrate was present, 
the hydrogel undergoes 
enzymatic changes, which 
lead to drug release 
 
 
In order to enhance the response from a responsive hydrogel, one may incorporate acidic or 
basic groups into the hydrogel. These hydrogels are termed polyelectrolyte or ionized 
hydrogel. Such hydrogel consisted of three species, namely the solid matrix network, 
interstitial fluids and ionic species. The depiction of the polyelectrolyte hydrogel is provided 
in Figure 2.1. 
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Figure 2.1. The structure of a polyelectrolyte hydrogel (Li, 2007) 
 
Polyelectrolyte hydrogel such as polyacrylic acid, along with sodium or potassium as its salt, 
is a popular research material (Chansai, 2008; Adnadjevic, 2007; Huang, 2007; Wang, 2006; 
Li 2005 and Philippova, 1996). Other hydrogel which have been synthesized previously 
included hyaluronic acid hydrogel sodium salt entrapped hydrogel. It was discovered that 
when the hydrogel was placed between two electrodes, there was shrinkage in volume at 
the anode and therefore drug release (Sutani, 2001). Factors which affected drug release 
from the hydrogel included degree of swelling, crosslinking density and the composition of 
the monomers used for the synthesis of the polyelectrolyte hydrogel.  
 
This drug release may be due to the ionizable groups of the polyelectrolyte hydrogel, which 
was responsible for the physical and chemical changes in the hydrogel (Gao, 2003). This 
phenomenon could be attributed to the charges on the polymer backbone which formed the 
hydrogel. These charges allowed interactions with the external electric fields or surrounding 
ionic surfactants. Interactions between polyelectrolyte hydrogel and surrounding ions were 
particularly interesting in the field of engineering, where it could be used to selectively 
remove surfactants from water (Zieliήska, 1999). 
 
The 2 mechanisms which were responsible for the release or drugs upon electrical 
stimulation included (Kulkarni, 2009):  
• Migration of the drug towards the electrode of opposite charge. 
• Hydrogel contraction causing the drug to emit from the hydrogel. 
The mechanisms listed above were not exhaustive and other mechanisms may be present. 
Figure 2.2 depicted these two mechanisms of which the drug migrated outward from the 
hydrogel. 
11 
 
 
Figure 2.2. a) The migration of positively charged drug particles towards the negatively 
charged anode. b) The forced exudation of the drugs out of the hydrogel system due to 
contraction of the hydrogel. 
 
The migration of the drug particle outside the hydrogel may be determined by the porosity 
and the network structure of the hydrogel, in addition to any fixed charge in the hydrogel, as 
in the case of polyelectrolyte hydrogel. The forced exudation of the drug out of the hydrogel 
was caused by the contraction of the hydrogel. This contraction caused a build-up of positive 
pressure within the hydrogel, which resulted in the exudation of the hydrogel matrix in order 
to decrease this pressure build-up. Drugs dissolved within the hydrogel matrix may therefore 
be released via this mechanism. By controlling the rate of this contraction, one may be able 
to control the amount of drugs that was exuded from the hydrogel. Hydrogel may also be 
responsive towards electric current, and exhibited contraction when exposed in an electric 
field. Human muscle is an example of an ionic EAP, and it is therefore not surprising that 
ionic EAPs have been an extensively researched material for the purpose of artificial muscle. 
It is important to note that although the EAP and muscle were both responsive towards 
electric current, human muscle utilizes a sodium potassium pump and calcium pump for the 
movement of ions in and out of the cell and is generally much more intricate and complex 
than the ion movements found in a responsive hydrogel. However, the use of an EAP as 
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artificial muscle is still promising and basic movements from an ionic EAP have been 
achieved. 
 
2.2. The method of preparation of a responsive electroactive polymer-based 
hydrogel 
 
The importance of hydrogels in a wide variety of fields meant that it is a very versatile 
material (Hoffman, 2002). The result was that many varieties of hydrogels have been 
synthesized using different methods. These varieties of hydrogels are still capable of 
retaining water within its structure and swell without dissolving, however, the degree of 
swelling differs according to the degree of crosslinking. Certain hydrogels are capable of 
absorbing water many hundred times more than its dry weight and are called 
superabsorbent hydrogels (Francis, 2004). These hydrogels seems like a practical approach 
for the purpose of environmental cleaning. An increase in crosslinking within a hydrogel 
would increase the structural integrity, resulting in a decrease in the swelling of the hydrogel. 
This in turn would decrease the amount of water that the hydrogel can hold (Rokhade, 2007). 
A hydrogel may be synthesized as a blend, a co-polymer, a graft, an inter-penetrating 
network (IPN) or a composite and each was structured differently. A blend hydrogel was 
synthesized by the interaction between two or more reagents. One example would be a 
hydrogel formed via the esterification of PVA and gelatine (Pawde, 2008). The esterification 
occurs between the hydroxyl group of the PVA and the carboxyl group of the gelatine, 
forming a hydrogel. Sometimes, the hydrogel may be the result of two monomers reacting 
together to form a polymer, or by incorporation of one polymer into another. These hydrogels 
are termed co-polymer hydrogels. A study done by Henderson and co-workers (2010) has 
managed to form a hydrogel which consisted of a crosslinked tri-block copolymer network 
(Henderson et al., 2010). A graft hydrogel would be similar to a copolymer hydrogel, as the 
polymer which was used to form the hydrogel was a graft co-polymer (Sui, 2010). A graft co-
polymer is a type of branched co-polymer with the side chain that was different and separate 
from the main chain. In the case of the graft co-polymer, the co-polymer formed usually 
combined the properties of both polymers which formed the co-polymer (Kulkarni, 2009). 
The difference between the block co-polymer and graft co-polymer may be depicted by 
Figure 2.3 where A and D represents two different monomers.  
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Block copolymer
Graft copolymer  
Figure 2.3. The chemical structure of a block co-polymer and a graft co-polymer. 
 
The next hydrogel structure which may be formed was the IPN hydrogel, which was 
essentially a network within the hydrogel network itself. It may be classified as a class of 
polymer as it blends in a network fashion, in which at least one component was polymerized 
in the presence of the other (Prashantha, 2001). EAPs were commonly incorporated into the 
hydrogel in the form of IPN. This may increase the conductivity of the electrical stimulation 
into the hydrogel and improve the electro-response of the hydrogel. The IPN hydrogel may 
be formed by initially creating a solution containing both the raw materials for the hydrogel 
and the EAP. The initiator and crosslinker would be added into the solution simultaneously. 
The crosslinking and polymerization can continue for several hours until the hydrogel was 
formed (Lϋ, 2010). IPN hydrogels were commonly synthesized with incorporation of an EAP. 
The last class of hydrogel was the composite hydrogel. A composite hydrogel was formed 
when a particle has been embedded within the hydrogel network. These particles did not 
have any direct interactions with the hydrogel. Composite hydrogels can be synthesized as a 
responsive hydrogel, where the drug was entrapped within the hydrogel. The responsive 
hydrogel swelled or de-swelled when exposed to various stimuli and resulted in drug release 
(You, 2010). With all these possible structures, one may be able to synthesize a responsive 
hydrogel which may suit individual needs in accordance with swellability, structural integrity, 
response and biocompatibility. In certain cases, a combination of hydrogel types may be 
formed, such as the incorporation of an IPN in a grafted co-polymer hydrogel. The 
importance of responsive hydrogels in controlled substance delivery is crucial.  
 
2.3 The application of electroactive polymers in the Stimuli-Actuated Polymeric 
Device as a responsive drug release strategy 
 
Polymers were initially discovered in 1909 in the form of resin for adhesives and paints. 
Since then, chemists have continued to formulate new polymers, which lead to the discovery 
of the EAPs. Polymers may be classified as either addition polymers or condensation 
polymers, depending on the reaction that was used for its synthesis (Ebbing, 1996). The 
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polymerization process was important as it may determine the electrical properties of the 
resultant EAPs. More recently, a new technique of polymerization has emerged, and this 
was the process of electropolymerization. 
 
Electropolymerization is a useful technique that can be used for the development of a 
modified EAP. The end result of electropolymerized materials is usually one that possesses 
unique properties than that of its monomers (Karyakin, 1998). One major drawback which 
limits the use of electropolymerization in industry is that a small amount of polymers are 
formed each time since the electropolymerization process occurs only on the surface of the 
electrodes (Asami, 2005; Ali, 2006; Wang, 2007 and Walter, 2010). Therefore, the mass 
production of EAP using such methods may prove to be unfeasible.  
 
Electrical properties of a polymer can be extremely diverse. The imposition of an electric 
charge upon a polymer would cause a redistribution of any charge of that polymer, provided 
that these charges were mobile enough to respond to the charge. Another subclass of the 
EAP in the field of drug delivery was that of the conducting polymer. A conducting polymer is 
a polymer that is capable of carrying electrical charges along its length (Kumar, 1999), while 
EAPs are polymers which exhibit size or shape changes when exposed to electric current 
(Dubois, 2006). The changes were usually reversible once the electric current was removed 
with no permanent change in the volume. One reason why conducting polymer is popular is 
because they possessed both the conducting property of the metal and the favourable 
mechanical properties of a non-conducting polymer. Conducting polymers are, however, a 
sub-category of EAP and a small amount of swelling does occur when electric current is 
passed along its length. 
 
It is now generally accepted that during the oxidation or reduction of an EAP, 
electrochemical charge is transported through the polymer by an electron hopping 
mechanism. The rate of reduction or oxidation within a polymer film can be expressed in 
terms of the diffusion coefficient (DE). This coefficient described the efficiency of charge 
percolation through the polymer and could be determined by the use of cyclic voltammetry or 
chronoamperometry (Lyons, 1990).  The response time of an EAP may also be affected by 
the type of EAP which it belonged to. Electronic EAP exhibited a rapid response time of 
milliseconds but required higher voltage in order for actuation to occur, whereas ionic EAP 
has a slight slower response time, but required much lower voltage for actuation to occur 
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Hydrogels, on the other hand, are crosslinked 3-dimensional system which are capable of 
swelling and is not soluble in the solvent into which they were placed (Wang, 2010). 
Hydrogels are themselves, not responsive, but EAPs may be incorporated into the hydrogel 
in order to render them responsive. Responsive hydrogels are hydrogels which are 
responsive towards external stimuli (Deng, 2009). Responsive hydrogel is also an area of 
interest for researchers due to its potential as actuators (De Rossi, 1991), separation device 
(Park, 1992) and even responsive drug delivery systems (He, 2008 and Bikram, 2007). 
These gels are capable of swelling and de-swelling when exposed to various stimuli and 
thus altering the rate of drug release. These responsive hydrogels were termed ‘intelligent’ 
hydrogels, and were responsive towards several stimuli, including electrical stimulation 
(Murdan, 2003). Similar to other responsive hydrogel, swelling or de-swelling may occur 
when the electro-responsive hydrogel was exposed to electric current, which altered the rate 
of drug release. 
 
The use of the EAP and responsive hydrogel may be suitable for situations where drug 
release is preferred in the presence of certain external stimulus to allow the patients control 
over the drug release from the system. One challenge regarding the use of these ‘intelligent’ 
materials was that physical properties such as drug size, charge and solubility have to be 
taken into account during formulation.  Therefore, formulation of a responsive device for 
multiple drugs or combination therapy may require adaptations of the device in order to 
achieve an ideal drug release profile for each of the drugs. The use of these responsive 
materials for drug delivery may improve the compliance with a decrease in side effect profile. 
 
2.4. Electroactive polymers as a constituent of a polymeric substance delivery system 
 
Currently, two of the most promising responsive delivery platforms that have undergone 
intense research are the responsive hydrogels and EAPs (Kim, 2005 and Bawa, 2009). In 
order to develop a drug delivery system which ensured an optimal drug release profile, it 
was important to consider possible drug-hydrogel interactions and drug-EAP interactions. 
The most common EAPs that was researched included that of PANi (Bidez, 2006), ethylene 
vinyl acetate, polyethylene (Kamalesh, 2000) and PPy (Wang, 2003). Other materials that 
could be used include biocompatible EAP such as polylactic acid (PLA), polyglycolic acid 
(PGA), polylactic-co-glycolic acid (PLGA), ethylene-vinyl acetate (EVA) co-polymer and 
polyaniline (PANi). EVA is a soft and flexible material that can be moulded.  Although 
ethylene-vinyl acetate co-polymer was not biodegradable, it was also inert in the human 
body and therefore did not cause any reactions or unwanted effects in the body. PANi is a 
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conducting polymer with high electrical conductivity. It was readily available, stable and 
requires simple doping chemistry.  It was also characterized by controllable electrical 
conductivity and has rich redox chemistry. Furthermore, it was a biocompatible substrate 
and its biocompatibility can be further enhanced by adding side chains such as collagen or 
gelatin (Huang et al., 2006).  
 
Another possible material that could be used is polypyrrole (PPy). It exhibited high electrical 
conductivity, stability and rich redox reversibility. However, two drawbacks were the fragility 
and insolubility (Li, 2007). Polyamide groups that could be considered included those with 
oligoaniline and ferrocene in the main chain or polymerization of macro-monomer of 
oligoaniline and p-phenylenediamine. This has shown characteristics of reversible 
electrochemical property with a conductivity of 7.6 x10-7Scm-1 at room temperature (Chao, 
2006). PANi and its derivatives were especially popular because it could be processed into 
different redox states in addition to a controllable conductivity and stability. Its uses have 
been extended to the field of dentistry such as thoracic, maxillo-facial surgery and dental 
implants (Kamalesh, 2000). Uses of PANi in other fields include antistatic applications 
(Lekpittaya, 2004), gas sensor (Kincal, 1998) and dye removal (Lopes, 2004). 
 
Another popular use of EAPs outside the field of drug delivery was the synthesis of artificial 
muscle. The polymers could change its size and shape upon actuation with electrical 
stimulation. Currently, there are other responsive polymers which respond to stimuli such as 
chemical, pneumatic, optical and magnetic and have already been synthesized. When 
compared to these responsive polymers, EAPs could be tailor-made into different 
behaviours when doped with various counter ions. Practitioners in the field of biomimetic 
science have been able to mimic basic insect and animal movements by the use of EAPs. 
Previously, EAPs have received little attention due to its poor actuation abilities and short 
selection of material. This has changed in the past fifteen years as new materials were 
discovered and synthesized (Bar-Cohen, 2007). Furthermore, the uses of EAPs in the field 
of drug delivery have been gaining significant attention due to its promising prospective for in 
vivo use. With an increased application for these polymers in human tissue, great concerns 
have begun to arise as to the biocompatibility of these EAPs. A study was done on ethylene-
vinyl acetate co-polymer (EVAc), polyethylene and PANi in its emeraldine, pernigraniline and 
leucoemeraldine state by implantation of these EAPs into male Sprague-Dawley rats for a 
period of 19-90 weeks in order to assess for any histological changes in rat tissue. This was 
due to concerns that prolonged implantation of these EAPs in human tissue may cause 
increased risk of tumor (Kinoshita, 1995). However, results obtained from the study has 
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showed that the Sprague-Dawley rat cells did not show any carcinogenic behaviour even 
after two years of implantation and that these polymers were indeed biocompatible enough 
to be implanted subcutaneously (Sengothi, 1999).  
 
There are other EAPs groups which also exhibited biocompatibility in humans other than 
PANi. One such polymer is that of the PPy group. Like PANi, not only was it compatible with 
human tissue, but it also exhibited controllable physicomechanical properties. The synthesis 
of PPy can either be chemical or electrochemical. Figure 2.4 depicted the chemical 
polymerization of PPy from the monomer pyrrole. 
Oxidization
Reduction  
Figure 2.4. The chemical synthesis of polypyrrole.  
 
The polymerization process of most EAPs indeed followed the same concept as the 
mechanism depicted in Figure 2.4. The polymerization began via the oxidation of the 
monomer pyrrole. C- Is the counter-ion used in the synthesis of the PPy membrane and was 
incorporated into the polymer due to its negative charge which compensated for the positive 
charge on the polymer backbone (Zhao, 1996). Figure 2.4 has demonstrated that it was 
possible to incorporate various counter-ions during the polymerization process, thus altering 
the physicomechanical properties of the finished product. Although there were a wide variety 
of counter-ions to choose from, the selection was dramatically reduced when taken into 
account the conductivity and the mechanical property of the final product. Sometimes, a 
mixture of counter-ions may be used in order to achieve optimum conductivity and physical 
property (Zhao, 1998).  
 
The counter-ions, especially the anions, incorporated into the polymer were responsible for 
the transport mechanism. If enough negative potential was applied, it would force the anion 
out of the polymer and the reaction undergoes reduction. If a repetitive pulsed potential 
waveform was applied to the membrane, transportation through the membrane via this 
mechanism was maintained. The counter-ions may be incorporated into the polymer 
membrane via the process of electropolymerization. Some suitable counter-ions that may be 
used include that of sulphonated aromatic groups. However, some counter-ions may 
inevitably become trapped during the polymerization of the polymer which rendered it 
immobile in terms of ion transportation (Zhao, 1994). 
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Once an anion was incorporated into the polymer, it could be expelled and re-incorporated 
into the polymer again by using an appropriate repetitive pulsed potential waveform. When 
the polymer doped with the anion was left in a solution with cationic electrolytes, the cations 
may directly displace the anions incorporated into the polymer. If the surrounding solution 
contained anionic electrolytes, then the anions that were originally incorporated in the 
polymer may diffuse outwards and eventually be replaced by the anions in the surrounding 
solution (Mirmohseni, 1995). In the case where the solution contained both anions and 
cations, there was generally a combination of both cationic and anionic movements (John, 
1993). 
 
In order for this electroactive transport system to be effective, the membrane system must 
be capable of the following (Zhao, 1996): 
• The transport mechanism should have a rapid ‘on-off’ switching mechanism when 
necessary. 
• Controllable flux and sustainable level of transport. 
• Controlled selectivity with regards to the ionic species undergoing transportation. 
 
2.4.1. Polyaniline as a component of the electroactive polymer-based drug delivery 
system 
PANi-derived EAPs have attracted much attention from researchers across various fields 
due to its high stability in air, moisture, high electrical conductivity and unique redox 
properties (Moon, 1993), although several challenges still remained when it came to 
synthesizing PANi for commercial use. The synthesis of PANi required harsh conditions and 
PANi synthesized usually exhibited poor processability (Samuelson, 1998). Another 
challenge regarding the use of PANi was the limited solubility in solvents. To date, 
researchers have combined aniline with other water-soluble monomers during the 
polymerization to obtain a PANi copolymer which could offer better solubility whilst 
maintaining the desirable mechanical properties and electrical conductivity of a PANi (Wang, 
2003). Several researches have already synthesized water-soluble PANi in order to improve 
the processability of the PANi (Zhang, 2006; McCarthy, 2002 and Kenji, 2000). This was 
done either by the process of electropolymerisation or simply polymerizing a water-soluble 
analogue of the monomer aniline. By using electropolymerisation as the process for 
developing EAPs such as PANi, we allowed better incorporation of dopant ions into the 
polymer than that of chemical polymerization. To further enhance the mechanical property of 
the synthesized polymer, one may also synthesize the polymer as a film by ordinary casting 
method or via the preparation of composite polymer (Kitani, 1997). Another method would be 
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synthesizing PANi as a co-polymer along with another water soluble polymer. One 
disadvantage of electropolymerisation was that the polymers could only be synthesized as a 
thin film on the electrode and production on a large scale would be unfeasible (Palaniappan, 
2006). The fabrication of a large electrode itself was also difficult to achieve (Lindström, 
2001). Therefore, for large scale production of electroactive polymer (EAP), the preferred 
method was still the chemical polymerization. In order for polymerization to occur, the 
monomers would have to be oxidized first before the polymerization could occur. The 
traditional oxidant used in the past has been ammonium persulfate (Huang, 2007; Chao, 
2006 and Aldissi, 1997). However, because the reaction with such oxidant was exothermic, 
controlling the temperature under which the polymerization occurred was difficult and due to 
the temperature fluctuation, polymers with a wide range of molecular weight may occur as a 
result (Palaniappan, 2006). In recent years, new oxidation reagents such as benzyl peroxide 
have been used which offers better temperature control for the polymerization method. 
Despite the temperature fluctuation experienced with these oxidation agents, the problem 
may be solved by a simple method such as the use of a water bath during the polymerization 
process as a mean of temperature regulation (Geng, 1998).  
 
2.4.2. Polypyrrole as a component of the electroactive polymer-based drug delivery 
system  
Another popular EAP which underwent intensive research was the PPy-derived EAPs 
(Sutar, 2007; Ansari, 2006; Kim, 2006 and Chen, 1990). PPy are similar to PANi with regard 
to chemical structures and both of these EAPs belonged to the same family. Like the PANi, 
PPy also has three oxidation states, one state being completely unoxidized and the other 
two states being oxidized to various degrees (Chen, 1989). Similar to the PANi, PPy 
exhibited high electrical conductivity as a property. The mechanism of conductivity was an 
area of research, but it is now accepted that both polarons and bipolarons played a crucial 
part in this mechanism (Brédas, 1984 and Scott, 1983). The dopants used also have a 
crucial effect on the conductivity of the PPy, such as an increase in sulfonate group in the 
PPy film decreases the conductivity (Kuwabata, 1988). In addition, the use of monovalent 
anions instead of a multivalent anion resulted in a decrease in the intensity of crosslinking in 
the PPy film. Besides electrical conductivity, PPy also exhibited high thermal and 
environmental stabilites with the ease of synthesis (Lederc, 1999). Similar to the PANi, one 
drawback with the use of PPy as a drug delivery system was the poor processability of PPy 
due to its lack of solubility in most solvents (Bae, 2005). Several studies were conducted in 
order to improve the solubility of PPy. One method was a substitution reaction with an alkyl 
group at the β-position of the pyrrole ring prior to polymerization. The end result was a PPy-
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derived EAP which was soluble in organic solvents under neutral condition (Lee, 1995). 
Another method was to dissolve the PPy in an organic solvent in the presence of a 
surfactant, such as sodium dodecyl sulphate (Panero, 1992 and Naoi, 1995). However, the 
solubility of PPy produced with this method was still poor in polar solvents and water. 
Various studies have been done in order to improve the water solubility of the PPy. Another 
method was to synthesize the PPy from modified water-soluble monomers of pyrrole (Hong, 
2009). PPy may also be obtained via counterion-processability such as the oxidative 
polymerization of pyrrole in the presence of poly acrylic acid or poly vinyl pyrrolidone (Lee, 
1997). Lastly, the PPy may be synthesized as a self-doped co-polymer, with the co-polymer 
containing high sulfonic moiety in order to act as a dopant for the PPy (Yin, 2001). By 
improving the water-solubility of the PPy, the processability improves and allowed the PPY 
to be incorporated into more applications and technologies. PPy holds a promising future for 
development in the field of biomimetics, robotics and pharmaceuticals.  
 
2.4.3. Polythiophene as a component of the electroactive polymer-based drug delivery 
system 
Polythiophene (PT) was another EAP which has been developed into a conductive film 
which exhibited considerable electrical conductivity. This EAP may be differentiated from the 
other EAP such as PANi or PPy in a way that PT was synthesized from the monomer 
thiophene, which contained a sulphur heterocyclic structure, as opposed to PANi or PPy 
which contained imine groups. The mechanism of conductivity was relatively similar to that 
of the PANi or PPy. Doping a PT would result in bipolaron formation along its backbone. 
These polarons and bipolarons acted as charge carriers, thus resulting in electrical 
conduction (Gnanakan, 2009). PT has also been researched for application in other fields 
such as light-emitting diodes, electrochromic devices, field effect transistors and recording 
materials (Fichou, 1999; Granstrom, 1999 and Heeger, 2001). The incorporation of PT into 
these systems was possible due to the interesting optical properties as well as electroactivity 
possessed by the PT. These optical properties may be modified and may at times be non-
linear (Schrof, 1998). By modifying the PT and its optical properties, it may be used 
successfully in electrochromic devices and light-emitting diodes. The electroluminescence 
was generally believed to have originated from the recombination of electrons injected into 
the conduction band and holes within the valence band to form single exitons (Sakurai, 
1997). Similar to other EAPs, PT exhibited good environmental stability, thermal stability, 
processability and mechanical strength with the ease of fabrication (Roncali, 1992; Braun, 
1992; Chen, 1993; Andersson, 1995; Chen 1996). PTs may also be modified with alkyl or 
alkoxy side chains in order to improve its solubility in common organic solvents at room 
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temperature (Braun, 1991). The advantage a soluble EAP was that moulding would be 
possible by pouring the polymer solution into an appropriate mould. PTs with an alkyl side 
chain were soluble in most organic solvents in both doped and undoped form. One drawback 
to the alkyl substituted PT was that it lacked flexibility due to the rigid backbone that it 
exhibits (Hotta, 1987). With the application and research of these types of EAPs increasing, 
it was promising to say that EAPs can one day be used in a broad field of technology with 
tailor-made requirements to suit individual needs. The processability also means that 
synthesis and incorporation of these EAPs into future technology should be easier and 
feasible.   
 
2.5. Electropolymerization as a method of synthesis for the electroactive polymers 
and factors affecting the polymerization effect 
 
Polymerization is the process whereby the monomers react with each other to form long 
chains of polymers. Most polymers used today were formed by using chemical methods 
such as bulk polymerization or solution polymerization. Another method which is less 
commonly used for the polymerization of EAPs is the process of electropolymerization. 
During the process of electropolymerization, the monomer was dissolved in a suitable 
solvent along with the desired anionic doping salt. The monomer was oxidized at the anodic 
electrode. Due to the oxidation, free cationic radicals of the monomer formed interacted with 
each other, forming oligomeric products followed by polymeric products (Sadki, 2000). 
Electropolymerization is an intricate procedure and can be influenced by factors such as: 
• Monomer substitution. 
• Choice of electrolyte in the solvent. 
• Choice of solvent. 
• The pH of the solvent and aqueous medium. 
• The choice of electrochemical method used for synthesis. 
By manipulating some or all of these factors, it was possible to synthesize a novel polymer 
or a new synthesis method in order to obtain a polymer with the desired properties. By using 
a monomer which undergoes redox reactions rapidly, it increased the rate of polymerization. 
Similarly, by substituting a monomer which was a water-soluble analogue of the original 
monomer, the polymer formed would have higher water solubility. The choice of electrolyte 
in the solvent directly affected the current intensity, which could affect the amount of 
polymers formed (Pistoia, 1978). Different solvents have different donor numbers and 
deprotonation of the cation radical monomer formed would be affected. Furthermore, 
different solvents also exhibited different dielectric constants, which would affect the chain 
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propagation during the process of electropolymerization (Yamada, 1995). The solvent should 
be stable at the oxidation potential of the monomer and provided an ionically conductive 
medium (Sadki, 2000). The solubility of the monomers in the solvent was also an important 
factor as monomers which were insoluble in solvent cannot undergo electropolymerization. 
The pH of the solvent also has a great influence over the solubility of the monomer and the 
physical properties of the polymers formed, as it may have a chemical reaction with the 
monomers. Aniline was typically polymerized under acidic condition because the protonation 
of PANi yields higher conductivity due to the doping effect (Roeder, 2006 and Hatchett, 
1999). The methods of electropolymerization used also played a fundamental role in the 
physicochemical properties of the polymer formed. During electropolymerization, the 
monomer was dissolved in the solvent along with the anionic doping salt and oxidized at the 
anode via anodic potential. This oxidation allowed the monomer to react with each other and 
polymerization occurs. Acetonitrile was considered a good solvent for electropolymerization 
because it has a large oxidation potential window and allowed good dissociation for a wide 
variety of electrolytes (Bard, 1980). The anode used for electropolymerization was usually 
that of an inert material such as platinum, gold or glassy carbon (Shabani-Nooshabadi, 2009 
and Kowalski, 2008). If a partially reactive metal was used for the electrode, the electrode 
may undergo dissolution during anodic polarization and prevented the polymers to be 
formed on the electrode surface.  
 
Taking all points into consideration, the monomers have to be dissolved in a suitable solvent 
followed by exposure to the oxidation potential. Polymerization occurred following oxidation 
and a film of EAP was formed on the electrode. The thickness of the EAP film may be 
adjusted by the amount of anions present in the solvent. The anion was incorporated into the 
EAP during polymerization and was essential in maintaining the electroneutrality of the EAP 
formed. However, because the EAP may only be formed as a film on the electrode, the 
amount of EAPs formed was determined by the size of the electrode and production on a 
large scale may be time-consuming and unfeasible. In comparison to electropolymerization, 
the chemical synthesis of a polymer allowed a more stable yield of an EAP with a more 
consistent molecular weight. This was due to the exothermic reaction which occurred during 
the chemical oxidation of the monomer, such as the oxidation of aniline (Cirić-Marjanovic, 
2009). This fluctuation in temperature affected the chain length of the EAP formed and in 
turn the molecular weight. EAPs intended for mass production should be synthesized under 
well-controlled environmental conditions, as it was possible to produce EAPs with a 
comparable conductivity than EAPs synthesized via electropolymerization (Rodrigues, 1991). 
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However, EAPs intended for research may be synthesized via the electropolymerization 
method.  
 
2.6. Doping – A crucial process for the optimization of electroactive polymer 
conductivity  
 
Amongst the researches which were conducted on the EAPs, most efforts were directed 
towards achieving an EAP with desirable conductive, optical and mechanical properties. 
Doping is the process of introducing a chemical agent which directly interacted with the 
polymer chain itself. Doping is an important process because it played an important role in 
the physicomechanical properties of the EAPs formed. An example of the doping process is 
outlined in Figure 2.5 where the nitrogen atom from the quinoid group of PANi was 
protonized by a protonic acid (Dimitriev, 2003). 
 
Benzoid group Quinoid Group
Protonation
+ 2H+
 
Figure 2.5. Schematic of polymer protonation by conventional protonic acid. Acid counter-
ions are not shown (Adapted from Dimitriev, 2003). 
 
Most doping procedures for an EAP involved combining the EAP in base form, in most 
cases, preferably with an acid. This was often due to the increased conductivity exhibited in 
some EAPs when it was protonated. This was thought to be associated with the protonation 
of imine nitrogen which led to increased polarons (MacCall, 1989 and 1990). Therefore, this 
theory should apply particularly to EAPs in the PANi and PPy group because both of these 
EAPs have imine groups present as a part of the polymer backbone. As a result, PANi 
should be synthesized in an acidic condition, ensuring that the product formed would exhibit 
good conductivity (Taka, 1994). It was also for this reason that the synthesis of these 
polymers was deemed harsh and unfavourable. Sometimes, the acid may be mixed with 
other solutions. Doping agents such as 1:1, acetone:1 M HCl acid has been used as a 
Benzoid Group Qui id Group 
rotonation 
 2H+ 
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dopant for PANi film. The PANi was immersed in the solution for 24 hours in order to allow 
sufficient time for the doping process and vacuum dried for 48 hours (Mirmohseni, 2003). 
More recently, new doping agents were discovered and efforts were made to utilize these 
doping agents in order to produce an EAP with better mechanical, optical and conductive 
properties. 
Newer doping agents such as transition metals have been used as an alternative doping 
agent as opposed to the conventional protonic acids. With the use of a conventional doping 
agent, only the dopant change was induced on the polymer. However, when transition 
metals such as NiCl2, EuCl3 and ZnCl2 were used, it induced both dopant and morphological 
changes in the PANi as opposed to the conventional doping agents (Dimitriev, 2003). 
 
When EAPs such as PANi was prepared via emulsion polymerization, it was possible to 
obtain a conducting salt without the need for a post-doping process step with the acid 
(Palaniappan, 2005). Sometimes, acid may be added into the emulsion polymerization in 
order to facilitate additional doping. One example of the emulsion process may be 
demonstrated by the works done by Kinlen and co-workers (1999). The process was initiated 
by utilizing a water-soluble organic solvent such as 2-butoxyethanol that facilitates the 
polymerization of PANi salts of hydrophobic organic acids such as dinonylnaphthalene 
sulfonic acid (DNNSA) (Kinlen et al., 1999). In addition, acid such as dodecylbenzene-
sulfonic acid (DBSA) has emulsifying properties and can be used both as a dopant and an 
emulsifier (Kim, 2007).  
 
2.7. Redox reaction as an essential process for the conductivity of electroactive 
polymer 
 
In order for an EAP to be responsive, it must be able to undergo reversible oxidation and 
reduction processes. EAPs may either be categorized as a redox polymer or a conducting 
polymer. Redox reactions were important because it provided us with a model to explain 
how the transport of ions in and out of the EAPs was achieved, and thus controlled 
movement of these ions from the conductive polymer films. The difference between a redox 
polymer and a conducting polymer was that redox polymer contained spatially and 
electronically localized redox sites (Inzelt, 1986). These sites may either be covalently 
bounded or electro-statically bounded to the polymer. Conducting polymer, on the other 
hand, contained delocalized electronic states (Bott, 2001). In the case of PANi, the redox 
centres are the amine groups that were oxidized to imine group. After the oxidation was 
completed, PANi would become conductive to certain degree. Another example of 
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conducting polymer would be the PPy, PT and its derivatives (Posada 2004). The redox 
process generally occurred in the film/solution interface, where the dissolved ion in the 
solution was able to react with the conducting polymer and was involved in charge balance. 
The EAPs were synthesized as a film via the process of electropolymerization and were 
immersed in a solution with various counter-ions dissolved.  
Four phenomenons occurred when a polymer undergoes redox switching: 
• Conformational changes. 
• Entry or exiting of solvent molecule which may change the state of swelling. 
• Changes in ion configuration which were bound to the polymer. 
• Injection/ejection of ions in order to balance the electroneutrality of the polymer. 
Figure 2.6 depicted the mechanism under which the oxidation reaction of 4 monomer unit of 
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Figure 2.6. A depiction of the mechanism under which the polyaniline undergoes oxidation 
reaction. The downward arrow represented the oxidation reaction (Posada, 2004).  
 
Currently, several methods which involved substance delivery from an EAP included the 
incorporation of an electrostatically charged substance into the polymer membrane. The 
induction of an electric current resulted in the inward and outward movement of the counter-
ions for charge balance. An outward movement of the electrostatically charged ions from the 
polymer membrane therefore resulted in release of the substance. Research has been done 
on electrostatically charged glutamate (Zinger, 1984) and ATP (Pyo, 1994) in order to 
achieve controlled release of these two substances. EAPs such as PANi and PPy allowed a 
PANi occurred. 
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high flux of cations during the oxidized state. Therefore, it was possible to achieve a 
transport of ions across these polymer membranes when oxidation potential was applied to 
these conductive membranes. 
 
Another mechanism which may have contributed to the ion transport process exhibited by 
the EAP was the conformational changes which occur during the redox switching of the 
EAP. These conformational changes may have resulted in swelling, de-swelling or a change 
in shape of the EAP, allowing it to act as artificial muscles (Otero, 2004). This moulding 
effects are called slow-relaxation or memory effect. Several EAPs such as those in the PANi 
group showed this kind of relaxation effect, while polymers such as poly(o-aminophenol), 
poly(o-phenylenediamine) or poly(bencidine) did not exhibit this relaxation effect (Moina, 
2003). A study by Genoud and co-workers (1985) has been done to explain such behaviour 
(Genoud et al., 1985). These relaxations may be observed after the EAP has undergone 
reduction and was independent of the composition and concentration of the surrounding 
electrolyte. Instead, the electrolytes tend to influence the relaxation time of the EAP (Silk, 
1996). There is currently no confirmed model on the mechanism of these relaxations, as 
EAP relaxation also occurs during oxidation, such as PPy (Otero, 1994). The general model 
is, however, based on the penetration of counter-ions into the polymer matrix. This relaxation 
allowed entrapped drug molecules to become liberated provided there was no interaction 
between the drug, the polymer and the surrounding medium. Therefore, by utilizing this 
relaxation property of certain EAP, it was possible to achieve controlled release of an 
entrapped drug. 
 
2.7.1. Techniques for the evaluation of redox reactions in electroactive polymers 
The degree of swelling, de-swelling and electroactivity is closely related to the redox 
capability of the polymer. It is for this reason one should assess the reduction-oxidation of a 
polymer during electrical stimulation in order to determine the electroactivity of an EAP. 
Several techniques are available in order to determine the redox capability of a polymer. 
 
2.7.1.1. Linear sweep voltammetry 
Linear sweep voltammetry is a method whereby the current of the working electrode is 
measured against a known range of potentials. Any oxidation or reduction which occurred in 
the EAP would be registered as a peak or a trough in the voltammogram. Aside from the 
redox reactions which occur, linear sweep voltammetry may also be used for quantifying 
purposes, such as the determination of free chloride ions in water or the amount of sulphites 
present in wine samples (Scampicchio, 2007 and Pathiratne, 2008). Linear sweep 
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voltammetry was initially used as an assessment tool for the voltammetric response of the 
EAP (Chambers, 1985). The applications of linear sweep voltammetry in EAP researches 
nowadays are limited as it is now widely replaced by cyclic voltammetry. This was due to the 
advantage whereby more data can be obtained from a cyclic voltammetry as compared to a 
linear sweep voltammetry. 
 
 2.7.1.2. Cyclic voltammetry 
Cyclic voltammetry is a potentiodynamic electrochemical measurement and is an extension 
of the linear sweep voltammetry. In linear sweep voltammetry, a known potential is applied 
across the working electrode and is increased in a linear fashion as time progresses. Cyclic 
voltammetry extends this technique further by inverting the working electrode potential once 
the end potential is reached. This allowed the observation of both oxidation and reduction 
behaviour of the material under analysis, should the sample being analyzed exhibit any 
reversible redox reaction. The current at the working electrode would be plotted against the 
applied potential difference to give a cyclic voltammogram trace. During cyclic voltammetry, 
the potential was increased in a linear fashion. As the potential drew close to the oxidation 
potential of the analyte, the current would increase and eventually drop when the 
concentration of the analyte decreased near the electrode due to the oxidation. The potential 
would be reversed and if the analyte was capable of reversible redox coupling, the oxidized 
anaylte would undergo reduction once the reduction potential was reached. This produced a 
reduction peak similar to that of the oxidation peak. It is used generally to study the 
electrochemical properties of an analyte in solution (Nicholson, 1964 and Heinze, 2003), but 
is also used to assess the redox capability of a material. Figure 2.7 demonstrated an 
example of cyclic voltammetry done on PPy-para-toluene-sulfonate in 0.2M KCl as 
supporting electrolyte. 
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Figure 2.7. Cyclic voltammetry performed on polypyrrole-para-toluene-sulfonate in 0.2 M 
KCl as supporting electrolyte. The scan rate is 100mV.s-1 A/B represents the redox peak 
associated with cation insertion/expulsion while C/D represents the redox peak associated 
with anion insertion/expulsion (Zhao, 1996). 
 
By using Figure 2.7 as an example, it was possible to demonstrate that PPy-para-toluene-
sulfonate is capable of undergoing both reduction and oxidation at various potential 
differences. The oxidation potential and the reduction potential in this case were 
approximately 0.5V and -0.5V, respectively. Cyclic voltammetry is still one of the most 
popular techniques used in electrochemical analysis in order to determine an 
electrochemical property of a substance and is one of the most valuable tools in order to 
assess the redox reaction of the polymer and its electroactivity. 
 
2.7.1.3. Impedance spectroscopy 
Impedance spectroscopy is a versatile tool used to characterize the intrinsic electrical 
properties of any materials and its interface. The data that one can obtain from the use of an 
impedance spectroscopy included the conductivity, dielectric coefficient, the static properties 
of the interface and its dynamic change due to adsorption of charge-transfer phenomenon. 
The technique itself is non-destructive and has been modified recently in order to assess 
body composition in those suffering from obesity or being over-weight (Cox-Reijven, 2002, 
Fortunato, 2005). Another property which could be measured by impedance spectroscopy 
was the conductivity of an EAP. The impedance of an EAP may be used for conductivity 
studies, as well as providing us with an understanding of the kinetics and the 
electrochemical reactions occurring in the EAP (Gabrielli, 2000). Furthermore, it may be 
used to characterize an EAP such as PANi or PPy in order to confirm a proposed model 
such as the diffusion of ions in and out of the EAP in a solvent (Musiani, 1990) or counter-ion 
and electron diffusion at the EAP/solvent interface (Lyons, 1990). Since impedance 
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spectroscopy could be used to assess the diffusion of electrons and counter-ions, it may be 
useful for evaluation and confirmation of a redox process of an EAP. Due to its versatility, it 
may be used in several applications such as corrosion studies, energy storage device, 
interfacial electrochemistry, biosensors, semiconductors and liquid-liquid interface studies. 
Some limitations regarding the use of impedance spectroscopy was that data interpretation 
is usually difficult and it cannot be used as a stand-alone technique.  
 
2.7.1.4. Chronoamperometry 
Chronoamperometry is a technique where the potential is maintained for a certain period, 
then stepped and the current resulting from the faradic process is then recorded. The current 
is a result of oxidation or reduction which occurs from the analyte. The polymer analyzed 
was usually coated as a thin film around the electrode, although the presence of a perturbed 
current in chronoamperometry may deviate the results obtained (Yap, 1987). 
Chronoamperometry may be employed in cases where elucidation was required for the 
migration flux of a charged particle in an EAP. This may be done by analyzing the 
concentration distribution and current-time curves of a polymer film in a constant electric field 
(Yap, 1983). Conversely, conductive EAPs have been used in chronoamperometry as a 
sensor for the detection of simple electroactive or non active species, in addition to more 
complex species (Nguyen, 1999). Chronoamperometry is still important and may be used for 
elucidation of the kinetics of charged species migration and diffusion.  
 
2.8. Controlled release of substance from the electroactive polymeric-based hydrogel 
 
Over the past few years, pharmaceutical researchers have been looking at developing a 
drug carrier which could release drug in response to a change in the environment. These 
changes may be endogenous (e.g. change in blood glucose, change in pH or inflammation) 
or it may be exogenous i.e. external stimulus was required. These drug carriers were termed 
‘intelligent’ drug carrier because of its ability to release an adequate amount of drug at the 
correct place and time (Murdan, 2003). The use of this drug delivery system proved to be 
beneficial for both the patients and the health care providers, due to the improved patient 
compliance and decreased side effects. Even for researchers in other fields of study, EAP or 
other intelligent polymers have demonstrated its usefulness and was extensively 
researched. A study done by Singh et al in 2008 has demonstrated that a smart polymer 
may even have its uses in the field of cell cultivation. Animal studies have always been a 
controversial issue and it was hoped that with the aid of cell cultivation, it is possible to 
replace animal studies or reduce the numbers of studies that have to be done on animals 
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(Singh, 2008). Therefore, it can be seen EAP researches have vast impact on a wide variety 
of fields.  
 
Controlled release from an EAP-based hydrogel is mainly due to the movement of charged 
particles in and out of the hydrogel. To date, there have been a few models which tried to 
explain the mechanism in which drug was released from the electroactive hydrogel. The 
following 3 models have been proposed by Murdan et al. (Murdan, 2003) in relations with 
drug release from an electroactive hydrogel. 
• Forced convection of drug as gel de-swells.  
• Drug electrophoresis due to migration of drug toward charged electrodes. 
• Drug liberation when an electroactive hydrogel was eroded upon electrical stimulation. 
There were, however, certain limitations in which drug released from an EAP-based 
hydrogel can be exploited. Firstly, only a charged drug may be used in order for 
electrochemical control of movement of drug in or out of the hydrogel. Secondly, drugs in 
high volume cannot be easily absorbed or released by the EAP-based hydrogel, and lastly, 
the ionic exchange between the drug and the surrounding medium slowly diminished the 
electrochemical control of the drug release from the hydrogel (Lira, 2005). 
 
Controlled release of charged particles has been studied previously, as done by Zinger and 
co-workers (1984), controlled release of a neurotransmitter from a polymer coated electrode 
has been successful. The charged particles were covalently bound onto the polymeric 
backbone and remained on the polymeric electrode until a pulse of electric current was sent 
through the electrode. The polymer used was PPy attached onto a glassy carbon electrode. 
PPy was doped with both glutamate as the drug and ferrocyanide in order to enhance the 
conductivity of the PPy. This has demonstrated that PPy can indeed be used to control the 
release of anionic drugs (Zinger et al., 1984).  
Cationic drug release can also be controlled in a similar manner. Cationic drugs such as 
protonated dimethyldopamine have been incorporated into a cationic poly(N-methyl-
pyrrole)/polyanion composite and released anodically. This study has demonstrated that 
amines could be bound as its conjugate acid while dopamine, which was a model cationic 
drug, may be released in a time controlled manner (Zhou, 1989). Biological actives have 
also been demonstrated for its controlled release capability by using bi-layered polymer, an 
inner layer which was separated by the outer layer via a seperation film. The inner layer 
exhibited a low redox potential while the outer layer exhibited a high redox potential. This 
design not only allowed release of charged particles, but also the reuptake of certain 
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charged particles in the surrounding medium as well. The materials used were PPy and 
polystyrene sulfonate (PP/PSS) as the inner layer while the outer layer was comprised of 
either poly (N-methyl pyrrole) (PNMP) or poly (vinyl ferrocene) (PVFc) (Pyo, 1995). The 
schematics of this dual layer transport system may be depicted in Figure 2.8. 
 
 
Figure 2.8. The mechanism by which the duo layered transport system works. When 
polypyrrole becomes oxidized, it lost an electron and become positively charged, thus 
repelling drug M which also possessed a positive charge. Similarly, when PVFc becomes 
oxidized, it becomes positively charged and thus attracts the negatively charged drug X 
(Pyo, 1995). 
 
In order to determine the behaviour of the electroactive hydrogel, it was important that 
current is applied to the hydrogel appropriately. The hydrogel may be immersed in a 
conducting medium and either one or both electrodes should be embedded or in contact with 
the hydrogel or the hydrogel may simply have contact with the electrode without any 
conducting solutions (Murdan, 2003). It is important to note the different methods used here 
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would result in different release profiles of the hydrogel and thus the method with an 
optimized result should be used.  
 
By using similar mechanisms, other researchers have used model drugs such as 
sulfosalicyclic acid in a crosslinked PVA hydrogel. The amount of drugs used is determined 
by UV visible spectroscopy. It was discovered that drug release may vary in a linear fashion 
with the square root of time, and moreover, the diffusion coefficient of drug-loaded PVA 
hydrogel also depended on the electric strength applied (Kanokpom, 2008). Aside from the 
electrical current and the crosslinking from the hydrogel, another factor which was important 
for drug release from the hydrogel was the use of polyelectrolyte. These polyelectrolyte may 
form the main component of the hydrogel which transformed the hydrogel into electrical and 
pH responsive hydrogels. 
 
2.9. Polyelectrolyte and their uses in biological applications 
 
Polyelectrolyte is defined as water soluble electrically charged polymer. Its shape and 
movement are governed by a combination of its charge and Brownian motion. As a result, it 
may coil up or stretch out and may be classified either into polyacid, polybase or 
polyampholytes. This can be determined according to its ionizable groups, depending 
whether it was acidic group such as carboxylic, sulfonic or phosphoric groups or basic 
groups such as amino groups (Katchalsky, 1964). What makes these hydrogels important in 
the field of stimulus-actuated drug delivery was its structural response induced by a change 
in pH, temperature and even electrical current (Sorenson, 2009). Structures in our body such 
as DNAs are polyelectrolyte, and therefore, it was possible to synthesize a biocompatible 
polyelectrolyte. Biodegradable polyelectrolyte has also been investigated as a pulmonary 
drug delivery system which may be a desirable route of vaccine delivery (De Koker, 2009). 
 
When polyelectrolytes were incorporated into a hydrogel, these polyelectrolytes could swell 
and collapse when placed in solution containing different charges or pH (Huang, 2007; Li, 
2005 and Budtova, 1994). Besides swelling and collapsing, polyelectrolyte hydrogel was 
also capable of bending and change in shape. To date, several materials were reported to 
have been electrically responsive. Some of them including poly(acrylic acid) and poly(vinyl 
alcohol) co-polymer membranes, sulfonated crosslinked polystyrene gel, acrylamide/acrylic 
acid co-polymer with PPy/carbon black and chitosan/carboxymethylcellulose hydrogel 
(Shang, 2008). Other materials which were also being researched includes poly(N-
isopropylacrylamide) and its derivatives, poly(methyl methacrylate) and its co-polymers with 
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methacrylic acid, poly(acrylonitrile), poly(2-acrylamido-2-methyl-1-propanesulfonic acid), 
poly(propylene phosphate) and poly(N-acryloyl-N’-propylpiperazine) based on a study done 
by Jabbari and co-workers (Jabbari, 2007). Some of the polyelectrolytes have even exhibited 
good electrical response over a wide range of pH.  
 
In order to utilize polyelectrolyte hydrogel for the purpose of drug release, it was important to 
understand its kinesis upon electrical stimulation. The mechanism under which 
polyelectrolyte hydrogel collapses and/or changes shapes are yet to be elucidated. There 
are, however, several models which attempted to explain and achieve such mechanism. 
When a polyelectrolyte hydrogel was connected to an electrical circuit, the hydrogel 
collapsed as depicted in Figure 2.9. 
 
Figure 2.9. The collapsing of the polyelectrolyte hydrogel upon electrical stimulation. These 
contractions are what caused the water to exude and thus drug release along with the 
solvent (Budtova, 1995). 
 
Figure 2.9 indicated two areas of contraction. The first one occurred at the area of high gel 
response at the positive terminal and that may be due to electrochemical process that obeys 
Faraday’s law with a correction coefficient. The second was an area with low response at the 
negative terminal, and that may be due to the electro-osmosis release of water (Budtova, 
1995). The collapse occurring at the anode or cathode was dependent on whether the 
hydrogel was anodic or cathodic in nature. An anodic hydrogel would collapse predominantly 
at the anode and vice versa.  
 
Other useful application of environmentally sensitive polyelectrolyte hydrogel included 
biosensors, DNA hybridizations, micro-surgical tools and miniature bioreactors. 
Polyelectrolyte hydrogel have shown promising results with regards to electrical stimulus and 
biocompatibility. PH-Sensitive and temperature-sensitive drug release from this 
polyelectrolyte has been investigated. A study by Inoue and co-workers (Inoue et al., 1997) 
has managed to prepare polyelectrolyte hydrogel loaded with drugs and soaked in distilled 
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water in order to assess drug release when immersed at various different pH. Only cationic 
or hydrophobic drugs were used in this case and, as predicted, the hydrogel had a different 
swell rate in different pH and different drug release profiles. Drugs were loaded into the 
hydrogel by immersing the hydrogel into drug-dissolved solutions. Drug entrapment 
efficiency was determined by measuring difference in drug concentration before and after 
the hydrogel immersion. 
 
2.10 Current responsive hydrogel system and future prospective 
 
EAPs and stimulus responsive hydrogels have been a subject of interest for research, not 
only in the field of drug delivery, but also in various other fields. Although the mechanisms 
for these electroactive components are yet to be elucidated, various models were made in 
order to explain the change in behaviour of these electroactive components upon actuation. 
These models mainly focused on the change of ionic strength and charge which led to 
repulsion or attraction. Therefore the EAP, hydrogel and model drug all has an impact on 
each other, and all three components have to be considered prudently in order for the 
system to operate smoothly as a whole.  
 
Another system which was also under intensive research was the possibility of a 
biodegradable stimulus-actuated polymer. These polymers would be implanted at target site, 
and upon actuation, it may degrade and release the drug held within. Once these polymers 
underwent degradation, it will be metabolized and excreted from the body, due to its 
biocompatibility. Possible materials included gelatin and dextran (Kurisawa, 1998). There 
were other biodegradable EAPs which also possessed the potential for controlled release of 
various substances. Examples of this polymer included multiblock polylactide and aniline 
pentamer co-polymer used by Huang and co-workers (2008). The biocompatibility of this 
polymer has been tested on rat models and the broken down metabolites were further tested 
and proved to be non-toxic (Huang et al., 2008). Another EAP which was synthesized by 
Guimard and co-workers (2009) was also shown to be biodegradable is the 5,5’’’-
bis(hydroxymethyl)-3,3’’’dimethyl-2,2’:5’,2’’:5’’,2’’’-quarterthiophene-co-adipic acid polyester 
(QAPE). This polymer was synthesized by incorporating alternating electroactive 
quarterthiophene units and biodegradable ester units into one macromolecular framework 
(Guimard et al., 2009).  
EAPs may also be utilized within the nano-scale range (Sohn, 2007), and EAPs have been 
demonstrated electroactivity even at scales of 100nm (Peteu 2007). This is a promising and 
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interesting prospective for the future of EAP developments. Nanobots or nanobiosensors 
may one day be injected into a patient and drugs could be released simply by environmental 
activation, either endogenously or exogenously.  
Whichever the case may be, EAP and its family of stimulus actuated polymers have proven 
to be valuable not only in the field of drug delivery, but also in the field of robotics, 
biomimetics and space engineering. However, further research is still required so that these 
polymers may be utilized to its full potential. 
 
2.11. Concluding remarks 
 
The aim of this study was to formulate a drug delivery system which allows patients suffering 
from chronic pain to obtain a therapeutic dose of drugs at the target site, at the required 
moment. In order to construct a design for the purpose of electroactive drug delivery, various 
factors must be taken into account. The crosslinked hydrogel system, the EAP and finally the 
drugs selected, each one played an important role in affecting the system as a whole. In 
order to design a system which allowed release of drug, one may attempt to construct a 
hydrogel system which swells and de-swells under electric current, or one may construct a 
hydrogel system which undergoes degradation under electric current. One advantage of 
using NSAIDs as a drug for release directly at the target site was that they exhibit high 
protein binding when administered orally (Bater, 1988). Therefore, by focusing on target site 
delivery, only minute quantities of the drug need to be administered to achieve COX II 
inhibition effect. Another benefit of this system was that it should reduce the GI side effects 
which are experienced with an oral NSAID. Some products deliver NSAIDs in an enteric 
coating in order to reduce the GI side effect (Goldstein, 2008; Hawthorne, 1991), but 
absorption from the GIT still takes time and it does not completely eliminate the ulceration 
experienced with NSAIDs. The device should be flexible in design and be an appropriate 
size which is suitable for subcutaneous implantation. Since the human skin is capable of 
conducting electricity (Williams, 1996), an external device may be used in order to allow 
electric current to travel through the skin and in turn activating the device implanted below. 
This system should also eliminate the strong resistance that was experienced by solutes and 
ions when it was moving across the stratum corneum during cutaneous drug delivery 
(Karande, 2006). The development of this system should improve patient compliance while 
reducing side effects which would improve the treatment outcome of patients suffering from 
chronic pain. As this system was aimed to release NSAIDs directly at the target site, drugs 
such as opioids which act centrally could not be used. Therefore, in conditions such as 
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neurological chronic pain where NSAIDs are not the primary drug of treatment, this system 
may not be effective as the oral opioids or anti-depressants. However, in conditions such as 
osteoarthritis, back pain or gout, this system may prove to be beneficial. 
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CHAPTER 3 
PRE-FORMULATION STUDIES OF THE STIMULUS-ACTUATED POLYMERIC DEVICE 
 
 
3.1. Introduction 
 
This pre-design study was conducted by using PANi as an EAP in order to enhance drug 
release. To date, several EAPs which were capable of redox reactions were under intensive 
research for several different applications. These EAPs are also termed stimuli-responsive 
hydrogels, ‘intelligent’ or ‘smart’ polymers. An EAP may be defined as a polymer which 
responds to an electrical stimulation via size or shape changes. These polymers were first 
discovered over a decade ago and have interested many scientists ever since. Initial 
displacements of these EAPs were confined to small size or shape changes, but recently 
EAPs with larger displacements have been discovered (Bar-Cohen, 2002). These polymers 
can mimic muscle movements and were termed artificial muscles. Scientists in the field of 
nano-robotics and bio-mimetic have favoured EAPs into their design due to the EAPs’ 
unique ability to respond to an electric current, alongside their low weight, fracture tolerance 
and pliability (Bar-Cohen, 2007). 
 
More recently, EAPs have been investigated for its use in drug delivery and biosensors 
(Pernaut 2000). A few EAPs which exhibited promising characters included those of PPy, 
PANi and PT groups. It was previously thought that PANi was rigid, hard to process and 
insoluble. Recent discovery of PANi’s solubility in a solvent of N-methyl-pyrroldine have 
allowed PANi to be processed into a film or fibre, thus improving its physical and mechanical 
properties. Furthermore, PANi could be doped by using different counter-ions, and this 
resulted in PANi with varying conductivity (Geng, 1997). Once polymerized, PANi may exist 
in one of three states: leucoemeraldine, emeraldine or pernigraniline. These states can 
usually be differentiated by its appearance, as leucoemeraldine has a white/clear colour, 
emeraldine has a dark green/blue colour and pernigraniline has a blue/violet colour (Huanga, 
2006). These three oxidation states may be depicted by Figure 3.1. 
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Figure 3.1. The three oxidation states of polyaniline. Pernigraniline is the fully oxidized state 
with imine links instead of amine links. Leucoemeraldine is the fully reduced state. 
 
Emeraldine state was considered the most useful state of the PANi due to its high stability at 
room temperature and that upon doping, the emeraldine salt form is electrically conducting. 
Another important component of the system is the hydrogel. Some hydrogel systems were 
also ionized and it were termed polyelectrolyte hydrogels, with fixed charges attached onto 
its polymeric network (Luo, 2007). Within these hydrogels were the mobile ions, which, in 
some cases, were free to enter and leave the hydrogel upon stimulation and were 
suspended by fluids which were absorbed by the hydrogel. A hydrogel may be responsive 
towards temperature (Sun, 1999), pH of the surrounding medium (Zhang, 2007; Mohanan, 
2009), enzymes (Thronton, 2006), magnetic and ultra-sound irradiation (Kim, 1996). Another 
stimulus which is also under investigation is electrical currents in order to achieve structural 
changes in hydrogels for the purpose of drug delivery (Kulkani, 2009). These structural 
changes may be bending of the hydrogel towards the anode or cathode, or it may be 
swelling or de-swelling of certain regions of the hydrogel and several models exists to date 
to explain the phenomenon. A hydrogel is capable of drug release upon de-swelling and 
swelling, due to its dynamic mechanism of release. An electro-responsive hydrogel which 
was attached between an anode and a cathode may exhibit de-swelling either at the anode 
or the cathode. When the hydrogel de-swelled, it squeezed out any solvents which it 
contained, and any drug dissolved in the solvent would inevitably be expelled out of the 
hydrogel along with the solvent, resulting in drug release (Sutani, 2002). When the electric 
current was ceased, the gel absorbs surrounding solvent and swelled back to its original 
size. In a different model, a hydrogel in its de-swelled state may form a crosslinked system 
which held the drug molecule. When the hydrogel was stimulated, the hydrogel swelled up, 
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leading to increased pore size and free surface area, which resulted in drug diffusion 
outward (Kim, 1992). 
 
Several other models also existed in order to explain possible release mechanisms of the 
hydrogel. In the case of electroactive hydrogels, there may be drug electrophoresis due to 
migration of drug towards charged electrodes or there may be drug liberation when a 
hydrogel was eroded in the presence of an electrical current (Murdan, 2003). 
 
In this Chapter, the main focus was on the design and application of an indomethacin-loaded 
crosslinked hydrogel system. Four different devices with varying compositions were built and 
each was loaded with indomethacin. The four devices were placed under electrical 
stimulation and the drug release was assessed. In the pre-design study, the four devices 
were basically comprised of a hydrogel compartment, a crosslinker, an EAP and the drug. 
 
3.2         Materials and Methods 
 
3.2.1       Materials 
Polyvinyl alcohol (PVA) 8/88 (Unilab, Krugersdorp, South Africa) was used in order to form 
the main composition of the hydrogel. The molecular weight as indicated by the 
manufacturer was approximately 49000g. Another grade of polyvinyl alcohol was used and 
had a molecular weight of 89000-98000g (99% hydrolysed) (Sigma-Aldrich, Steinhelm, 
Germany). Polyethylene glycol (PEG) 4000 (Unilab, Krugersdorp, South Africa) with 
molecular weight approximately 3600-4400g was used as a crosslinker with Eudragit®. Two 
different grades of Eudragit® were used in this study, the first, Eudragit® L100 powder 
(Methacrylic acid-methyl methacrylate co-polymer 1:1) (Degussa, Darmstadt, Germany) was 
used. The second was Eudragit® RL100 pellets (Ammonio methacrylate copolymer type A) 
(Evonik Industries, Darmstadt, Germany). The solvents used were distilled water, 
Hydrochloric acid (Merck Chemicals (Pty) Ltd., Germiston, South Africa) and 
Dichloromethane (Merck Chemicals Pty Ltd., Germiston, South Africa) with a purity assay of 
>99%. Aniline monomer (Sigma-Aldrich, Steinhelm, Germany), PANi emeraldine base 
(Sigma-Aldrich, Steinhelm, Germany) with molecular mass approximately 20000g was used 
as an electroactive agent. PPy (Sigman-Aldrich, Steinhelm, Germany) was used as a 
possible EAP for the SAPD. Finally, the drug used was indomethacin, diclofenac sodium, 
ibuprofen and aspirin (Sigma-Aldrich, St Louis, MO, USA). All reagents were used as 
received. Light microscopy performed on the SAPD was the Olympus SZX7 ILLD2-200 
(Olympus, Tokyo, Japan). Drug concentration was measured with a UV-visible 
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Spectroscopy, model Lambda 25 UV/Vis Spectroscopy (Perkin-Elmer, Shelton, CT, USA). 
Chemical structure analysis was performed with a Fourier Transform Infra-Red (Perkin 
Elmer, Life & Analytical Science Inc., Shelton, CT, USA) 
 
3.2.2. The design of an electroactive polymer-based implantable system 
This study focused on the design of an EAP-based implantable device which would be able 
to release a desired quantity of drug directly to the target site upon application of an external 
stimulus for the purpose of chronic pain relief. This device would be engineered as a mono-
layered membranous system in which the drug can be loaded and released in a controlled 
manner. The external stimulus was that of an electric current applied via an external device. 
The drug-loaded disks may be actuated by applying electrical stimulation. This device would 
allow the patient to deliver various quantities of drugs by triggering drug release via selecting 
the adequate external electric current strength as well as the duration. Drug release would 
cease as a result of removing the external electric current. Therefore by applying either low 
or high electrical current, we can control the amount of drug released with a single charge. 
Figure 3.2 provided the setup of the circuit upon which drug release would occur. 
 
 
 
Figure 3.2. The setup of the circuit in the stimuli-actuated polymeric device. 
 
The battery and the circuit would be in the form of a portable device when the SAPD was 
implanted into the patient. When the circuit was closed, electric current would pass through 
the device, resulting in a release of drug. The disk-shaped device would allow implantation 
into the patient due to its flat shape. This device would be implanted subcutaneously. 
Electrical stimulation applied externally should actuate the device through the skin. 
 
 
 
This system is a simple 
mono-layered drug loaded 
system which will release 
drug upon stimulation by 
an electric current. Cell 
+ 
- 
SAPD 
Copper Wire 
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3.2.3. Preparation of the electroactive polymer-based implantable device  
The SAPD could be implanted subcutaneously at extremities such as the arm. By implanting 
the SAPD subcutaneously, it allowed sufficient electric current or stimulus to induce changes 
in the SAPD. One of the many possible EAPs that may be employed in the design of the 
SAPD may include the groups of PPy, PANi and EVA as a membrane. This SAPD can be 
electro-chemically controlled to transport ions across the surface and can be switched on 
and off when applying potential difference of approximately 1V. Even the rate of 
transportation across the membrane could be controlled in situ by means of potential 
difference applied. In addition, the use of various counter-ions not only affects the electro-
conductivity of the membrane, but also the mechanical and transport activity. This transport 
mechanism involved incorporation or expulsion of ions as the membrane was continuously 
oxidised and reduced using a repetitive pulsed potential waveform. This reaction was 
demonstrated in Figure 3.3. 
 
(p/m)
- e-
+ e-
(s)
-
(p)
-
Polypyrrole with counter-ion A Polypyrrole reduced with counter-ion A 
expelled into solution
Polypyrrole prior to the
addition of cation X
- e-
(p/i) (p/i)
+ e-
 
Figure 3.3. Demonstration of the oxidation and reduction reactions of polypyrrole (Zhao, 
1998). 
 
A- is the counter ion used in the synthesis. X+ is the cation in the electrolyte solution in which 
the polymer was either oxidised or reduced. A-(p/m) was the counter ion that was within the 
polymer and has sufficient mobility to be expelled into the solution during the reduction. One 
of the possible designs of the SAPD may comprise PPy which contained a para-toluene 
sulphate (PTS). The SAPD would be prepared by electro-polymerization from a solution of 
0.20M pyrrole and oxidizing agents as initiators. A constant current could be applied for 
approximately 12 minutes in reagents such as 40% sodium benzene sulfonate and 60% 
distilled water. A stainless steel plate may be used as a working electrode. By incorporating 
such reagents into the SAPD, it would allow transportation of an array of sulfonated aromatic 
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compounds across the membrane. The use of a twin electro-chemical controller continued 
the oxidation and reduction portions of the potential cycle to different parts of the cell which 
may make the membrane either an anion or a cation transport system.  
 
3.2.4. Effects of counter-ions on the properties of Stimuli-Actuated Polymeric Device 
One advantage of the PPy was that it may be synthesized into a membrane. In addition, the 
conductivity of the PPy may also be tested. The conductivity of the PPy can be changed by 
incorporating different counter ions such as benzene sulfonate (BSF), para-toluene 
sulphonate (PTS), ethylene-benzene sulphonate (EBS), mesitylene sulfonate (MS), 
benzenedisulfonate (BS) and naphthalene disulphonate (NPS). By incorporating these 
counter-ions, one could adjust not only the conductivity but also the tensile strength of the 
PPy membrane. The effects of the aforementioned variety can be seen in Table 3.1. 
Table 3.1. Effect of the counterion on the tensile strength and conductivity of the membrane 
(Zhao, 1994). 
Membranes 
                        
 
3
Tensile
Strength
Conductivity
(S/cm)
17-23 70-80 60-70 36-47 40-55 40-50
19-20 90-110 50-70 47-70 50-70
3
3
3
90-110
33 33
 
 
3.2.5. In vitro drug release study of polypyrrole membrane 
In order to assess the drug release behaviour of the PPy matrix system, a matrix device of 
drug-loaded PPy should be left in a solution of high electrical conductivity. The solution of 
choice was NaCl as it is a strong electrolyte. Direct electric current would be passed through 
the solution while a volt meter was attached to the circuit to measure the current. Samples of 
the solution would be taken at specific time intervals to test the drug concentration. 
Generally, a potential difference of 4V or less would be required for the actuation of the EAP 
(Lin, 2011), so tests may run from as small as a few milli-volts up to 4V. The schematic of 
the in vitro test of drug release of the SAPD may be presented as in Figure 3.4. 
PP/BSA PP/PTS PP/EBS PP/MS PP/BS PP/NPS 
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Figure 3.4. The in vitro test that was conducted on the stimuli-actuated polymeric device in 
order to assess its drug release. 
 
The SAPD was developed with a thickness of approximately <1mm. The release of the 
drugs was determined by High Performance Liquid Chromatography (HPLC) and Ultra-
Performance Liquid Chromatography (UPLC). Research has shown that membranes doped 
with appropriate drugs towards chloride exchange in a 0.1M NaCl solution offered a good 
result in terms of drug delivery (Kontturi, 1998).  
 
3.3. Results and Discussion 
 
3.3.1. The constituents and its role in the responsive hydrogel 
The EAPs used for the purpose of drug delivery included PANi and PPy or its derivatives, 
which exhibited elastic properties and conductor properties. The electrical conductivity that 
these polymers possessed was mainly due to the conjugated backbone structure. These 
conjugated backbone structures contained the free valance electrons which were required 
10mL samples will be taken at 
time intervals (30 minutes – 1 
hour) to test for drug 
concentration in the solution. 
The drug is released due to 
polymer movements 
SAPD in a solution of 
NaCl, 0.1M NaCl 
solution has good 
electrical 
conductance. The 
SAPD was left at the 
bottom of the solution 
Power source – 
which could range 
from 1-5V. One or 
more AA batteries 
can be used. 
 
Voltmeter would measure 
voltage between the ranges 
of 0-30V may be used. 
Ammeter was used to assess 
ampere. A reading of 300mA or 
more can kill a person and 
therefore should be avoided. The 
ammeter can thus be used to 
assess the safety of SAPD. 
Copper wires and 
electrodes were used 
since they offered 
good conductivity and 
were readily available. 
The solution was 25mL saline 
obtained from SABAX (South 
Africa) in volume with and 
temperature may be adjusted to 
either 37ºC (core) or 25ºC 
(peripheral). 
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for electrical conduction. This study aimed to achieve drug delivery through the use of the 
following three groups of materials as the foundation of the device: 
• An EAP was incorporated into the device due to its conduction of electrical conductivity 
into the delivery device. These included PANi or PPy and its derivatives. 
• Hydrogel was used as the main component where the drug was held and stored as a 
matrix. A hydrogel consists of a 3 dimensional network of a crosslinked polymer-based 
network. In order to enhance the performance of the hydrogel, one may incorporate 
acidic or basic groups into the hydrogel. These hydrogels are termed polyelectrolyte or 
ionized hydrogel and consists of three species, namely the solid matrix network, 
interstitial fluids and ionic species.  
• Analgesic drugs which would be used for the purpose of controlled drug release. These 
drugs may be conventional Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as 
indomethacin, ibuprofen, diclofenac, mefenamic acid or any of the COX II inhibitors, 
including COX II specific inhibitors such as celecoxib. Although drugs of the opioid class 
are used for moderate to severe chronic pain, it was less popular due to its abusive 
properties (Glajchen, 2001; Weinstein, 2000 and Furstenberg, 1998). Long-acting opioid 
drugs have to be administered daily and do not offer controlled on-site delivery. In 
addition, the local release of opioids still depends on the action of the drug at the central 
nervous-system. Local release of opioids therefore offered no benefit for the patient. The 
use of NSAIDs would be more beneficial as a chronic pain relief in this implantable 
device.  
 
3.3.2. Model drugs incorporated into the responsive hydrogel system 
There were several NSAIDs which were considered for the design of the SAPD. Drugs such 
as indomethacin, ibuprofen, diclofenac sodium and aspirin were used. These drugs were 
selected due to the high potency and the ability of the drug to act locally, via inhibition of 
COX II in the cell membrane, when released directly at the site of pain. 
 
3.3.2.1. Indomethacin as a model drug in the Stimuli-Actuated Polymeric Device 
Indomethacin is a potent drug which exhibits analgesic, anti-inflammatory and anti-pyretic 
properties. It is used for conditions such as acute gout attacks, ankylosing spondylitis, 
osteoarthritis, rheumatoid arthritis and other musculo-skeletal disorders which resulted in 
chronic pain. The chemical structure of indomethacin was depicted as in Figure 3.5. 
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Dipole
Dipole
 
Figure 3.5. The chemical structure of indomethacin. 
 
Indomethacin is practically insoluble in water, mainly due to its minor dipole movement which 
existed on the oxygen and the chlorine atoms as indicated. The majority of the compound 
was still composed of long carbon and hydrogen chains, which decreased its water solubility. 
The solubility did increase when placed in slightly alkali solvents or when the temperature of 
the solvent is elevated. Indomethacin has a solubility of 1 in 50 in alcohol and 1 in 30 in 
chloroform (Martindale, 1996). Indomethacin is primarily an anionic drug, and therefore can 
interact with other cations, such as heavy metal ions. At higher concentrations, indomethacin 
is capable of self aggregation. Indomethacin dissolves slowly at a pH lower than 8, and is 
insoluble at an acidic pH. However, when indomethacin is immersed in aqueous mediums of 
pH 9 or higher, degradation starts to occur. The degradation occurs more rapidly when the 
pH is 10. Therefore, it is important to dissolve indomethacin in a buffer where the pH is 
controlled (Fini, 2001). The molecule of indomethacin has an indole moiety linked with p-
chlorobenzoic acid via an amide bond, and it is this link that is responsible for the 
degradation of this drug at higher pH. The presence of a bulky hydrophobic head and a polar 
head makes this molecule a surfactant. Furthermore, this drug has shown electroactive 
properties and is capable of undergoing reduction under electric current. It is ideal that 
indomethacin exhibits solubility at pH 7.4, as this renders this drug suitable for release from 
a subcutaneous implantable device. 
 
Thermal stability of indomethacin has been proven to be good, even at high temperatures. 
Indomethacin heated under the temperature of 95ºC for 15 hours has shown no signs of 
changes in structure (Lu, 2007). Indomethacin has been dissolved in 100ºC of water in order 
to enhance its solubility which has also shown no signs of degradation when carried out in 
the laboratory. Therefore, it is quite possible to use indomethacin as a drug for the purpose 
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of a stimulus actuated polymer device provided that the electric current used for the 
stimulation is low. 
 
Indomethacin is readily absorbed by the gastro-intestinal tract (GIT) and a peak plasma 
concentration is reached after 2 hours. Protein binding of indomethacin is 99% and it is 
found in synovial fluid, the central nervous system (CNS) and the placenta. Since 
indomethacin exhibits such a high protein binding, it is a desirable drug to be delivered 
locally to the target site, as only a low dose is required to achieve therapeutic effect. The half 
life of indomethacin may range from 2.6 hours to 11.2 hours in adults and is metabolized by 
liver into its glucuronide conjugate and is excreted predominantly in the urine (Martindale, 
1996). 
 
3.3.2.2. Calibration curve of indomethacin through serial dilution from a stock solution 
of indomethacin 
In order to determine the amount of indomethacin present in any given sample, a calibration 
curve of indomethacin was plotted by the use of an UV-visible spectroscopy. This curve 
plotted a graph of concentration versus absorbance which enabled us to work out the 
amount of drug present according to the readings obtained from the UV-visible 
spectroscopy. In order for the absorbance to be measured, the indomethacin was mixed with 
the PBS until fully dissolved. The UV wavelength used for this spectroscopy was 318nm 
(Kamal, 2008 and Anoopkumar-Dukie, 2003). The initial plot for the calibration curve had a 
concentration of 0.0625mg/mL, which was then diluted in the ratio 4:1 of drug solution: PBS.  
This calibration curve was depicted as Figure 3.6 
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Figure 3.6. The calibration curve for the drug indomethacin in pH7.4 PBS at 25ºC.  
 
3.3.2.3. Diclofenac sodium as a model drug in the Stimuli-Actuated Polymeric Device 
Diclofenac sodium is another drug which falls under the class of NSAIDs, which was the 
sodium salt of the drug diclofenac. The reason for incorporating the sodium salt is to 
increase the water solubility of diclofenac. Diclofenac on its own was sparingly soluble, 
whereas diclofenac sodium is freely soluble in water. Another common salt which is used 
with diclofenac is potassium salt. Both salt are combined with the drug and are protonated 
once they are in the gastric acid, with the only difference being the potassium salt offers 
higher water solubility for diclofenac as compared to the sodium salt. The chemical 
structures of diclofenac sodium and the effect that sodium salt has on water solubility are 
shown as in Figure 3.7. 
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Figure 3.7. The effect of sodium salt on diclofenac. 
 
In the case of unsalted diclofenac, the dissociation of the diclofenac forms H3O
+ ions in the 
surrounding medium, thus resulting in an acidic surrounding solution. On the other hand, the 
sodium salt forms NaOH which results in alkaline solution. Diclofenac is insoluble in an 
acidic pH (1-3) but soluble in basic pH (5-8) (Manjunatha, 2007). Therefore, the diclofenac 
with the sodium salt would be more soluble in water as compared to the unsalted diclofenac. 
 
Diclofenac was rapidly absorbed from the GIT, but 50% of the dosage form is subject to first-
pass metabolism. Like indomethacin, diclofenac is more than 99% protein bound at 
therapeutic dose, which indicates that a low dose is required at the target site in order to 
achieve therapeutic dose. Diclofenac has a terminal half life of 1-2 hours, which indicates a 
fast acting drug with fast excretion. It is excreted mainly through urine and a minor portion 
through the bile. Conditions which are indicated for diclofenac sodium includes musculo-
skeletal and joint disorder such rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. 
Other conditions include bursitis, tendonitis, sprains, strains and other chronic pain condition. 
3.3.2.4. Calibration curve of diclofenac sodium through serial dilution from a stock 
solution of diclofenac sodium 
In order to plot a calibration curve of diclofenac sodium, the diclofenac sodium was initially 
dissolved in PBS. An initial concentration of 0.05mg/mL was used because it has a 
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favourable absorbance of 1,131. Then it was diluted in a 4:1 drug solution: PBS and the 
absorbance were recorded after every dilution. For this calibration curve, a wavelength of 
276nm was used (Aurora-Prado, 2002). The calibration curve was then plotted and depicted 
as in Figure 3.8. 
 Concentration (mg/mL)
0.00 0.01 0.02 0.03
A
bs
or
ba
nc
e
0.0
0.2
0.4
0.6
0.8
1.0
1.2
y = 27.257 x
R2 = 0.9943
 
Figure 3.8. The calibration curve for the drug diclofenac sodium in pH7.4 PBS at 25ºC.  
 
3.3.2.5. Aspirin as a model drug in the Stimuli-Actuated Polymeric Device 
Aspirin is a salicylate drug which contains anti-pyretic, anti-inflammatory and analgesic 
properties. In low doses, it also has an anti-coagulant effect and can be used for prevention 
of heart attacks, strokes and blood clot formation for patients with a high risk for emboli 
(Manson, 1990). The main side effect of aspirin is gastro-intestinal ulcers, tinnitus and blood 
thinning. When used in children under the age of 16, there is a possible risk of causing 
Reye’s syndrome (Macdonald, 2002). The structure of aspirin is demonstrated in Figure 3.9, 
along with the salicylate group for comparison. 
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Phenolic hydroxyl group
Sailcylic acid
 
Figure 3.9. The chemical structures of aspirin and salicylate when compared to each other. 
Aspirin may be synthesized by esterification of the phenolic hydroxyl group of the salicylic 
acid. 
 
Aspirin is a weak acid and ionizes slightly after it is ingested. A reason why aspirin should be 
used as a medication for this implant is due to its acidic nature, aspirin has a low solubility in 
the stomach, and is only absorbed in the large intestine. Therefore, a longer time is required 
to achieve Cmax. Protein binding of aspirin is estimated to be approximately 58.3% ± 9.6% 
(Ghahramani, 1998). Furthermore, as much as 80% of the therapeutic dose of aspirin is 
metabolized by the liver via conjugation (Levy, 1972). Due to its poor availability of drug at 
the target site, it is more prudent to incorporate aspirin into this implant so that it may be 
released directly at the target site and at the desired moment.  
 
3.3.2.6. Calibration curve of aspirin through serial dilution from a stock solution of 
aspirin 
In order to plot a calibration curve for aspirin, the drug was initially dissolved in PBS to form 
a solution. An aspirin solution with a concentration of 0.5mg/mL has an absorbance of 
1.3307. The wavelength of which aspirin absorbs the UV light was determined as 320mm 
(Li, 2009). The calibration curve was then plotted and depicted in Figure 3.10. 
Aspirin Salicyclic Acid 
henolic Hydroxyl 
Group 
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Figure 3.10. The calibration curve for the drug aspirin in pH7.4 PBS at 25ºC.  
 
3.3.2.7. Ibuprofen as a model drug in the Stimuli-Actuated Polymeric Device 
The last drug which was considered for the incorporation of the SAPD was ibuprofen. Like 
many drugs mentioned in this section, it is a NSAID and acts through COX II inhibition and is 
mainly used for the treatment of arthritis, primary dysmenorrhoea, fever and other 
inflammatory conditions. It is derived from propionic acid (Adam, 1992). This therefore 
explains the poor solubility of ibuprofen in water and the increased solubility under basic 
conditions. The structure of ibuprofen is depicted in Figure 3.11. 
 
 
 
Figure 3.11. The chemical structure of ibuprofen. 
 
The therapeutic dose of ibuprofen is 200-400mg three times daily, preferably after meals in 
order to prevent gastric ulceration. However, the pharmacokinetics of ibuprofen has 
indicated a bioavailability of approximately 75% and a protein binding of 99%. This indicates 
that ibuprofen is highly potent and a low dose is required at the target site in order to have 
anti-inflammatory effects. The half life is approximately 2 hours, which indicates a rapid 
Propionic Acid 
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onset of action, and thus its suitability for use in the SAPD. Another important fact to note is 
that ibuprofen exists in both the (R) and the (S) enantiomers. In a human body, only (S)-
enantiomers exhibits anti-inflammatory property, however, the body is capable of converting 
the inactive (R)-enantiomers into the active (S)-enantiomers (Avgerinos, 1991). The 
existence of the two isomers should not have interference on the use of this drug in the 
SAPD. 
 
3.3.2.8. Calibration curve of ibuprofen through serial dilution from a stock solution of 
ibuprofen 
Since ibuprofen exhibits poor solubility in the PBS, the PBS has to be heated to boiling point 
before the ibuprofen was added. An initial concentration of 1mg/mL was used, which was 
scanned under a UV wavelength of 273nm (Manzano, 2008). The calibration curve was then 
plotted as depicted in Figure 3.12. 
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Figure 3.12. The calibration curve for the drug ibuprofen in pH7.4 PBS at 25ºC.  
 
3.3.3. Preparation of the crosslinked polyvinyl alcohol Stimuli-Actuated Polymeric 
Device with indomethacin as a model drug 
  
3.3.3.1. Composition of the drug-loaded polyvinyl alcohol/polyaniline-based 
Stimuli-Actuated Polymeric Device 
Four different devices were constructed and loaded with indomethacin in order to assess its 
electroactivity. The compositions of the four devices were depicted in Table 3.6. The method 
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of preparation for the first device was different than that of the other three devices and is 
discussed separately. In these devices, the PVA formed the hydrogel component, aniline 
and PANi acted as the EAP, Eudragit® formed the crosslinker and indomethacin was the 
drug intended for targeted delivery. 
 
Table 3.1. The composition of all four devices synthesized. Indomethacin was loaded in all 
four devices, while varying grades of Eudragit® and PVA was used in order to assess 
difference in indomethacin released under the presence of electric current. 
Reagents for the PVA/PANi -based SAPD 
 
Device 1   -    PVA 8/88 (10g) 
- Aniline (5g) 
- Ammonium Persulfate (6.126g) 
- Indomethacin (100mg) 
Device 2   -    PVA 8/88 (5g) 
- PANi emeraldine doped (1.5g) 
- Eudragit® RL 100 (5g) 
- PEG 4000 (5g) 
- Indomethacin (100mg) 
Device 3   -    PVA 8/88 (5g) 
- PANi emeraldine doped (1.5g) 
- Eudragit® L100-55 (5g) 
- Indomethacin (100mg) 
Device 4   -    PVA 8/88 (5g) 
                  -     Eudragit® L 100-55 (5g) 
                  -     PEG 4000 (5g) 
                  -     PANi emeraldine doped (1.5g) 
                  -     Indomethacin (100mg) 
 
 
3.3.4. The synthesis of drug-loaded Stimuli-Actuated Polymeric Device 
Device 1 was prepared by dissolving PVA (10g) into 100mL of 1.0M HCl acid. Aniline (5g) 
was added into a 50mL of 3.0M HCl acid and stirred until fully dissolved and added into the 
polyvinyl alcohol solution. This mixture was left to cool in an ice bath. Ammonium persulfate 
(6.126g) was dissolved in another 50mL of 3.0M HCl acid separately and added drop-wise 
into the PVA/Aniline mixture for a time period of one hour whilst being stirred vigorously in an 
ice bath. This was to ensure that the polymerization of aniline was carried out under cold 
conditions. The ammonium persulfate acts as an oxidizing agent and an initiator to the 
polymerization of aniline. Following the addition of ammonium persulfate, the suspension 
was left to stir in an ice bath over a period of five hours before it was left in the fridge 
overnight for the polymerization to complete. The suspension was placed under a fume 
cupboard for 96 hours at room temperature in order to achieve maximum evaporation of the 
solvent. This method was adopted from a study by Mirmohseni and co-workers (Mirmohseni 
et al., 2003). It was immersed in a 1:1 solution of acetone and 1.0M HCl solution for 12 
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hours to wash away all unreacted monomers. The hydrogel was dried for another 24 hours 
to ensure further evaporation of solvents. In order to load drugs into the system, 100mg 
indomethacin was dissolved in 100mL of heated PBS, the hydrogel was dissolved in 100mL 
heated distilled water and the two solutions were mixed together. Since PBS is miscible with 
water, it would ensure a homogenous mixture of the drug into the PVA hydrogel. The 
resulting drug-loaded PVA hydrogel was then left to stand in a mould until solidified. 
 
The preparation for Device 2, 3 and 4 were identical, except for variation of the ingredients 
used (Table 3.6). PVA (5g) was dissolved in 20mL of boiling water followed by cooling to 
room temperature. Eudragit® (5g) and PEG 4000 (5g) were dissolved in two separate 
beakers with 20mL dichloromethane and mixed together once both were fully dissolved. 
Indomethacin (100mg) was added into the Eudragit®/PEG 4000 mixture and stirred until 
dissolved followed by addition into the cooled PVA solution. Due to the immiscibility between 
dichloromethane and water, the volume of water was kept to a minimum of 20mL. The 
resulting emulsion was blended with a pestle and mortar for ten minutes, followed by 
homogenizer for one minute. The emulsion was poured in a mould and left to dry in a fume 
cupboard for a period of 96 hours to ensure evaporation of the solvent. Once dried, the 
SAPD was rinsed with distilled water to ensure removal of any drug not incorporated into the 
hydrogel. 
 
3.3.5. Gel compression measurement of the Stimuli-Actuated Polymeric Device 
After the SAPD was synthesized, the hydrogels were tested for their strength to withstand 
forces. This was important as gel compression allowed us to assess the degree of 
crosslinking in the hydrogel. Gel strength was assessed with the use of a texture analyzer. 
The SAPDs were weighed and placed onto the TA.XT.plus Texture Analyzer (United 
Scientific, Gauteng, South Africa) where it was compressed by the rounded end probe. In 
this test, the rate of compression and time was set as a constant, while the force required for 
such compression was measured. The Texture Analyzer was set to move at a rate of 
1.535mm/sec for a period of 2.890 seconds. The total compression into the hydrogel is 
depicted as Equation 3.1. 
 
Total Compression = Rate of movement  Time             Equation 3.1   
 
According to Equation 3.1, the total compression into the hydrogel was 4.436mm. The force 
required for such compression was measured and the result is depicted in Table 3.7. 
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Table 3.2. The force required for compression of each device as measured by the texture 
analyzer. 
Hydrogel Device Force Measured During Compression 
 
Device 1 
 
0.9969 N 
Device 2 1.3011 N 
Device 3 0.9750 N 
Device 4 0.0011 N 
 
 
Based on the results obtained in Table 3.7, it was noted most force was required for the 
compression of Device 2. This may indicate an increased crosslinking between PVA and 
Eudragit® RL when compared to Device 1 and 3, while Device 4 required the least force for 
compression. This indicated that Device 4 may have to be handled with care due to its weak 
structural integrity and may not be favoured as a pharmaceutical formulation. All hydrogels 
were capable of returning to its original shape after compression which suggested that the 
yield value for these hydrogel may be much higher.  
 
3.3.6. Surface morphology of the Stimuli-Actuated Polymeric Device  
The next part was to assess the surface morphology of the SAPD. The surface morphology 
was closely linked to the texture and also gave an indication of the drug release profile of the 
SAPD. A porous hydrogel should release drug easier as opposed to a hydrogel which 
possessed a non-porous structure. The surface morphology of the SAPD was determined by 
using light microscopy. In addition, a porous hydrogel would probably be preferred due to its 
increased ability to absorb solvents and faster drug release profile as opposed to non-porous 
hydrogels. Surface morphology was captured under 40X magnification. Figure 3.13 a-d 
depicted the surface morphology of the 4 SAPDs. 
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Figure 3.13. The surface morphology of Device 1-4 under 40X magnification, which showed 
a non-porous surface morphology. 
 
Device 2, 3 and 4 have shown enhanced porosity in comparison to Device 1. This indicated 
that Device 2 may be the favoured Device, due to its porous structure and its ability to 
withstand high stress. Although Device 1 and Device 3 have both shown promising ability to 
withstand stress, Device 1 possessed a smooth surface morphology and therefore drug 
release from Device 1 may be hindered. Thus far, Device 2 and 3 seemed to be the most 
promising for the purpose of drug delivery. 
 
3.3.7. Setup of the circuit for in vitro assessment of drug release from the Stimuli-
Actuated Polymeric Device in the presence of an electric current 
In order to determine the drug release profile of the drug-loaded SAPD, the devices were 
immersed into 100mL of PBS and electric currents were allowed to pass through it. The 
source of the current was obtained from a 9V battery cell. Copper wires 20cm in total length 
with a diameter of 2mm were used as the conductor and the electrodes used were iron 
electrodes. A multi-meter was connected in series in order to assess the amount of current 
passing through the circuit at any given time. The setup of the circuit was as depicted as in 
Figure 3.14 
 
a) b) 
c) d) 
0.05cm 0.05cm 
0.05cm 0.05cm 
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Figure 3.14. The setup of the circuit where drug release profile of the SAPD was conducted. 
 
The devices were placed into 100mL of PBS and 9V of potential difference was applied to 
the circuit. The reading on the multi-meter indicated that 30mA of currents were passing 
through the circuit at the time of testing. PBS samples of 5mL were drawn via a syringe and 
replaced with 5mL of fresh PBS at various time intervals. The samples were analyzed for 
any presence of drugs in order to assess the behaviour of drug of the device. The time 
intervals for this study were 1, 2, 3, 4 and 5 minutes. These samples were tested for drug 
concentration via the use of an UV-visible spectroscopy. For comparison purpose, the 
device was divided into two pieces and one half was placed in 100mL of PBS in the absence 
of electric current to serve as control. Samples in the control group were collected at the 
same time intervals and assessed for any difference in drug concentration than that of the 
experiment. 
 
3.3.8. The drug entrapment efficiency of the Stimuli-Actuated Polymeric Device  
In order to test the drug entrapment of these devices, Device 4 was duplicated and loaded 
with 120mg of indomethacin. The Device weighed a total of 4.295g. This test was done in 
triplicate in order to ensure a consistent result. For the first test, a portion of the device with a 
mass of approximately 22mg was removed and dissolved in 80mL of heated PBS with the 
aid of a homogenizer. A sample of 1mL was taken from the 80mL and diluted with 4mL PBS. 
This diluted sample was scanned under UV-visible spectroscopy and the UV absorbance 
recorded was 0.01A.  
 
Multimeter Cell 
Electrodes 
pH7.4 PBS 
SAPD 
Copper Wire 
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0.01=9.7735 x                  
 
Which gave us  equals 0.0010mg/mL in the 1:4 diluted samples. Working backwards, we 
multiplied by five to obtain the amount of drugs in 1mL of the sample, and finally multiplied 
by eighty to obtain the total amount of drug in the 22mg sample which was dissolved in 
80mL PBS. Therefore, the total amount of drug present in the entire device equals 0.409  
(4295/22) = 79.85mg and the total drug which was entrapped equals 66.54 % 
 
For the second test, Device 4 was duplicated, with a total weight of 8.565g and loaded with 
200mg indomethacin. 0.430g of sample was removed and dissolved in 100mL PBS, after 
which 1mL was diluted with 4mL of PBS again and scanned under the UV-visible 
spectroscopy. The reading obtained was 0.121A. We can therefore calculate the amount of 
drug entrapped in the device by using the same method for the first drug entrapment test. 
The total amount of drug present equated to 6.2 mg indomethacin in the 0.430g sample. 
Therefore, the drug entrapment efficiency was 61.74% 
 
For the third test, Device 4 was duplicated and loaded with 200mg of indomethacin. The total 
weight of the device was 7.654g and a 0.385g sample was removed and assessed. The 
sample was dissolved in 100mL PBS, after which 1mL sample was extracted and diluted 
with 4mL PBS. The results obtained from the UV/visible spectroscopy indicated an 
absorbance of 0.145A. Therefore, the total amount of drug in the 0.385g sample was 
7.418mg. This equated to 147.474g of indomethacin in the Device and a drug entrapment 
efficiency of 73.737% 
 
From the above three tests, the drug entrapment efficiency of the device fell approximately in 
the range of 60-70% during synthesis.  
 
3.3.9. The amount of drug release from Stimuli-Actuated Polymeric Device under the 
influence of electrical current 
The samples were previously evaluated for any presence of drug by employing the UV-
visible spectroscopy. The results obtained for both experimental and control Devices 1-4 is 
shown in Tables 3.8-3.11. The results are obtained in UV absorbance at a wavelength of 
318nm. Study done on PANi has indicated that PANi has an absorbance peak at 365nm, 
460nm and over 820nm (Nabid, 2008). 
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Table 3.3. The UV-absorbance of samples collected from Device 1. 
Device 1 1 minute 2 minutes 3 minutes 4 minutes 5 minutes 
 
Experiment 
(4.637g) 
 
0.0001 
 
0.0001 
 
0.0002 
 
0.0002 
 
0.0002 
Control 
(4.204g) 
 
0.0001 0.0001 0.0001 0.0002 
 
0.0002 
 
As indicated in Table 3.8, there was no drug release from both the experiment and the 
control. There was negligible difference with regards to the amount of drug present in the 
sample and this device was not electroactive. 
Table 3.4. The UV-absorbance of samples collected from Device 2. 
Device 2 1 minute 2 minutes 3 minutes 4 minutes 5 minutes 
      
Experiment 0.055mg 0.054mg 0.041mg 0.044mg 0.046mg 
Control 
 
0.015mg 0.016mg 0.019mg 0.015mg 0.020mg 
 
The results obtained from Device 2 have indicated an enhanced release of indomethacin in 
the presence of electric current, as opposed to the control, which had a decreased rate of 
release. The slight decrease in drug concentration between various time intervals may be 
due to the dilution of the conducting medium when 5mL of PBS was used to replace the 
samples that were taken. These values were transformed into the quantity of drug present in 
the sample and would be discussed further on. 
Table 3.5. The UV-absorbance of samples collected from Device 3. 
Device 3 1 minute 2 minutes 3 minutes 4 minutes 5 minutes 
      
Experiment 0.213mg 0.233mg 0.258mg 0.280mg 0.338mg 
Control 
 
0.106mg 0.100mg 0.102mg 0.129mg 0.219mg 
 
Results from Device 3 have also indicated an enhanced release of indomethacin in the 
presence of electrical stimulation.  
Table 3.6. The UV-absorbance of samples collected from Device 4. 
Device 4 1 minute 2 minutes 3 minutes 4 minutes 5 minutes 
      
Experiment 0.051mg 0.111mg 0.084mg 0.082mg 0.115mg 
Control 
 
0mg 0mg 0mg 0mg 0mg 
 
Device 4 successfully released drug only in the presence of electrical current, while 
withholding the drug in the absence of electrical stimulation. Device 4 seemed the most 
promising following the assessment of the drug release profile in the presence of an 
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electrical field. However, the weak structural integrity meant that it should be handled with 
caution. It was also composed of a porous structure which indicated that it was capable of 
fluid absorption. The initial drug release study has shown that Device 4 may have the 
optimum drug release profile, however, further studies should be performed in order to 
assess the consistency and the mechanism of drug release of Device 4. 
 
According to these results, indomethacin released from a Device 4 was too low to obtain 
therapeutic effects. This may be due to one of the three following reasons:  
• The total amount of indomethacin used (100mg) was insufficient. Increased quantities of 
indomethacin could be use in future in order to assess for any possible increase in drug 
release from the SAPD. 
• Electro-responsive behaviour from a hydrogel was mainly a surface phenomenon (de las 
Heras Alarcon, 2005) and initiating a response rapidly from the centre of a hydrogel is 
difficult. The surface area of the device could be increased to in order to enhance its 
drug release. 
• Even though 100mg of the drug was used for the synthesis of these devices, the drug 
entrapment was only approximately 60-70%. Furthermore, the device was divided into 
halves when tested for drug release. These devices were halved as the presence of 
excess polyaniline in the testing solution hindered the process of UV spectroscopy. 
Therefore, rendering only approximately 30-35mg of the indomethacin left in the device 
during the test. The SAPDs were only halved during this study only. 
 
Although Device 3 has shown a release of a therapeutic dose of indomethacin, the drug 
leakage presented a problem and could not be used. This leakage should be addressed 
through better understanding of the physicochemical properties of the SAPD. 
 
3.3.10. Chemical structure analysis of the Stimuli-Actuated Polymeric Device 
In order to obtain better elucidation of the chemical structures of these four devices, FTIR 
was used in order to assess the IR peaks. By analyzing these peaks, it allowed us to 
observe any difference in chemical composition of the four devices, and therefore the cause 
of difference in drug release. Figure 3.15-3.18 depicts the FTIR results of the individual 
components of the devices, while Figure 3.19-3.22 depicts the FTIR results of Device 1-4 
respectively. Peaks were labelled as (wavelength, % Transmittance). 
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Figure 3.15. FTIR spectrum of Indomethacin. 
 
Figure 3.16. FTIR spectrum of polyvinyl alcohol.  
Indomethacin (tom)_1
Name Description
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Figure 3.17. FTIR spectrum of Eudragit®. 
 
Figure 3.18. FTIR spectrum of polyaniline. 
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Figure 3.19. FTIR spectrum of Device1. 
 
 
Figure 3.20. FTIR spectrum of Device 2. 
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Figure 3.21. FTIR spectrum of Device 3. 
 
Figure 3.22. FTIR spectrum of Device 4. 
 
The results obtained from the FTIR allowed us to conclude the following: 
• Device 2 lacked the broad peak between 3200-3600cm-1 which indicated the lack of 
hydrogen-bonded alcohols, or phenolic groups. 
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• Weak bands at 3000cm-1 and 1600cm-1 followed by a moderate peak between 800-
1000cm-1 indicated a para-substituted aromatic group as seen in PANi. These peaks 
were observed in all 4 Devices. Therefore PANi was confirmed as a component in all 
devices and this was further substantiated by an increased drug release when an electric 
current was applied across the device.  
• In general one can observe that the FTIR spectra of the devices were a composite of the 
individual ingredients, with the exception of Device 2 which lacked the broad peak from 
3200-3600nm of polyvinyl alcohol. Other variations may be due to the different ratios of 
the ingredients. 
• The peaks exhibited by Device 1 and Device 4 were very similar, although it exhibited a 
very different drug release profile. This indicated that even though similar chemicals 
were used, the method of synthesis for the device also greatly alters the drug release 
profile. This may be attributed to the varying degree of crosslinking when using different 
methods for synthesis. This may be substantiated by the presence of bands at the same 
wavelength but with varying intensity between Device 1-4. 
 
3.3.11. Proposed release mechanism of the Stimuli-Actuated Polymeric Device 
 
The information that was obtained from this pre-formulation study has indeed shown that the 
use of PVA/ PANi in the SAPD does enhance the release of indomethacin upon the 
activation of an electric current. Although the crosslinking of the hydrogel enabled it to 
withhold more drug molecules, it also limited the rate of drug release from the hydrogel. 
Another important element which seemed to affect drug release was possibly the porosity of 
the hydrogel formed. As seen from the data obtained from Device 1, there was a lack of 
porosity as compared to Device 2, 3 and 4. This resulted in no drug release from Device 1, 
as compared to Device 2, 3 and 4. The drug entrapment of these devices also ranged from 
60-70%.  
 
A study done by Murdan and co-workers (2003) has suggested three possible mechanisms 
by which the movement of a drug out of the hydrogel may be controlled (Murdan et al., 
2003). These mechanisms include: 
• Forced convection of drug as the hydrogel de-swells. 
• Drug electrophoresis due to migration of drug toward charged electrodes. 
• Drug liberation when the hydrogel was eroded upon electrical stimulation. 
 
66 
 
The mechanism of the effusion of drugs from the polymeric hydrogel device was thought to 
be that similar to that of iontophoresis. Under the presence of electric current, the anionic 
drug indomethacin (Fini, 2001) was drawn towards the positively charged cathode. It was 
this attractive force that enhanced the diffusion of the drug out of the SAPD. This mechanism 
was depicted in Figure 3.23. When a cross-linked Eudragit®-polyethylene glycol system was 
incorporated into the hydrogel, the drug was held in the hydrogel by a 3-dimensional network 
and movement out of the hydrogel toward the cathode may be hindered. This may have 
accounted for the decrease in drug release.  
 
 
Figure 3.23. The possible mechanism for movement of the drug indomethacin out of the 
hydrogel 
 
This mechanism was similar to that of iontophoresis which involves the migration of a 
charged drug towards an oppositely charged electrode. From the data obtained, a 
crosslinked hydrogel combined with PANi and indomethacin may prove to be useful for the 
purpose of the controlled release of indomethacin. 
 
3.4. Concluding remarks 
 
This study has shown that the use of PANi as an electro-responsive polymer in a crosslinked 
hydrogel may be used for the controlled release of indomethacin. The degree of response 
from these polymers may vary depending on the conditions of synthesis of these polymers. 
EAPs incorporated into a crosslinked hydrogel have shown electrical conductivity, and the 
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release of indomethacin was enhanced when indomethacin was blended into the hydrogel 
with an EAP in the presence of an electric current in the present study. Hydrogel systems 
which were undoped did show drug release even without the presence of an electrical 
current, although the degree of drug release was to a much smaller extent. The crosslinking 
of the hydrogel did successfully withhold the drug within the hydrogel, but such crosslinking 
also retarded the extent of drug release in the presence of electrical stimulation. This release 
may be due to the repulsive force caused by the like-charges of the negatively charged 
electrons from the electric current and the negatively charged (anionic) drug indomethacin, 
or it may be linked to processes such as iontophoresis.  The use of PANi along with a 
crosslinked hydrogel may be a prospective drug delivery device for the controlled release of 
indomethacin by the means of an electrically-activated and controlled device in patients. 
 
Aniline, which underwent polymerization in the solution of polyvinyl alcohol in 1.0M HCl acid 
showed no response when placed in electric current for the purpose of controlled release of 
indomethacin. However, PANi emeraldine which was incorporated into the polymeric 
hydrogel device did indeed demonstrated enhanced release of indomethacin. These release 
rates have shown to increase linearly as time progresses. In order for these devices to 
become practical, characteristics such as increased drug release should be investigated 
further. In addition, the response time should not exceed 1-2 minutes. This could be 
achieved by increasing the surface area of the hydrogel which would allow more drugs to 
move towards the charged electrodes. The enhanced effect of drug release may yet require 
further research before it could be used optimally, however, it does prove to be a potential 
and novel system for the controlled release of indomethacin via the stimulation of electrical 
currents. 
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CHAPTER 4 
DESIGN AND FORMULATION OF A NON-SOLUBLE ELECTROACTIVE POLYMER-
INCORPORATED HYDROGEL SYSTEM FOR THE CONTROLLED RELEASE OF A NON-
STEROIDAL ANTI-INFLAMMATORY DRUGS 
 
 
 
4.1 Introduction 
 
Following the release of indomethacin from the SAPD, it was possible to construct an 
electroactive drug delivery system based on these preliminary designs. In order to achieve 
an improvement on the preliminary design, an understanding of chemistry was important. In 
this Chapter, we focused more on the chemical interactions which could possibly occur 
during the synthesis and release of the SAPD. Several factors were considered, such as 
drugs which carried negative charges which would be attracted to the positively charged 
cathode and vice-versa, while the degree of crosslinking would affect the amount of drugs 
entrapped in the system and its release profile. The degree of crosslinking may be 
determined by the amount of crosslinkers present, while the degree of polymerization was 
determined by the amount of initiators added with the monomer. Other factors such as 
methods which could be employed for incorporation of drugs and EAPs into the hydrogel 
system were also important, as the most efficient methods should yield the most stable 
system. 
 
One of the problems encountered in Chapter 3 was the inability of the system to form a 
homogenous solution when dichloromethane was added with water. Therefore, when the 
SAPD was left to stand to enable solvent evaporation, separation of dichloromethane and 
water occurred. In order to rectify this problem, the first approach was to repeat the study but 
using different solvents. The solvent employed should be more polar when compared to 
dichloromethane, thereby allowing better miscibility with water. This should enhance the 
homogeneity of the system and yield a more precise release of drug dosage.  
In the ensuing investigation, chloroform was used as a substitute for dichloromethane, since 
its chemical structure is similar to dichloromethane, although slightly more polar, which 
should exhibit better miscibility with water.  
 
 
69 
 
4.2. Materials and Methods 
 
4.2.1. Materials 
Chloroform (Unilab, Wadeville, Gauteng, South Africa) was used as a solvent. Polysodium 
styrene sulfonate (Sigma Aldrich, Steinhelm, Germany) was tested as a polyelectrolyte, 
Glycerine (Merck, Wadeville, Gauteng, South Africa) and tri-ethyl citrate (Sigma Aldrich, 
Steinhelm, Germany) was used as the plasticizer, Methylcellulose (Merck, Wadeville, 
Gauteng, South Africa) was assessed as a component of the hydrogel, Ethyl acetate, 
acetone, hexane, propylene glycol, liquid paraffin, chloroform, formic acid, sodium hydroxide, 
propionaldehyde, pyridine, formaldehyde and benzaldehyde were all obtained from Merck 
(Merck, Wadeville, Gauteng, South Africa) and used as solvents for the methylcellulose. 
Eudragit L100, S100, L100-55, E100, RS (Degussa, Darmstadt, Germany) was used as 
possible crosslinker with PEG 4000 (Merck, Wadeville, Gauteng, South Africa). Titanium 
dioxide, sodium benzoate, sodium thiosulfate, sodium chloride and potassium iodide (Merck, 
Wadeville, Gauteng, South Africa) were tested as salts for crosslinking. Diethyl 
acetamidomalate (DAA) (Fluka Chemie, Buchs, Switzerland) was also tested as a 
crosslinker for the hydrogel system. 
 
4.2.2. Determination of the physicochemical and physicomechanical properties of the 
Stimuli-Actuated Polymeric Device 
The determination of the physicochemical and physicomechanical properties of the SAPD 
was important as we could use this data to assess the storage conditions of the SAPD, 
factors which affect its drug release profile and its stability in various environments. The 
physicochemical and physicomechanical properties would be analysed by using an array of 
techniques and equipments which would be essential for the understanding of the SAPD as 
a controlled release system. 
 
4.2.3. Determination of chemical structures of the Stimuli-Actuated Polymeric Device 
Various tests were performed in order to assess the physicochemical characters of the 
SAPD. Chemical structures of the SAPD were assessed by using the Fourier Transform 
Infra-Red (Perkin Elmer, Life & Analytical Science Inc., Shelton, CT, USA) to determine if 
there were any chemical reactions between the EAP, the excipients or the drugs.  
 
4.2.4. Calorimetric analysis of the Stimuli-Actuated Polymeric Device 
Differential Scanning Calorimetry (DSC1 Stare, Mettler Toldeo System, Uster, Zurich, 
Switerland) was used to assess the chemical structures of the polymer and drug when 
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exposed to various temperatures. Phases such as glass transition, crystallization and 
melting point allowed assessment of the transition temperature and enthalpy of the EAP. 
The transition temperature would play an important role in deciding the physical 
characteristics of the polymer such as brittleness and elasticity.  
 
4.2.5. Determination of in vitro drug release from the Stimuli-Actuated Polymeric 
Device 
The quantity of drug released into the PBS solution assessment was done using Ultra Violet 
(UV) spectroscopy (Cecil CE 3021, Cecil Instruments Ltd, Milton, Cambridge, UK). UV 
spectroscopy determines the quantity of drugs present by measuring the amount of light 
refraction. Therefore, drug concentration at various time intervals was measured by taking 
5mL of the saline sample and running it under UV spectroscopy.  
 
4.2.6. Surface morphology and textural analysis of Stimuli-Actuated Polymeric Device 
Scanning electron microscopy (JSM 5600 Scanning Microscope, JEOL Ltd, Tokyo, Japan) 
will be used to determine the surface morphology of the SAPD. The SAPD would be viewed 
under high magnification and cross-linking or chain-shifting of the EAP may be visualised.  
 
4.2.7. Assessment of possible erosion in the Stimuli-Actuated Polymeric Device 
The erosion rate of the SAPD may be determined by weighing the difference in mass of the 
SAPD should any erosion occur. By using Equation 4.1, disk erosion under the absence of 
electrical stimulation was determined: 
% weight loss  Initial weight-Remaining Weight
Initial Weight
                                           Equation 4.1 
4.2.8. Electric conductivity test on the Stimuli-Actuated Polymeric Device 
Electric conductivity of the SAPD may vary when doped with various counter ions. This 
would affect the behaviour and tensile strength of the SAP. The conductivity would be 
assessed by using the OAKTON® TDS TestrTM (Model UD-35661-70, Solon, OH, USA). The 
electrode would be immersed in the saline solution and conductivity test would be performed 
on the SAPD. Conductivity was measured in µSiemens 
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4.3. Results and Discussion 
 
4.3.1. The use of chloroform for the formulation of a Stimuli-Actuated Polymeric 
Device and the assessment of drug release profile of chloroform-substituted device 
The implantable system was synthesized in this experiment using different solvent, in order 
to assess for any difference in drug-release profile of the SAPD. Chloroform was used in the 
place of dichloromethane, due to the triple chlorine atoms bound to the carbon atom. This 
would theoretically increase the dipole movement when compared to dichloromethane, 
therefore an increased polar and miscibility with water. With regards to the chemical 
structure of dichloromethane, the dipole movement occurs on the two chlorine atoms which 
renders it only slight polar and immiscible with water. By replacing dichloromethane with 
chloroform, we should be able to increase the miscibility of the two liquids. Figure 4.1 depicts 
the dipole movements of the two compounds. 
CCl
H
δ- δ+
Dichloromethane Chloroform
C
δ- δ-δ+
δ-
δ-
H
Cl
Cl Cl Cl
H
 
Figure 4.1. The dipole movements of dichloromethane and chloroform. In the case of 
dichloromethane, the dipole on both sides cancels each other out, while chloroform exhibits 
weak dipole movement from the third chlorine atom. 
 
For this study, the methods and materials used were identical to that mentioned in Chapter 3 
Section 3.3.5 for Device 2, with the exception that the dichloromethane which was used was 
replaced with chloroform. The resultant implant which was formed had a mass of 
3.1835±0.2436g and did indeed show less signs of separation between the individual 
chemicals used. In order to test the drug release profile of the implant, the implant was 
immersed in 40mL of PBS and a potential difference of 0.5V was applied for 40 seconds. A 
sample of 5mL was taken and assessed for presence of drug. The control showed no 
release of drug even after 20 minutes. The results were tabulated in Table 4.1.  
Table 4.1. The results obtained from the drug release assessment of the chloroform-
substituted SAPD.  
Time 40 seconds 80 seconds 120 seconds 160 seconds 200 seconds 
      
Drug (%) 
 
0.000261 
±0.000032 
0.000766 
±0.000122 
0.001214 
±0.000256 
0.001464 
±0.000381 
0.001507 
±0.000212 
 
Dichloromethane Chloroform 
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The implant was left in the PBS for another 72 hours and samples were taken in order to 
assess if there was any leakage of drugs into the PBS in the absence of electric current. 
Two samples of 5mL were taken and the results shown in Table 4.2.  
Table 4.2. The quantity of drugs present in the control sample after been immersed for 72 
hours.  
 Sample 1 Sample 2 
   
Drug (%) 
 
0.002576±0.000342 0.002489±0.000132 
 
The results shown in Table 4.2 have indicated that drug leakage was still a problem, even in 
the chloroform-substituted SAPD. One possible alternative was to employ different drug, 
which might yield different drug release profile and behaviour.  
 
4.3.2. The employment of diclofenac sodium as a model drug in the Stimuli-Actuated 
Polymeric Device  
A SAPD which was identical to the one synthesized in Chapter 4 Section 4.3.1 was made 
except the indomethacin was substituted with diclofenac sodium. Diclofenac alone is only 
slightly soluble in water, while its sodium salt is readily soluble in water and therefore the 
sodium salt was preferred. By dissolving diclofenac sodium in water and adding it into the 
SAPD, it ensured homogenous dispersion of the drug. The preparation and the drug release 
profile were done identically as mentioned in Chapter 3 Section 3.3.10. The drug 
assessment result of this implant was shown as per Table 4.3. 
Table 4.3. The drug release profile of the diclofenac-substituted implant after several time 
intervals. 
Time 40 seconds 80 seconds 120 seconds 160 seconds 200 seconds 
      
Drug (%) 0.000492 
±0.0000352 
0.000673 
±0.0000532 
0.000711 
0.0000843 
0.000847 
±0.000121 
0.000794 
±0.000084 
 
 
Firstly, the implant was assessed for any drug release in the absence of electric current. 
However, samples were taken every 5 minutes in order to determine the time when the drug 
leakage occurs, if any. The control implant was placed in 40mL PBS and 5mL samples were 
taken at 5 minutes interval to assess for any presence of drug. The results are tabulated in 
Table 4.4. 
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Table 4.4. The release of diclofenac sodium in the absence of the electrical current. 
Control 5 minutes 10 minutes 15 minutes 20 minutes 25 minutes 
      
Drug (%) 0 0.000873 
±0.000101 
0.000294 
±0.000021 
0.000361 
±0.000043 
0.000384 
±0.0000418 
 
 
This result has indicated that the drug leakage of the diclofenac-substituted system still 
occurred after 5-10 minutes. This indicated a problem which was not likely to be solved with 
substitution of drug since the molecular size of diclofenac sodium was relatively similar to 
other NSAID’s such as indomethacin or ibuprofen. Therefore, another way in which to obtain 
controlled drug release from the SAPD would be to manipulate the hydrogel. One way to 
achieve this was to increase the degree of crosslinking, which would decrease the 
absorption of the hydrogel while increasing its structural integrity. This meant that the drug 
was more likely to be entrapped within the hydrogel which would in turn reduce or remove 
any possible drug leakage in the absence of an electrical stimulation.  
 
The ensuing Sections focused on the possibility of using new materials for the synthesis of 
the SAPD in an attempt to resolve the drug leakage experienced. 
 
4.4. The investigation of prospective materials which could be used as an 
electroactive polymer-incorporated hydrogel for the purpose of an electrically-
controlled drug release system. 
 
4.4.1. Incorporation of polysodium styrene sulfonate as a polyelectrolyte hydrogel for 
the purpose of controlled delivery of diclofenac sodium 
In order to resolve the problem of drug leakage, polysodium styrene sulfonate (PSS) was 
chosen, due to its ability to dissociate completely in water which allows conduction of 
electrical current. In order to test the use of PSS as an electroactive hydrogel, 3 devices 
were synthesized, the first device with only PSS in order to test the efficacy of the 
electroactive hydrogel when PSS alone was used. The second and third had PANi and PPy 
respectively incorporated into the hydrogel as an EAP in order to enhance the electro-
conductivity, which allowed us to compare the drug release profile with that of a PSS 
hydrogel. The PSS system was incorporated as indicated in Table 4.5. 
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Table 4.5. The compositions of the modified Devices 5-7. 
Device Constituents 
 
Device 5 
 
PSS (1g) 
Diclofenac sodium (500mg) 
Glycerine (5mL) 
 
Device 6 
PSS (1g) 
 
PANi (100mg) 
Diclofenac sodium (500mg) 
Glycerine (5mL) 
 
Device 7 
 
PSS (1g) 
PPy (100mg) 
Diclofenac sodium (500mg) 
Glycerine (5mL) 
 
 
The implant was formulated by dissolving the PSS in 50mL of distilled water, followed by the 
diclofenac sodium and glycerine. Once all the components were dissolved, PANi and PPy 
were added into PSS Device 6 and PSS Device 7 respectively. These mixtures were 
homogenized for two minutes and left to stand for 72 hours until the water was evaporated 
from the system. 
 
These devices were unsuitable as an implantable device due to their water solubility when 
they were submerged in the water. Since PVA exhibited insolubility in water at room 
temperature once it dries out from a solution it was decided to incorporate the PSS with PVA 
to prevent the dissolution of the PSS device in the water. This was done by adding 1g of 
dissolved PVA into each of the three devices as a last step during the synthesis. The 
solution was left to dry and the resultant hydrogel would again be tested. The results have 
indicated that the addition of PVA did not resolve the problem. This may be attributed to the 
lack of crosslinking between the PSS and PVA, or any of the components of the hydrogel. In 
addition, PSS itself exhibited plasticizing effects, which further lowered the structural integrity 
of the PVA. Therefore, the use of a PVA-PSS hydrogel system was inefficient and alternative 
materials should be investigated. 
 
4.4.2. The use of methylcellulose as the hydrogel component of the Stimuli-Actuated 
Polymeric Device 
One of the possible solutions to prevent drug leakage from the implant was to use different 
materials as a hydrogel. For this part of the study, methylcellulose was selected as a 
hydrogel into which an inter-penetrating network of PANi would be synthesized. 
Methylcellulose was selected to form the basis of the hydrogel because it has relatively low 
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cost, non-digestible, biocompatible and hypoallergenic. The chemical structure of 
methylcellulose resembles a polymer consisting of glucose molecules linked together and is 
shown in Figure 4.2. When placed in solvents, the hydroxyl group loses a hydrogen atom, 
which results in an O- group and allows further chemical reactions. The CH3 group does not 
offer any possible interactions and is therefore not part of the crosslinking process. 
 
n
 
 
Figure 4.2. Chemical structure of methylcellulose. When dissolved in solvents, the OH group 
loses the hydrogen and allows chemical interactions. 
 
In order for the methylcellulose to form a hydrogel, it has to be initially dissolved in a solvent 
followed by drying. The reason for this is that methylcellulose may undergo crosslinking 
when dissolved in certain solvents. Once the solvent evaporated from the system, the 
methylcellulose remains crosslinked. The aim was to form a three dimensional structure 
which allowed hydration while still remaining intact when placed in water or PBS. Various 
solvents were investigated in this study and the dissolved methylcellulose was allowed to dry 
for 48 hours in order to ensure total evaporation of the solvent. For this study, 
Methylcellulose with a mass of 2g was weighed out and dissolved in 30mL of various 
solvents. It was homogenized for one minute and left to stand under the fume hood in order 
to allow solvent evaporation. The solvents used and the hydrogels formed may be 
summarized as Table 4.6. 
 
 
 
 
 
 
 
 
 
R = CH3 or H 
Interaction Point 
Interaction Point 
Interaction Point 
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Table 4.6. The reactions of various materials with methylcellulose. 
Reagents Results 
Acetone No crosslinking of methylcellulose was observed when methylcellulose 
was mixed with acetone. 
Ethyl acetate No crosslinking of methylcellulose was observed when methylcellulose 
was mixed with ethyl acetate. 
Hexane No crosslinking of methylcellulose was observed when methylcellulose 
was mixed with hexane. 
Propylene glycol Methylcellulose was slightly soluble in propylene glycol. When the 
solvent was left to evaporate from the mixture, the resulted product 
was one which exhibited a greasy texture. This also indicated a lack of 
crosslinking between the methylcellulose and made it unsuitable for a 
hydrogel. 
 
Liquid paraffin There was minimal dissolution of methylcellulose in liquid paraffin. 
When this mixture was left to dry, a slurry mixture was obtained which 
was unsuitable for hydrogel formation. 
Chloroform Chloroform had successfully crosslinked with the methylcellulose 
mixture and when left to dry. It formed a hydrogel capable of hydration. 
However, the structural integrity also broke down in water and did not 
remain intact 
Formic acid Formic acid had successfully crosslinked with the methylcellulose. 
When left to dry, the resulting product was a thin, hard film of 
transparent methylcellulose. When this film layer was placed in PBS, 
degradation had started to occur after 72 hours. 
Sodium hydroxide A transparent hydrogel was formed when the compound was left to 
dry. When the hydrogel was left in water, swelling had occurred after 
30 minutes, followed by degradation of the hydrogel, thus rendering it 
unsuitable for drug delivery. 
Propionaldehyde No chemical reaction was observed with this mixture and the result of 
this chemical combination was same as that of acetone combination. 
Pyridine Crosslinking of methylcellulose had occurred when pyridine was used 
as solvent and a hydrogel was obtained. Similar to the hydrogel 
obtained from sodium hydroxide, this hydrogel broke down under 
prolonged submersion in water 
Formaldehyde Crosslinking occurred rapidly when methylcellulose was mixed with 
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formaldehyde. When left to dry, the resulting hydrogel had a white 
gelatinous texture and was resistant to water degradation when 
immersed for 4 hours. Peripheral degradation of the hydrogel occurred 
after 24 hours of immersion, which also rendered this combination 
unsuitable as subcutaneous implant. 
Benzaldehyde No chemical reaction was observed and resulted in a white flaky 
powder forming with a distinct almond smell. 
 
After a series of tests conducted on methylcellulose as a component for the hydrogel, it was 
apparent that the reversible breakage of the crosslinked bonds rendered it unsuitable for the 
purpose of an implantable hydrogel. This reversible breakage of crosslinked bonds may be 
attributed to the high affinity of methylcellulose for any polar solvents. Crosslinking 
methylcellulose with various solvents was not capable of overcoming such affinity and 
crosslinked bonds broke down rapidly after the immersion of the hydrogel into a polar 
solvent. The concept of using methylcellulose was not feasible, as a sustained breakdown of 
this hydrogel would result in sustained release of indomethacin rather than a controlled 
release system. Alternative materials have to be investigated for the formation of an 
irreversible-crosslinked hydrogel. 
 
4.5. Assessment of prospective crosslinkers and solvents for the synthesis of the 
Stimuli-Actuated Polymeric Device 
 
4.5.1. Assessment of crosslinking behaviour between various grades of Eudragit® and 
polyethylene glycol 4000 
In an attempt to resolve the drug leakage experienced from the SAPD, three possible 
solutions were deployed into the implantable system. One was to increase the degree of 
crosslinking within the hydrogel system, which would result in a hydrogel system with 
increased mechanical property, but also higher drug entrapment and therefore decreased 
drug leakage. The second option was to employ a different hydrogel. Different hydrogel 
offers different physicomechanical properties and therefore different drug release profile with 
the possibilities of holding more drugs. The third option was to use a different model drug, 
since different drugs exhibits different pKa, solubility and various chemical and physical 
properties. However, a study done on various drugs has indicated that substitution of 
different drugs in the system does not effectively prevent the leakage of the drug. Therefore, 
the first two options were still the ideal methods for drug entrapment. Methylcellulose did not 
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provide sufficient crosslinking in order to withhold the drug. Alternative materials and 
methods should be investigated.  
 
This part of the test involved using different Eudragits® crosslinked with polyethylene glycol 
(PEG) in order to assess its crosslinking behaviour. PEG was selected as the crosslinker 
due to the two hydroxyl groups at the end of its chain which may be used to link the 
Eudragits®. Four different grades of Eudragit® were used, namely Eudragit® L100, Eudragit® 
S100, Eudragit® L100-55 and Eudragit® E100 in order to determine which grades exhibited 
the best crosslinking properties. All four of the Eudragit® has a functional group as to allow 
interactions with PEG. PEG with a high molecular weight should be used due to its 
intermediate hydrophobic property which would reduce the re-dissolution of the crosslinked 
hydrogel into any polar solvent and thus preventing any possible degradation of the 
hydrogel. The method of synthesis is depicted as follows: each of the above mentioned 
Eudragit® was weighed out into 2g and dissolved in 20mL of acetone. Similarly, 2g of PEG 
4000 was dissolved in 20mL of water. The dissolved Eudragit® solution was added to the 
PEG 4000 solution while being stirred. The results were presented as Table 4.7. 
Table 4.7. The reactions of various grades of Eudragit® 
Grades of Eudragit® Results 
L100 A crosslinked hydrogel was formed which exhibited degradation in 
the presence of PBS.  
S100 A slurry sticky solution was formed, which crosslinked instantly 
when PEG 4000 solution was added. When the resultant 
crosslinked product was left to dry, a brittle white mass was 
formed without any swelling or de-swelling properties, which made 
it unsuitable as a hydrogel. 
L100-55 The product formed was a slurry white crosslinked solution when 
mixed with PEG 4000. The product was left to dry for 48 hours 
under a fume hood. The result was a soft, white crosslinked 
network which was capable of water absorption. This was one of 
the favourable results which indicated that Eudragit® L100-55 
crosslinked with PEG may be used. 
E100 Insoluble in acetone 
 
The swellability of the SAPDs in this study was determined by any increase in size after 
submersion in the liquid until absorption was saturated. 
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4.5.2. The use of various solvents for the dissolution of Eudragit® and its effects on 
crosslinking 
After Eudragit® L100-55 was selected as a favourable material for the purpose of 
crosslinking with PEG 4000, the affects of the solvents used were investigated. The 
crosslinking method was identical to that which was described in Chapter 4 Section 4.5.1. 
However, instead of acetone been the solvent of choice for the Eudragit®, it was replaced 
with methanol, ethanol and isopropyl alcohol. These three solvents were chosen as 
Eudragit® L100-55 exhibited high solubility in all three of these solvents. The resultant 
product was compared against each other in order to assess for any difference in texture or 
quantity. In all three cases, the texture of the product was constant, although the yield 
varied. By using the method described in Chapter 4 Section 4.5.1, methanol had the highest 
yield, with the dried product weighing 3.652±0.349g, as compared to ethanol which was 
1.745±0.153g and isopropyl alcohol which only yielded 0.843±0.122g. This yield was also 
higher compared to acetone, which has a mass of 2.548±0.217g. According to the results 
obtained from this experiment, the solubility of Eudragit® L100-55 seemed slightly higher in 
methanol, therefore resulting in a higher yield of crosslinked hydrogel and was the solvent of 
choice. 
 
4.5.3. Assessment of drug entrapment efficiency of a crosslinked polyethylene glycol 
4000/Eudragit® hydrogel system 
From the four Eudragit® which was experimented with in Chapter 4 Section 4.5.1, the 
optimal materials which could be used for crosslinking was Eudragit® L100-55. A crosslinked 
PEG 4000 and Eudragit® system was made by initially dissolving 2g of PEG 4000 in 20mL 
water and 2g of Eudragit® dissolved in 20mL methanol in two separate beakers. In addition, 
100mg of indomethacin was dissolved in the methanol solution containing the Eudragit®. 
Crosslinking occurred when the two solutions were mixed with each other whilst being 
stirred. With the indomethacin dissolved with the Eudragit®, the drug should be entrapped 
within the hydrogel system as the crosslinking occurs. In this way, drug entrapment was 
determined by assessing the amount of the drugs in methanol before and after crosslinking 
has occurred. This was done by collecting 1mL of the sample from the 20mL crosslinking 
solution followed by sample assessment under UV/visible spectroscopy. The result had 
indicated an absorbance of 1.8180. The quantity equated to 1.98mg in the 20mL sample. 
The original amount of indomethacin in the 20mL sample was 100mg, therefore, the drug 
entrapment efficiency would equate to 100 – 1.983 = 98.017%. This method of drug 
incorporation has proved to be very efficient and may be suitable for the further development 
of the implant. 
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4.5.4. The stability of the Eudragit® crosslinked system in the presence of water and 
phosphate buffer solution 
Following the study done on the selection of a prospective crosslinker, Eudragit® L100-55 
has shown the best properties and was selected for this stability study. A crosslinked system 
was synthesized as per Chapter 4 Section 4.5.1 and immersed in water in order to assess 
for any leakage of drug from the device. After 24 hours of immersion, the sample was 
scanned under UV/visible spectroscopy and had exhibited no signs of drug leakage. The 
device was immersed in PBS and drug leakage was assessed again. Degradation of the 
SAPD in the PBS was visible with the naked eye as quick as 15 minutes after immersion. 
The degradation commenced on the periphery and the crosslinked SAPD soon dissolved 
into the PBS. This may be attributed by the possible pH sensitive nature of certain Eudragit® 
towards alkaline pH. This was substantiated by the fact that drug was detected from the 
sample under UV/visible spectroscopy analysis. In order to prevent further degradation of 
the SAPD, Eudragit® which is pH-insensitive with a similar structure should be used. For this 
purpose, Eudragit® RS100 was selected as a substitute for the crosslinked hydrogel system. 
 
4.5.5. The employment of Eudragit® RS100 for the purpose of crosslinking 
Following the series of tests done on the crosslinked system formed by Eudragit® L100-55 
and PEG 4000, it was essential that a different type of Eudragit® would have to be used in 
order to prevent the degradation of the crosslinked system. In this experiment, Eudragit 
RS100 was chosen because it is pH-insensitive, as opposed to Eudragit® L100, which is 
sensitive towards alkaline pH. The synthesis of the SAPD was carried out by dissolving 1g of 
PEG 4000 into 10mL of water and 1g of Eudragit® RS100 into 10mL of acetone in two 
separate beakers. The two solutions were added together and stirred with a glass rod. The 
result of this test had indicated that the two solutions did not form any crosslinking. This may 
be attributed to the functional group -C4H11NCl found on the Eudragit
® RS100 as opposed to 
the methyl group on the Eudragit® L100-55. The presence of the -C4H11NCl functional group 
takes up a larger amount of space as compared to the methyl group and prevented the 
attachment of PEG4000 on this side of the polymer. Compared to the Eudragit® RS100, 
Eudragit® L100-55 only has a methyl side chain and allowed crosslinking to occur on both 
sides of the chain, ensuring a fully interlinked network of crosslinked hydrogel system. For 
this reason, it was crucial that a new material should be investigated so as to form a 
crosslinked system with desirable physicomechanical and physicochemical properties. 
Alternatively, a different class of crosslinkers may be used in the place of PEG 4000 in order 
to crosslink the Eudragit® RS100. The new crosslinker should be smaller in size so as not to 
be interfered by the -C4H11NCl functional group. When Eudragit
® was dissolved in acetone, it 
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became negatively charged and therefore reactive towards positively charged ions, allowing 
crosslinking to occur. The use of simple molecules as opposed to the bulky polymers as a 
crosslinker may be a better alternative for crosslinking. For this reason, several salts were 
dissolved in water followed by the mixing with Eudragit® solution in order to assess the 
crosslinking behaviour of these two chemicals. When a salt is immersed in water, it 
undergoes dissociation, thus forming both cations and anions. Crosslinking should occur 
with the cation and the Eudragit® when the two solutions were mixed. Five different salts 
were chosen for this experiment, which included titanium dioxide, sodium benzoate, sodium 
chloride, sodium thiosulfate and potassium iodide. All of these salts were relatively small in 
size when compared to polymers and yielded cations when dissolved. The dissociation of 
these salts may be depicted in Figure 4.3. 
TiO2 Ti O2
-
NaC6H5CO2 Na C6H5CO2
Na2S2O3 S2O3
2-
Titanium Dioxide Titanium ion Oxygen ion
Sodium Benzoate Sodium ion Benzoic acid
Sodium Thiosufate Sodium ion Thiosulfate ion
NaCl Cl
Sodium Chloride Chloride ion
KI K I
Potassium Iodide Potassium ion Iodide ion
2 Na
-
-
Sodium ion
-
Na
 
Figure 4.3. The various salts that were used in this experiment and the ions that they 
dissociate into when dissolved in water. 
 
Eudragit® with a mass of 1g was weighed out and dissolved in 5mL of acetone, while 1g of 
the respective salts was dissolved in 5mL of water in two separate beakers. The two 
mixtures were added together and stirred with a glass rod. The resulting crosslinked product 
was rinsed with distilled water and left to dry overnight. It was assessed for its crosslinking 
Titanium Dioxide Titanium Ion Oxygen Ion 
Sodium Benzoate Sodium Ion oic A i  
Sodiu  Thiosulfate Sodium Ion Thiosulfate Ion 
Sodium Chloride Sodium Ion Chloride Ion 
Potassium Iodide Potassium Ion Iodide Ion 
C6H5COONa 
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properties and the one with the highest yields was selected. The results may be summarized 
as per Table 4.6 
Table 4.8. The quantity yielded by crosslinking with Eudragit® and the respective salts. 
Crosslinker 
Salt 
Titanium 
Dioxide 
Sodium 
Benzoate 
Sodium 
Thiosulfate 
Sodium 
Chloride 
Potassium 
Iodide 
 
Weight 
 
1.134g 
 
1.235g 
 
0.932g 
 
1.691g 
 
1.532g 
 
 
As seen in Table 4.6, the most desirable salt to use for this crosslinking was the sodium 
chloride, as it produced the greatest yield of hydrogel with elastic properties. All crosslinked 
system was white in appearance, however, crosslinking with titanium dioxide and sodium 
benzoate had produced a hard and brittle white solid which deemed it unsuitable for this 
implant. Potassium iodide had also produced a similar yield as opposed to sodium chloride, 
but the crosslinked system produced was more brittle when compared to sodium chloride 
and was not preferred.  
 
4.5.6. Crosslinking of Eudragit® RS100 and sodium chloride with indomethacin as a 
model drug for drug entrapment and drug release 
Following the decision of combining sodium chloride and Eudragit® for the purpose of 
crosslinking, indomethacin was further incorporated into this system in order to determine its 
drug entrapment efficiency and drug release profile, both in the absence and presence of 
electrical current. This was done by dissolving both 1g of Eudragit® and 100mg of 
indomethacin in 5mL of acetone, while 1g of sodium chloride was dissolved in 5mL of water. 
The two solutions were mixed together and stirred with a glass rod. The crosslinked system 
was yellow in appearance, which was attributed to the indomethacin. The crosslinked 
system was left to dry for 24 hours and immersed in PBS for 12 hours in order to assess for 
any possible degradation in alkaline PBS. The result indicated that Eudragit® RS100 did not 
breakdown in an alkaline pH due to its pH-insensitivity. The implantable system was re-
immersed in 20mL of PBS and 0.6 V of potential difference was applied for 40 seconds. 
Samples of 5mL were assessed under UV/visible spectroscopy. The result is presented in 
Table 4.7. 
Table 4.9. The drug release of the SAPD gathered at the specified time intervals. 
Time 40 seconds 80 seconds 120 seconds 160 seconds 200 seconds 
 
Drug 
release (%) 
 
0.000012 
±0.0000025 
 
0.000012 
±0.0000031 
 
0.000012 
±0.0000011 
 
0.000014 
±0.0000012 
 
0.000015 
±0.0000032 
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This result has indicated that drug was entrapped within the crosslinked SAPD and was not 
capable of moving outwards even in the presence of electrical current. This could be caused 
by the excessive crosslinking between the Eudragit® RS100 and the sodium chloride which 
prevented the drug from escaping the system. One possible solution to resolve this problem 
was the addition of a plasticizer into this system. A plasticizer improved the flexibility of this 
system while enhancing drug release and glycerine was chosen as the plasticizer for this 
part of the study as it has good biocompatibility and is readily available. In order to test this 
theory, five devices were made, each composed of varying amounts of plasticizer. It was 
loaded with drug and drug release was assessed. The composition of the three devices is 
summarized in Table 4.8. 
Table 4.10. The composition of the modified Devices 8-12. 
Devices Composition 
 
Device 8 
 
- Eudragit® RS100 (1g) 
- Sodium Chloride (1g) 
-Indomethacin (100mg) 
-Glycerine (3mL) 
 
Device 9 
 
- Eudragit® RS100 (1g) 
- Sodium Chloride (1g) 
-Indomethacin (100mg) 
-Glycerine (5mL) 
 
Device 10 
 
 
 
 
Device 11 
 
 
 
 
Device 12 
 
- Eudragit® RS100 (1g) 
- Sodium Chloride (0.5g) 
-Indomethacin (100mg) 
-Glycerine (7mL) 
 
- Eudragit® RS100 (1g) 
- Sodium Chloride (0.5g) 
-Indomethacin (100mg) 
-Glycerine (2mL) 
 
- Eudragit® RS100 (1g) 
- Sodium Chloride (0.5g) 
-Indomethacin (100mg) 
-Glycerine (1mL) 
 
 
The devices were made by dissolving the Eudragit® RS100 and indomethacin into 5mL of 
acetone, while sodium chloride was dissolved in water in two separate beakers. The amount 
of water used to dissolve the sodium chloride varies from 7mL in Device 10, 5mL in device 9 
and 3mL in Device 8. Once the sodium chloride was dissolved, the glycerine was added into 
the sodium chloride solution and stirred until homogenously blended. The contents of the 
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two beakers were mixed together and stirred until crosslinking was completed. The 
crosslinked system was left to dry for 24 hours and placed in 40mL PBS for 12 hours in 
order to assess for any drug leakage. This was done by gathering 5mL of the PBS samples 
after 12 hours and scanned with UV/visible spectroscopy for any presence of drugs. As 
predicted, the texture of the crosslinked SAPD exhibited increased elasticity, but this 
relaxation of the chemical structure may have led to increased drug release from the 
crosslinked system. The results obtained from the UV/visible spectroscopy has indicated that 
drug leakage does occur in all three devices. The results were indicated in Table 4.9. 
Table 4.11. The devices with varying amounts of plasticizer and its respective drug leakage. 
Devices Drug release (mg) 
 
Device 8 
 
0.3089 
Device 9 0.5389 
Device 10 
Device 11 
Device 12 
0.7406 
0.2127 
0.1228 
 
  
Plotting the above results into a graph of glycerine versus UV absorbance is an indication of 
the maximum amount of glycerine which may be used to improve the physicomechanical 
properties of the crosslinked system without the leakage of the drug into its surrounding. 
This was depicted in Figure 4.4, along with the Equation of the trend line. The Equation of 
the trend line may be depicted as Equation 4.2. 
 
y=0.1319 x-0.012                 Equation 4.2 
Therefore, in order to determine the maximum amount of glycerine which may be used as 
per Equation 4.2, we assume the absorbance, which was the y-value, was 0.  
The extrapolated maximum amount of glycerine which may be used is 0.094mL. This 
approach was impractical because addition of 0.094mL of glycerine into 10mL of 
crosslinking solution did not yield any significant difference to the drug release profile. A 
different approach should be considered in terms of the crosslinked system and its drug 
entrapment. 
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Figure 4.4. The relationship between the amount of glycerine used and the drug leakage 
from the stimuli-actuated polymeric device. 
 
The use of an alternative plasticizer should be considered. The plasticizer used in the place 
of glycerine was tri-ethyl citrate, since it is a commonly used plasticizer with a good 
biocompatibility. 
 
4.5.7. The employment of tri-ethyl citrate as a plasticizer 
In this experiment, triethly citrate (TEC) was used as an alternative substitute for glycerine in 
order to increase the elasticity of the crosslinked device while preventing the outward 
movement of the drug from the system to the surrounding fluids. In this study, 1g of 
Eudragit® RS100 was added into 10mL acetone and 1g of sodium chloride was added into 
10mL of water along with 5mL of TEC. The problem with this design was the immiscibility of 
TEC with water. This may be attributed to the structure of the TEC which is depicted in 
Figure 4.5. 
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Figure 4.5. The chemical structure of tri-ethyl citrate. 
 
Except for the few oxygen atoms which exhibited a weak dipole movement, the ethyl groups 
on the citrate structure were composed of hydrocarbons which would make this compound 
mainly non-polar in nature. Therefore, it exhibited immiscibility with polar solvents such as 
water. In order to improve the miscibility between water and TEC, 2.5mL Tween® 80 and 
1.5mL Span® 80 was added into the water/TEC mixture. The Hydrophile-Lipophile Balance 
(HLB) value for this combination of Tween® and Span® is 10.98, which is appropriate for an 
oil-in-water emulsion. After the emulsion was formed, the Eudragit® RS100/acetone solution 
was mixed with the emulsion and stirred. The resulting product was left to stand until all 
solvents were evaporated. The resultant product, however, remained an emulsion which did 
not solidify. This may be attributed to the fact that TEC, which was organic by nature, was 
introduced into the system. Since oil is hydrocarbon in nature, it does not facilitate 
evaporation of the solvents and this system remained an emulsion. An alternative method 
besides the use of plasticizer should be considered due to the incompatibility of plasticizers 
with this system. 
 
4.5.8. The employment of alternative materials as a component of the Stimuli-Actuated 
Polymeric Device  
Following the assessment of the plasticizer in a crosslinked system, results have indicated 
that it was unsuitable due to excessive drug leakage. An alternate method which may be 
used to increase the elasticity of the crosslinked system was to apply heat. Application of 
heat to the system may facilitate a break between the bonds of various chemical structures, 
and therefore a weakening in structural integrity. Heat was applied during the crosslinking 
process rather than afterwards, because heating of the SAPD after its formation would 
mainly result in peripheral weakening of the SAPD. PVA was added into the hydrogel in 
order to act as a plasticizer, as water was absorbed into the PVA allowed it to have elastic 
properties. In addition, PVA has high tensile strength, flexibility and is biocompatible. 
Dipole movement 
Dipole movement 
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Therefore, the addition of PVA into a crosslinked Eudragit® system should provide adequate 
structural integrity while preventing excess crosslinking which hinders drug release. For this 
study, three separate devices were made, each made of different chemical compositions in 
order to assess any difference in its physicomechanical properties after the completion of the 
device. The first was a standard hydrogel system, while the second had sodium chloride 
removed in order to determine if there was any interaction between the Eudragit® and the 
PVA. A device with ZnO2 as the crosslinker was formulated so that comparison with the 
sodium chloride-loaded SAPD could be made. The devices were termed Device 13-15 and 
the materials used are summarized in Table 4.10. 
Table 4.12. The composition of Devices 13–15. 
 Composition 
 
Device 13 
 
PVA13000 (1g) 
-Eudragit® RS100 (1g) 
-Sodium Chloride (1g) 
-PANi (0.2g) 
-Indomethacin (100mg) 
 
Device 14 
 
 
 
 
-PVA13000 (2g) 
- Eudragit® RS100 (1g) 
-PANi (0.2g) 
-Indomethacin (100mg) 
Device 15 -PVA13000 (2g) 
-ZnO2 (0.5g) 
- Eudragit® RS100 (1g) 
-Indomethacin (100mg) 
-PANi (0.2g) 
 
 
The devices were made by dissolving the PVA13000 in 10mL of water, followed by sodium 
chloride and the ZnO2 in the case of Device 13 and Device 15 respectively. The Eudragit
® 
RS100 was dissolved into 10mL of acetone, followed by PANi and indomethacin. The two 
solutions were added together and stirred with a glass rod. Crosslinking seemed to have 
occurred slightly as the viscosity thickened. This mixture was placed onto a flame to heat 
until the majority of the solvents have evaporated. The remaining mixture was left to stand 
for 48 hours to ensure further evaporation of the solvents. 
 
These three systems were assessed for any drug leakage similar to the test done on Device 
8. The result demonstrated these devices exhibited solubility in PBS and rapid degradation 
was observed when placed in the solvent. For further analysis, Device 13 was placed in 
several solvents to further determine its stability in various solvents and it has indeed 
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demonstrated solubility in solvents such as chloroform, aniline, ethanol, acetone, sulphuric 
acid, ethyl acetate, hydrochloric acid and acetic acid. This may be due to the high solubility 
of PVA13000 in polar solvents while Eudragit
® is soluble in most organic solvents. Therefore, 
using PVA13000 and Eudragit
® as the main body of the system may be the cause of this 
degradation, despite the fact the crosslinking of Eudragit® RS100 and its respective salts did 
occur. In fact, degradation also occurred in Device 14 and Device 15, which supported this 
assumption. In order to decrease this degradation, PVA13000 should be replaced with a less 
soluble polymer, which should be used to form the main frame of this crosslinked system. 
 
4.5.9. The employment of high molecular weight polyvinyl alcohol in a crosslinked 
system  
In order to prevent the degradation observed in the crosslinked PVA13000/Eudragit
® RS100 
system, PVAs with a higher molecular weight were chosen as a substitute as opposed to 
PVA with a lower molecular weights. High molecular weight PVA exhibits less water 
solubility and better crosslinking properties as opposed to the low molecular weight PVA. As 
part of this study, PVA with two different molecular weights were chosen, namely PVA49000 
and PVA88000.  
 
Since Eudragit® RS100 crosslinked with sodium chloride and not with the PVA, it was 
decided that Eudragit® RS100 and sodium chloride should be replaced with alternative 
chemicals which were capable of crosslinking with PVA. The aim was to replace the 
Eudragit® RS100 with PVA as the main body of the hydrogel. Since hydrogel is a three-
dimensional crosslinked system, it would be prudent that the PVA itself be crosslinked 
instead of the Eudragit® RS100. 
When PVA was dissolved in water, it presumably lost a hydrogen atom, which created a 
possible group for chemical reaction. This may create possible crosslinking between two 
PVA chains. This may be illustrated by Figure 4.6. 
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-H+ -
+A2+
Poly vinyl alcohol
Crosslinked Poly vinyl alcohol
 
Figure 4.6. The crosslinking mechanism of polyvinyl alcohol which may be used for the 
synthesis of a polyvinyl alcohol crosslinked system. Here, the polyvinyl alcohol chains are 
crosslinked by a divalent compound A. 
 
From the crosslinking mechanism seem in Figure 4.6, it was clear why a PVA with a longer 
chain would exhibit better crosslinking. It was for that reason a high molecular weight PVA 
was preferred over a low molecular PVA. 
 
The two types of PVA used in this study were PVA49000 and PVA88000. Both have substantially 
higher molecular weight than the PVA13000 used. In order to assess the crosslinking 
behaviour of these two PVAs, 1g of the respective PVA were dissolved in 10mL of water. A 
crosslinker was dissolve in a solvent contained in a separate beaker. The two solutions were 
mixed together and stirred with a glass rod in order to facilitate the crosslinking. For this 
study, diethyl acetamidomalate (DAA) was chosen as a crosslinker, as it also demonstrates 
good biocompatibility. DAA with a mass of 2g was dissolved in 10mL of acetone. This was 
then mixed with the PVA solution. Crosslinking occurred spontaneously. This mechanism is 
similar to the one described in Figure 4.5 and is demonstrated in Figure 4.7. The crosslinked 
compound was then left to dry for 24 hours.  
polyvinyl alcohol 
Cro slinked polyvinyl 
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Figure 4.7. The crosslinking mechanism between polyvinyl alcohol and diethyl 
acetamidomalate. 
 
The device formed with PVA49000 demonstrated slight degradation when placed in water 
under 24 hours. However, the device formed with PVA88000 demonstrated no degradation 
when placed under both water and PBS.  
 
4.5.10. The employment of polyvinyl alcohol88000 and diethyl acetamidomalate in a 
crosslinked system and assessment of its drug release profile 
Following the tests done on the higher molecular weight PVA, PVA88000, demonstrated the 
most favourable characteristic without any degradation when crosslinked with DAA. The next 
step was to incorporate a drug into the system which was capable of controlled release via 
an ‘ON-OFF’ mechanism. The drugs used included indomethacin, ibuprofen, diclofenac 
sodium and aspirin. Each of these drugs was dissolved in an appropriate solvent followed by 
Crosslinked polyvinyl 
poly i l lc l 
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incorporation of these drug solutions into the crosslinked system. The drugs and its 
appropriate solvents may be described as follows:  
• Indomethacin (100mg) – acetone (5mL) 
• Ibuprofen (100mg) – acetone (5mL) 
• Diclofenac sodium (100mg) – water (5mL) 
• Aspirin (300mg) – acetone (5mL) 
A quantity of 100mg was incorporated into each device as it was hoped that the device 
would release a controlled dose of a fraction of a milligram. This would ensure a prolonged 
release cycle could be achieved over a time period of 1-2 months. Aspirin dosage was 
increased as its potency is much lower when compared to drugs such as ibuprofen (Hersh, 
2000). The crosslinked system was achieved by dissolving 0.5g of PVA88000 into 10mL of 
water while 2g of DAA was dissolved in 10mL of acetone in a separate beaker. The drug 
solutions were added into the acetone/DAA solution and stirred until homogenous. Lastly, 
the DAA/drug solution was poured into the PVA solution and stirred until crosslinking was 
completed. This crosslinked system was left to dry for 24 hours and a total of five devices 
were made, each identical in composition except for the model drugs. These devices were 
named as follow for the purpose of identification:  
• Indomethacin-loaded Device – Device 16 
• Ibuprofen-loaded Device – Device 17 
• Diclofenac sodium-loaded Device – Device 18 
• Aspirin-loaded Device – Device 19 
One crucial assessment of these systems before any other assessments could be made 
would be its capability of withholding the drugs when placed in PBS without and activation 
from the stimulus. This was done by immersing the device into 30mL of the PBS for 24 
hours. Samples of 1mL were then taken from the PBS and assessed for any presence of 
drug. The results are shown as in Table 4.11. 
Table 4.13. The percentage of drugs which was present in the 30mL PBS sample. Device 
14 and 16 has indicated drug leakage and unsuitable for SAPD. 
Device Drug present 
 
16 
 
0.00853±0.00143% 
17 0.000% 
18 0.00340±0.000412% 
19 0.000% 
 
 
The results obtained have indicated the two devices which were suitable for further study 
were Device 17 and Device 19. These two devices were capable of withholding the drugs 
when placed in PBS. However, it should be noted that the result was obtained from the 
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hydrogel without an EAP. With the addition of an EAP, the formation of an IPN could alter 
the characters of the drug release profile as compared to the plain hydrogel. Further analysis 
with EAP-incorporated hydrogel should be made in order to assess any differences in the 
drug release behaviour. These tests would be carried out further after Device 17 and 19 
were assessed for its drug release profile.  
 
4.5.11. Further assessment of drug release profile of the aspirin-loaded device and the  
ibuprofen-loaded device  
 As discussed in Chapter 4 Section 4.5.10, the ibuprofen-loaded device (Device 17) and 
aspirin-loaded device (Device 19) were further subjected to electric current under PBS in 
order to assess for any release in these drugs. This was done by placing the respective 
devices into 40mL of PBS and actuated by a potential difference of 1.2V and a current of 
0.3A. The equipment used was a PGSTAT 302N potentiostat/galvanostat (Autolab, Utrecht, 
Netherlands) with platinum as the working electrode and gold as the counter electrode. The 
setup of the experiment may be depicted in Figure 4.8. 
 
 
Figure 4.8. The setup which was used to determine drug release of the device under electric 
current. 
 
Electric current was passed through the device for duration of 45 seconds before 1mL 
samples were taken. This was repeated three times, after which the sample was scanned 
via UV/visible spectroscopy for any presence in drug. The results obtained may be 
presented in Table 4.12. 
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Table 4.14. The results obtained from drug release (%) of the two Devices. 
Device  45 seconds 90 seconds 135 seconds 
 
Device 17 
 
0.001889±0.0003% 
 
0.002180±0.00021% 
 
0.002446±0.00031% 
Device 19 0.000% 0.000% 0.000% 
 
 
The results in Table 4.12 have indicated that Device 19 did not respond to electric current, 
while Device 1 resulted in a drug release under electric current. Further assessment of 
Device 17 should be performed in order to evaluate its potential uses for an electrically 
activated crosslinked system. 
 
4.5.12. Determination of a crosslinker ratio and its effect on the device 
In order to establish the drug release profile of the system, further analysis of Device 15 was 
performed in order to evaluate its potential as a stimulus activated system. For this part of 
the experiment, three derivatives of Device 17 were made, each with varying amounts of 
DAA. All the devices were made identically to that of Device 15, except for the DAA used 
were 2g, 1g and 500mg. These devices were termed Device 20, Device 21 and Device 22 
respectively. Each of these devices was exposed to electric current in order to assess its 
drug release profile. The results are summarized in Table 4.13.  
Table 4.15. The quantity of drugs released by the system converted to percentage 
Device 45 seconds 90 seconds 135 seconds 180 seconds 
 
20 
 
0.00170±0.0002% 
 
0.00242±0.0003% 
 
0.00823±0.0005% 
 
0.02543±0.003% 
21 0.02300±0.003% 0.02761±0.004% 0.04602±0.003% 0.05207±0.004% 
22 0.00436±0.0003% 0.00484±0.0005% 0.00536±0.0004% 0.01259±0.002% 
 
 
In order to achieve a therapeutic dose for ibuprofen, a minimum of 1.2mg must be present at 
the local site and the only device capable of achieving such dose was Device 21. The result 
has indicated that a crosslinker in the ratio of 1:1 DAA:PVA88000 would be preferred as 
opposed to other combination and was worth further evaluation. The optimum amount of 
each component to be used would be determined by the use of a Box-Behnken Design once 
appropriate variables were selected. 
 
4.5.13. Addition of polyaniline as an electroactive polymer for the purpose of drug 
release enhancement from the crosslinked system 
In order to enhance drug release from the crosslinked system, PANi as an EAP was blended 
into the crosslinked system in order to evaluate whether there was indeed an increase in 
drug release. For this study, Device 15 was made, with the addition of PANi which was 
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added into the acetone solution prior to the crosslinking. Five different devices were made, 
each with 10%, 5%, 2%, 1% and 0.5% of PANi incorporated into them. These devices were 
left to dry for 24 hours and immersed in distilled water for another 24 hours in order to rinse 
out any unreacted chemicals in the crosslinked system. The devices were assessed for its 
physical properties in order to determine its suitability to be used as a subcutaneous implant. 
It was discovered that the incorporation of PANi into the crosslinked system tends to 
decrease the integrity of the crosslinked system. The results have indicated that the higher 
the PANi that was incorporated, the lower the structural integrity. Crosslinked systems with 
10% and 5% PANi were too weak and have exhibited deterioration when handled, therefore 
rendered it unsuitable for the purpose of a subcutaneous implant. Crosslinked systems with 
2%, 1% and 0.5% PANi have shown good physical properties and could be handled without 
difficulty. For further study, the crosslinked device with the highest amount of PANi (i.e. 2%) 
and stability should be selected. During the formation of the crosslinked system, PANi was 
added in acetone and crosslinking were allowed to occur. PANi was only slightly soluble in 
acetone and much of it was unreacted. It could be possible that PANi may have been 
trapped between the 3-dimensional crosslinked networks of the crosslinked hydrogel system 
during its synthesis. The presence of the unreacted PANi between the crosslinked networks 
may have decreased the degree of crosslinking and a decrease in the structural integrity of 
the system as a whole. 
 
With the presence of PANi now incorporated throughout the entire crosslinked hydrogel 
system, the drug release should be assessed in order to determine whether the use of PANi 
in this system would be beneficial. For the next study, drug-loaded SAPD would be 
assessed for its drug release behaviour. Aspirin-loaded device was excluded this study due 
to its lack of response towards electrical stimulation as observed in Chapter 4 Section 
4.5.11. 
 
4.5.14 Assessment of ibuprofen release from the Stimuli-Actuated Polymeric Device 
in the presence and absence of an electric current 
Following the synthesis of an ibuprofen-loaded SAPD, the system was rinsed with distilled 
water three times, after which it was then immersed for a period of 12 hours in order to 
ensure complete removal of any unreacted chemical reagents or untrapped drugs. The 
SAPD was left to dry followed by immersion in the 50mL of PBS for 12 hours, after which 
1mL sample was extracted and tested for any presence of drug. The UV absorbance of the 
1mL sample has indicated that no leakage of drug had occurred in the absence of an electric 
current.  
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The next step was to assess the electroactivity of the SAPD when the system was in the 
presence of an electric current. For this part of the study, SAPD was placed in 20mL of PBS 
and PGSTAT was used with the same setup as in Figure 4.7. A potential difference of 1.2V 
was applied and 1mL samples were taken at a 45 second interval. After the 1mL sample 
was taken from the 20mL PBS, the stock solution was discarded and a fresh PBS was used 
for the next interval. A total of 6 samples were taken and assessed. The results may be 
summarized as per Table 4.15. 
Table 4.16. The quantity of ibuprofen present in the samples extracted during the drug 
release assessment. 
1 mL 
sampl
e 
45 
seconds 
90 seconds 135 
seconds 
180 
seconds 
225 
seconds 
270 
seconds 
       
Drug  
(%) 
0.049±0.00
1 
0.0446±0.0
02 
0.045±0.00
3 
0.0448±0.0
03 
0.0454±0.0
02 
0.0512±0.0
01 
 
 
 
As seen from the results in Table 4.15, a therapeutic dose of ibuprofen was released into the 
PBS in the presence of an electric current. The extent of these release cycles would have to 
be analyzed in further studies. 
Following the actuation of the SAPD, the crosslinked system may have experienced 
irreversible structural changes. These changes may affect future behaviour of the SAPD and 
therefore it was important that drug leakage test should be repeated again after the SAPD 
has been exposed to electric current. The SAPD was immersed in 10mL of PBS for 24 hours 
and a 1mL sample was assessed for any presence of ibuprofen. Contrary to the first result, 
drug was present in this sample, which indicated a possible change in structure of the SAPD 
or a change of ibuprofen characteristics after the application of electrical stimulation. The UV 
absorbance obtained from the sample was 0.0142, which equated to 0.226mg in the 1mL 
sample. The total amount of drug which leaked from the system was 2.26mg. If the 
ibuprofen-loaded SAPD was to be used, it would have to be further modified in order to 
ensure the proper functioning of the device.  
 
4.5.15 Assessment of diclofenac sodium release from the Stimuli-Actuated Polymeric 
Device in the presence and absence of an electric current 
The next study was performed on the diclofenac sodium-loaded SAPD. The first assessment 
was the test for any leakage of drugs in the absence of an electric current. The system was 
left in 50mL of PBS for 12 hours and the method used was identical to the one used in 
Chapter 4 Section 4.5.14. A sample of 1mL was taken and assessed under UV/visible 
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spectroscopy. The UV absorbance indicated a reading of 0.0800. Conversion of this reading 
to the quantity of drug equated to 0.59mg of diclofenac sodium which was in the 50mL 
sample. This indicated a leakage of a therapeutic dose of diclofenac sodium from the SAPD. 
The test was repeated twice more in order to confirm the leakage of diclofenac sodium and 
the UV reading indicated a presence of 1.87mg and 1.54mg of diclofenac sodium in the 
second and third test respectively. These results have confirmed that diclofenac sodium 
does continuously leak from the PANi-system and was unsuitable for an electro-active drug 
delivery approach.  
This finding was contradictory to the first result obtained when diclofenac sodium was 
entrapped in the hydrogel without PANi. This leakage may have occurred due to the 
decreased crosslinking when PANi was incorporated into the hydrogel. This decrease of 
crosslinking may be the cause of drug leakage from the SAPD. For further development of 
the diclofenac sodium-loaded SAPD, a decreased amount of PANi should be used or an 
alternative method to increase the crosslinking should be investigated.  
 
4.5.16 Assessment of indomethacin release from the Stimuli-Actuated Polymeric 
Device in the presence and absence of an electric current  
The last system to be tested was the indomethacin-loaded SAPD. The indomethacin-loaded 
SAPD was initially left in 50mL PBS for 12 hours and 1mL sample was taken in order to 
assess for any drug. The results obtained from the UV/visible spectroscopy has indicated no 
drug leakage in the sample. This was followed by a drug-release profile of indomethacin-
loaded SAPD in the presence of an electric current. The test method was done identically to 
Chapter 4 Section 4.5.14. and the results can be summarized in Table 4.16. 
Table 4.17. Indomethacin released from the SAPD when exposed to electric current. 
 45 seconds 90 seconds 135seconds 180 seconds 225 seconds 
 
Drugs (%) 
 
 
0.1200±0.02 
 
0.1778±0.03 
 
0.1022±0.01 
 
0.1061±0.02 
 
0.1108±0.01 
 
 
The results indicated by Table 4.16 have shown that drug release was achieved when the 
SAPD was placed under electric current. As mentioned in Chapter 4 Section 4.5.14, it was 
important that the SAPD was assessed afterwards in order to ensure irreversible structural 
changes did not affect the SAPD once it was exposed to electric current. The system was 
left in 50mL of PBS again for 12 hours, and 1mL sample was taken and assessed for any 
presence of the drug. The results obtained from the UV/visible spectroscopy has indicated 
that no drug leakage was detected. This suggested that an indomethacin-loaded SAPD may 
possibly be used for the purpose of an electroactive drug delivery system.  
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The SAPD was assessed for further drug release consistency and capacity. The SAPD was 
immersed in PBS followed by actuation as mentioned in Section 4.5.14. This time, 35 
samples were extracted and assessed by UV/visible spectroscopy for the quantity of drug 
released. The results were shown in Figure 4.9. 
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Figure 4.9. The amount of drug release from 35 release cycles. 
 
As indicated by Table 4.17, the drug release ranged from 0.081mg to 0.160mg. The SAPD 
was assessed one last time for any leakage of drugs and was immersed in 50mL of PBS for 
12 hours. A sample of 1mL was taken and the UV absorbance has indicated that there was 
no leakage of indomethacin when the SAPD was left immersed in the absence of electricity. 
 
One challenge with an electroactive device such as this was that its response may slowly 
decrease with time. As one may see from Table 3.14, there was a slight difference in drug 
release from the first ten samples as compared to the last ten samples. This was probably 
due to the slightly lagged response from the SAPD when it was left immersed and unused in 
PBS. Such a phenomenon was possibly due to the ion exchange between the SAPD and 
the surrounding medium, which tends to diminish the electrochemical control of the drug 
release (Lira, 2005). The last step in this study was to determine how much of the drug could 
be released before the device was totally depleted of the drug. The SAPD was continuously 
actuated and samples were assessed for the drug until the drug release cycles ceased. The 
results are indicated in Table 4.18 
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Figure 4.10. The drug release from release cycles 36-70 
The results obtained have indicated the SAPD was capable of 67 release cycles. In this 
study, diclofenac sodium, ibuprofen and indomethacin were used and results have indicated 
that indomethacin was the only suitable drug for this implantable system, as no leakage has 
occurred when electric current was not applied to the SAPD. One possible explanation for 
this phenomenon could be the larger molecular size of indomethacin as compared to 
diclofenac sodium and ibuprofen. This larger molecular size meant that indomethacin were 
more likely to be entrapped within the three dimensional network of the hydrogel system. 
Although most diclofenac sodium and ibuprofen were well entrapped in the center of the 
hydrogel, drug leakage may still occur on the surface. As the drug was entrapped in the 
hydrogel system, it was possible to suggest a release mechanism of passive diffusion from 
the SAPD during actuation.  
 
4.6. The synthesis of the Stimuli-Actuated Polymeric Device for the assessment of 
drug entrapment efficiency 
 
Following the study done on the SAPD, three different types of drugs were incorporated and 
assessed for their drug release behaviours and physical properties. Although some of the 
drugs tested previously showed no signs of activity, it was decided to repeat the test again 
with the addition of PANi, in order to compare the results obtained with the addition of PANi 
as opposed to a plain hydrogel. The three drugs used were namely ibuprofen, indomethacin 
and diclofenac sodium. Following the formulation of the drug-loaded SAPD, it was assessed 
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for its drug release in the presence of an electric current. For this study, 100mg of the drug 
was dissolved into 10mL of acetone, along with 500mg of DAA and 20mg of PANi. 500mg of 
PVA was dissolved in 10mL of water in a separate beaker. The only exception was the 
diclofenac sodium, which was added into the 10mL PVA solution since diclofenac sodium 
was soluble in water and not acetone. The two solutions were added together and stirred 
with a glass rod until the crosslinking was completed. The hydrogel system was left to dry 
and the crosslinking solution was assessed under UV/visible spectroscopy for the amount of 
drug remaining. This would allow us to determine the amount of drug which was actually 
entrapped in the hydrogel system during the crosslinking process.  
 
4.6.1 The drug entrapment efficiency of the Stimuli-Actuated Polymeric Device 
Following the crosslinking of the aforementioned hydrogel, 20mL crosslinking solutions 
which were present after the hydrogel was removed. One mL sample was taken and 
assessed with UV/visible spectroscopy. The DEE assessment was first performed on the 
ibuprofen-loaded SAPD. The solvent in this case was a 1:1 water:acetone mixture. One 
problem encountered when assessing the amount of ibuprofen in the water/acetone mixture 
was that acetone and ibuprofen absorbs at similar wavelengths of UV light, which made it 
difficult to quantify the precise amount of ibuprofen present (Shin, 2001 and Kimura, 1997). It 
was for that purpose a SAPD identical to Device 15 was constructed, but the DEE shall be 
carried out with PBS as the surrounding medium, as ibuprofen exhibits solubility in PBS. 
This SAPD was placed in 50mL of PBS and homogenized for 5 minutes, followed by 
sonification for a further 2 minutes. Sample of 5mL was drawn from the 50mL PBS and 
assessed for any presence of drugs. The UV absorbance of the 5mL sample was 0.1394.  
The amount of drug presented in the 50mL sample equated to 4.22mg and therefore a DEE 
of only 4.22% since 100mg of ibuprofen was initially added into the device. This low amount 
of DEE rendered the ibuprofen an inappropriate drug for use in the hydrogel system. 
 
For the second test, the indomethacin loaded SAPD device was tested. The UV absorbance 
in the 1mL sample obtained from the crosslinking solution was 0.138. The calibration curve 
may be presented as in Figure 4.9. The Equation for this graph was presented as Equation 
4.3. 
 
y=21.027 x                  Equation 4.3 
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Figure 4.11. The calibration curve of indomethacin dissolved in 1:1 acetone:water solution 
under a wavelength of 318nm of UV light. 
 
The amount of drugs present in the 1mL sample was assessed by using Equation 4.3. The 
amount of drugs present in the 20mL sample was 0.131mg and the amount of drug which 
was entrapped by the SAPD equated to 100-0.131 = 99.65mg. The DEE recorded was 
99.65%. 
 
The last drug which was tested was diclofenac sodium. Similarly, a calibration curve was 
constructed with diclofenac sodium dissolved in 1:1 acetone:water and is presented as 
Figure 4.10. Due to the overlapping absorption wavelength between the diclofenac sodium 
and the acetone at 235nm (Shin, 2001 and Bravo, 2002), the wavelengths was shifted 
further to 320nm, where absorption of the UV light only occurs in the diclofenac sodium and 
not the acetone. 
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Figure 4.12. The calibration curve of diclofenac sodium dissolved in 1:1 acetone:water 
solution under a wavelength of 320 nm of UV light. 
 
The Equation for this graph may be presented as Equation 4.4. 
 
y=2.5336 x                  Equation 4.4 
 
The DEE assessment was performed identically as mentioned in this Section and a UV 
absorbance of 1.37 was recorded. The amount of drug was calculated using Equation 4.4. 
The quantity of drug in the 20mL sample was 10.81mg. The DEE was 100 – 10.81 = 
89.19%. 
 
The indomethacin and the diclofenac sodium have exhibited good DEE when incorporated 
into the SAPD, with DEE higher than 85% in both cases. Ibuprofen has obtained DEE of less 
than 10% which rendered it unfeasible.  
 
Based on the results obtained from Chapter 4 Section 4.5.16 and Chapter 4 Section 4.6.1, 
the most appropriate drug for further development would be the indomethacin. Indomethacin 
was the only drug which had shown electroactivity with a relatively high DEE. The 
incorporation of this drug into the SAPD may be appropriate and should be further 
investigated. 
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4.7. The drug release mechanism of the Stimuli-Actuated Polymeric Device 
In this study, the drug release mechanism of the SAPD was explored. Murdan and co-
workers (2003) have suggested a few methods in which a drug may be released via electro-
responsive methods (Murda et al., 2003). These methods were forced eviction of drug due to 
de-swelling, electrophoresis of drugs towards charged electrodes and erosion of hydrogel 
which led to liberation of drugs. The drug release mechanism from the SAPD may be one of 
these three possible mechanisms. During the evaluation of the SAPD, visible changes were 
observed which suggested the release mechanism was due to erosion. The SAPD before 
and after exposure to electric current was depicted in Figure 4.11 a and b respectively. 
 
                 
Figure 4.13. a) The SAPD before exposure to electric current. b) The SAPD after exposure 
to electric current 
 
The SAPD in Figure 4.11 b) has shown erosions on the bottom side where the electrodes 
were placed. It was possible to assume that the release mechanism may be due to the 
erosion of the hydrogel, thus resulted in liberation of the drugs. When the same system was 
duplicated without the PANi, there were no signs of erosion, which suggested that PANi was 
linked to relate to the erosion of this hydrogel. Figure 4.13 depicts the SAPD after 60 release 
cycles. This figure clearly depicted the erosion which occurred on the SAPD when it was 
continuously exposed to electrical current. It was important to note that the erosion on the 
SAPD was a surface phenomenon only. 
 
 
a) b) 
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Figure 4.14. The erosion of the SAPD after 60 samples was taken. 
  
Spherical erosions can be seen at the erosion sites where the electrodes were placed on the 
hydrogel. The colour of the SAPD has lightened in places where PANi was absent. They 
appear as translucent areas in the hydrogel in Figure 4.12. Drug release study done beyond 
70 samples has shown that even though drug release no longer occurred, the SAPD was 
still undergoing erosion. This suggested that indomethacin did not contribute to the erosion 
of the SAPD.  
Another important aspect which must be explored was any possible interactions which could 
have occurred between the SAPD and the indomethacin. This was important from a release 
mechanism point of view because if there was a possibility of any drug-hydrogel interaction, 
it may affect the structural integrity of the SAPD and therefore the erosion rate. This would 
ultimately affect the release rate of indomethacin from the SAPD. In order to determine if 
there was any reaction between the indomethacin and the SAPD, two experiments were 
conducted, namely FTIR and Differential Scanning Calorimetry (DSC).  
 
4.7.1. Fourier Transform Infra-Red spectroscopy of the Stimuli-Actuated Polymeric 
Device with and without indomethacin  
This experiment was conducted in order to assess for any structural changes between the 
SAPDs which was loaded with indomethacin and without it. The hydrogels compared was a 
placebo device of the SAPD and a drug-depleted SAPD. The results of SAPD with the drug 
and without the drug are indicated by Figure 4.15.  
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Figure 4.15. The FTIR of the eroded SAPD (blue) and SAPD without the indomethacin 
(pink) 
As Figure 4.13 and 4.14 have indicated, there was no difference in the two structures and 
indomethacin did not have any direct interactions with the SAPD. This suggested that the 
drug was merely entrapped in the SAPD and was liberated when the SAPD underwent 
erosion. The drug was trapped in the SAPD during the crosslinking process and remained 
within the SAPD even during the swelled state until erosion occurred. There was no 
interaction between the drug and the SAPD. 
 
4.7.2. Differential Scanning Calorimetry of the indomethacin-loaded Stimuli-Actuated 
Polymeric Device  
Another method which was employed in order to determine whether there were any 
interaction between the drug indomethacin and the SAPD was DSC. The thermal reactions 
of the SAPD with and without the drug were compared, and any differences in the thermal 
reaction may suggest an interaction between the SAPD and the drug. The equipment used 
was the DSC1 Stare System (Mettler Torledo, Uster, Zurich, Switzerland). The DSC was first 
conducted on the indomethacin alone, followed by the SAPD without the indomethacin, and 
finally on the SAPD with the indomethacin. The results are shown in Figures 4.15-4.17.  
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Figure 4.16. DSC thermogram obtained for indomethacin. 
 
Figure 4.17. DSC thermogram of the stimuli-actuated polymeric device without the 
indomethacin. 
mW
-65
-60
-55
-50
-45
-40
-35
-30
-25
-20
-15
-10
-5
0
5
min
°C-20 0 20 40 60 80 100 120 140 160 180 200 220 240
0 2 4 6 8 10 12 14 16 18 20 22 24 26
 
  	 
  

 
  

       

 ff fi  flffi     !
"
#
"

mW
-200
-150
-100
-50
0
min
°C-20 0 20 40 60 80 100 120 140 160 180 200 220
0 2 4 6 8 10 12 14 16 18 20 22 24
$
%& '
()* +, (- ./01
23 4 5
%678 9:
(
8 ;'': < =%>
3
'? @;9AB98':'CD E
5F
))G
F
+
B 
C 
 
A 
 
 
 
 
106 
 
Figure 4.18. DSC thermogram of the stimuli-actuated polymeric device with the 
indomethacin. 
Figure 4.15 and Figure 4.16 were the thermograms obtained from the indomethacin and the 
SAPD respectively. Figure 4.17 has shown an endothermic reaction at approximately 165ºC. 
This endothermic reaction was most likely due to the melting of indomethacin, as previous 
studies have indicated that indomethacin has a melting point of 165ºC (Chokshi, 2007). 
Figure 4.16 showed an endothermic reaction at approximately 5ºC and a melting point of 
120ºC for the SAPD without the indomethacin. Figure 4.17 depicts the result of DSC 
obtained from the SAPD with the indomethacin loaded. In Figure 4.16, the endothermic 
reaction at peak A proposed represented glass transition of the SAPD due to the slight 
decrease in the baseline, as it returned slowly back to room temperature. Peak C might 
represent the melting point of the SAPD, which occurred at approximately 120ºC. The small 
endothermic reaction represented by peak B has occurred due to a eutectic impurity and 
was not presented in Figure 4.17. Peak D in Figure 4.17 represented the thermal 
decomposition of the SAPD. This thermal decomposition was not seen in Figure 4.16 and 
may be attributed to the indomethacin which was entrapped in the SAPD. Similarly to the 
PANi, as the indomethacin was entrapped in the SAPD, it decreased the degree of 
crosslinking which occurred in the SAPD. This decrease in crosslinking may have decreased 
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the structural integrity and therefore a decrease in the decomposition temperature of the 
SAPD. 
From Figure 4.16 and 4.17, one may see that the glass transition temperature and the 
melting point of the SAPD with and without the indomethacin were identical, which 
suggested identical chemical structure between the two. In Figure 4.17, peak E was present 
which was not seen in Figure 4.16, and may be due to the thermal degradation of the 
indomethacin. This may be verified by comparing it with Figure 4.15, which showed that the 
thermal degradation of the indomethacin was similar to the temperature range in peak E. In 
order to confirm the peaks D and E, modulated differential scanning calorimtetry was 
performed. The use of modulated differential scanning calorimetry allowed more accurate 
assessment of these endothermic reactions and differentiates it from the artefacts which 
were commonly seen with differential scanning calorimetry. In this modulated differential 
scanning calorimetry, a sinusoidal heat increase was compared against that of a linear heat 
increase and provided a more distinctive understanding of the polymeric thermal behaviour. 
For this modulated differential scanning calorimetry, the temperature range was set between 
160-180ºC for peak E and 215-220ºC for peak D, with an underlying heating rate of 1ºC per 
minute. The temperature amplitude of modulation was 0.5ºC with a loop segment of 1 and 
an increment of 0.8. Once the sinusoidal heat flow signals were obtained, these signals were 
averaged and a total heat flow could be obtained and allow for comparison against the 
standard DSC curve. The results obtained may be shown as Figure 4.18 a and b.  
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Figure 4.19. a) The MDSC thermogram obtained on peak E. b) The MDSC thermogram 
obtained on peak D. 
 
The melting point of indomethacin in the SAPD and that of indomethacin alone were also 
identical and therefore indicated there was no interaction between the indomethacin and the 
SAPD. The presence of the endothermic peaks in the modulated differential scanning 
calorimtery has confirmed the existence of peak D and E. 
Non-reversing curve 
Reversing curve 
Total heat flow 
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4.7.3. Microscopy of the eroded Stimuli-Actuated Polymeric Device 
 
4.7.3.1. Light microscopy of the eroded Stimuli-Actuated Polymeric Device 
By analyzing the surface morphology, one was able to determine if there were any 
differences between the SAPD and the erosion sites and therefore the possible cause of the 
erosion. The surface morphology imaging was depicted in Figure 4.19 and 4.20. These two 
images were surface morphology of two different erosion sites captured on indomethacin-
loaded SAPD.  
 
Figure 4.20. Microscopy of the first erosion site under 32X magnification. 
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Figure 4.21. Microscopy of the second erosion site under 32X magnification. 
 
As these two figures have shown, the colour of the SAPD at the erosion site was lighter. 
These areas are highlighted in red in the Figure 4.19 and 4.20. This may be attributed to the 
decrease in PANi as the erosion takes place, since it was the PANi that gives this hydrogel 
system the distinctive black colour. It was possible to link PANi to the erosions which 
occurred at these sites. As mentioned in Chapter 4 Section 4.7, the hydrogel system which 
was formed without PANi did not undergo any erosion when exposed to electric current, 
which strongly suggested that the interaction of PANi at the counter electrode played an 
important role towards the erosion of the SAPD. 
 
4.7.3.2. Electron microscopy of the eroded Stimuli-Actuated Polymeric Device 
Following the images obtained from the light microscopy on the erosion site of the SAPD, 
Scanning Electron Microscopy (SEM) was employed in order to obtain enhanced 
magnification of the erosion site. The model of the SEM used was the PhenomTM (FEI 
Company, Hillsboro, Oregon, USA). The application of the SEM allowed us to examine the 
surface morphology of the erosion site at 300-400 X magnification. The results are depicted 
in Figures 4.21 a) and b).   
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Figure 4.22. a) The surface morphology of an uneroded stimuli-actuated polymeric device at 
350x magnification. b) The surface morphology of an eroded stimuli-actuated polymeric 
device at 390x magnification. 
 
Figure 4.21 a and b depicts the difference in surface morphology of the two SAPDs. An 
uneroded SAPD exhibited a smooth surface morphology, which transformed to an uneven 
surface texture after the erosion has occurred. This may be due to the breaking of the 
crosslinked hydrogel structure, as pieces of the SAPD broke away from the main hydrogel, 
leaving the surface irregular and texturally rough. The use of this imaging has further 
confirmed that this erosion phenomenon occurred at a microscopic level. The study done 
thus far has indicated a possible mechanism of the erosion, however, further analysis using 
chemometric modelling would assist us further in determination of the erosion mechanism at 
an atomic level. This modelling is represented in Chapter 5 Section 5.4.3 and was 
undertaken once the SAPD was optimized. 
 
4.7.4. The effect of polyvinyl alcohol and diethyl acetamidomalate on the rate of 
erosion in the Stimuli-Actuated Polymeric Device in the presence of electrical 
stimulation 
In order to determine the affect of varying quantities of PVA and DAA on the erosion of the 
SAPD, five SAPDs with varying constituents were synthesized and exposed to electric 
current. Each system was synthesized with 20mg PANi, but the quantity of PVA and DAA 
were varied from 0.25-1.0g and 0.0-1.0g, respectively. This may be depicted as Table 4.19. 
 
 
 
 
 
 
 
a) b) 
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Table 4.19. Formulation template employed for preparing each SAPD system. 
Formulation DAA 
g (%) 
PVA 
g (%) 
PANi 
mg (%) 
Erosion 
(% of original 
mass) 
 
F1 
 
0.0 (0.0) 
 
0.5 (96.15) 
 
20 (3.85) 
 
14 
F2 1.0 (65.79) 0.5 (32.89) 20 (1.32) 4 
F3 0.5 (64.94) 0.25 (32.47) 20 (2.59) 6 
F4 0.5 (32.89) 1.0 (65.79) 20 (1.32) 7 
F5 0.25 (32.47) 0.5 (64.94) 20 (2.59) 11 
 
 
Each system (F1-F5) was immersed in 25mL of PBS and exposed to 1.2V of potential 
difference for 10 minutes. The formulations were assessed for the extent of erosion and the 
effect of PVA and DAA on the hydrogel system was evaluated. Results revealed that F1 
(14%) and F5 (11%) had higher rate of erosion compared to the minimal erosion rates of F2 
(4%), F3 (6%) and F4 (7%), with F2 having the lowest erosion rate. 
 
The rate of erosion was observed to be dependent on two factors: the extent of crosslinking 
determined by the hardness and the concentration of PANi in the hydrogel. Thus far, data 
has suggested that the lesser the degree of crosslinking and the higher the concentration of 
PANi, the higher the rate of erosion. Generally, crosslinking increases the structural integrity 
of the polymer matrix, thus decreasing the erosion rate (Emerson, 1993; Badenhorst, 2002 
and Couppé, 2009). The water uptake also decreased and the swelling resulted in the 
formation of the rigid structure which ultimately affected the transport of ions across the 
hydrogel (Rokhade, 2007). With regards to the synthesis of the SAPD, the addition of PVA 
formed a loosely bound hydrogel network, the addition of DAA resulted in a rigid crosslinked 
network. In F1, there was no crosslinking between the polymeric chains of PVA due to the 
absence of the DAA, which resulted in a loose network and allowed the erosion of PANi in a 
concentration dependent manner. In addition, the higher mass % of PANi resulted in a 
higher rate of erosion. In the case of F2, the quantity of DAA was increased to twice that of 
PVA, which resulted in a highly dense rigid network structure as compared to F1. The mass 
% of the PANi in the hydrogel system was, furthermore, the lowest as compared to the other 
formulations resulting in the lowest percentage erosion. In the case of F3, having the same 
degree of crosslinking compared to F2, the lower quantity of PVA and DAA employed 
decreased the total hydrogel volume causing the PANi mass % to rise to 2.59%. The 
percentage erosion of F3 was thus similar to but slightly higher than that of F2. Formulation 
F4 was similar to F2 except that the quantity of the DAA and PVA used were switched. F2 
was DAA dominant, which resulted in a rigid network, whereas F4 was PVA dominant 
thereby forming a loose network. Although it both possessed the identical PANi 
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concentration, F4 had a loosely crosslinked network and thus exhibited higher erosion when 
compared to F2. Formulation F5 demonstrated a higher erosion rate compared to F2, F3 
and F4 because, similar to F4, the PVA was dominant over DAA, thus form a loosely 
crosslinked network. Furthermore, the quantity of PVA used was lower compared to F4 and 
resulted in a higher PANi mass %. The concentration of PANi was, however, not higher than 
that of F1. Although it exhibited higher erosion compared to F2, F3 and F4, it was still lower 
than that of F1. 
In order to demonstrate the effect that volume had on the concentration of PANi, light 
microscopy was performed on SAPDs with various volumes. In this experiment, only the 
amount of PVA was varied, while the rest of the constituents were kept constant to the 
SAPD used in Chapter 4 Section 4.5.16. These pictures are demonstrated in Figure 4.22 a-
c. Figure 4.22 a) depicted a device with 0.25g of PVA, which had the smallest volume and 
thus the highest concentration. Figure 4.22 b) showed a microscopy of the device with 0.5g 
of PVA, which had an intermediate volume while Figure 4.22 c) showed the microscopy of a 
device with 1g of PVA, which had the largest volume amongst all three devices.  
 
Figure 4.23. The concentration of PANi when PVA is a) 0.25g b) 0.5g and c) 1g 
 
Figures 4.22 have shown that with an increase in volume of the SAPD, there was a 
decrease in concentration of the PANi, as indicated by a decrease in distribution of the black 
particles. As the volume increased, the more spread out the PANis become, and the less 
electro-responsive the SAPD became.  
 
In order to further substantiate the effects that PANi concentration has on the erosion rate of 
the SAPD, two separate SAPDs were formulated, each with 0.5g PVA, 0.5g DAA and 100mg 
indomethacin. The only difference was that the first SAPD had only 1% w/w PANi while the 
second device had 3% w/w PANi incorporated into it. The two devices were immersed in 
25mL PBS and a potential difference of 1.2V was applied for 400 seconds in order to assess 
the erosion rate. As speculated, the SAPD with the 3% w/w PANi has exhibited a significantly 
higher erosion rate than that of the 1% w/w SAPD.  It was important to bear in mind the PANi 
concentration of the hydrogel system when formulating the drug delivery system. 
a) b) c) 
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Another important factor which determined the erosion rate was the amount of DAA added 
into the system. The more DAA that was added into the system, the less the rate of erosion, 
which suggested that DAA played a role in hindering erosion rate, possibly due to the 
increased crosslinking within the SAPD. In order to confirm this speculation, texture analysis 
was done on 3 different SAPDs. The test performed was a gel compression test. The 
hydrogel was compressed to a distance of 3mm, with a compression rate of 1mm/second. 
The force required to compress the hydrogel over a distance of 3mm was recorded. All three 
SAPDs used were identical to the one used in Chapter 4 Section 4.7, except the amount of 
DAA used was varied to 0g, 0.25g and 1g. The force required to compress the SAPD was 
presented in Figure 4.23 a-c. 
 
Figure 4.24. a) The force required for compression of the stimuli-actuated polymeric device 
with no DAA. b) The force required for compression of the stimuli-actuated polymeric device 
with 0.25g DAA. c) The force required for compression of the stimuli-actuated polymeric 
device with 1g DAA. 
 
From the results obtained from Figure 4.23, there was an increase in the force required for 
compression of the SAPD by 3mm when DAA was incorporated into the SAPD. The required 
force for compression was the same for 0.25g DAA and 1g DAA, indicating there is an upper 
limit to the crosslink between PVA and DAA. This increase in force for compression when 
DAA was added may have indicated a crosslink between the DAA and the PVA as opposed 
to PVA alone. 
 
a) b) c) 
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This crosslinked system may also be tested by formulating two SAPDs, one with DAA and 
one without DAA. The two SAPDs were assessed for its drug release capability in the 
presence and absence of electric current. The two SAPDs were immersed in 20mL of PBS 
and a potential difference of 1.2V was applied for duration of 5 minutes. Samples of 4mL 
were taken afterwards and assessed for drug release. The PBS was discarded and the 
SAPD was immersed in a fresh batch of 20mL PBS. Samples were taken from 5 different 
SAPD. Figure 4.24 depicts the drug release from a SAPD with DAA and Figure 4.25 depicts 
the drug release from a SAPD without DAA. 
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Figure 4.25. Drug release from the stimuli-actuated polymeric device with DAA. 
n = 3 
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Figure 4.26. Drug release from the stimuli-actuated polymeric device without DAA. 
 
From Figure 4.24 and Figure 4.25, one may see that drug release decreased significantly 
with the addition of DAA, suggesting the role of DAA in the SAPD as a crosslinker. Drug 
release was the highest initially and gradually dropped until a consistent drug release was 
reached. This may be due to the fact that this erosion was a surface phenomenon. As the 
SAPD erodes away, the surface-to-volume ration decreases, which rendered less and less 
surface to participate in the erosion until a consistency was reached.  
 
Based on the data obtained in this Chapter, the preliminary mechanism of drug release may 
be interpreted as follows. When the SAPD was placed under the two electrodes during the 
drug release study, PANi coated around the counter electrode. It was assumed that the 
PANi was drawn towards the counter electrode. The experiment done in Chapter 4 Section 
4.5.13 has shown that when PANi was incorporated into the crosslinked hydrogel system, it 
decreased the degree of crosslinking by becoming entrapped between the three dimensional 
network of the hydrogel system.  When the counter electrode was placed onto the surface of 
the hydrogel, the PANi which was entrapped became drawn to the electrodes, and released 
itself from the SAPD. The PANi may have broken the crosslinked bond between the PVA 
and the DAA during this process, thus resulting in a weakening of structure and ultimately 
erosion. Since only the PANi which was close to the gold counter electrodes were drawn, 
only the structures around the electrodes will be weakened. This may explain the 
phenomenon of surface erosion. This schematic may be presented by Figure 4.26. 
n  
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Figure 4.27. The proposed mechanism of the drug release from stimuli-actuated polymeric 
device. 
 
This mechanism of erosion would require an even and adequate distribution of PANi 
throughout the hydrogel in order to achieve optimum drug release. As seen in Figure 4.17, 
the opaque areas where PANi was depleted have ceased to erode in the presence of the 
electric current. An increased amount of PANi should be considered for the optimization of 
the hydrogel system, however, the exact mechanism of the drug release and the erosion 
should be elucidated by further characterization of the SAPD. 
 
4.8. Concluding remarks 
 
In order to synthesize a SAPD which was electroactive, a hydrogel with adequate structural 
integrity and drug entrapment was synthesized. Hydrogel such as methylcellulose lost its 
structural integrity in water and was unsuitable. A crosslinked hydrogel between PVA and 
Eudragit® retained its structural integrity in water but exhibited a weakened structure when 
placed in basic pH, such as the PBS used with a pH of 7.4. This may have rendered the 
PVA/Eudragit® unsuitable due to its instability under physiological pH. PVA with a lower 
molecular weight was used, but was eventually replaced with a high molecular weight PVA 
because it exhibited no structural degradation when placed in solvents like water or PBS. 
Like other hydrogels, it exhibited swelling and the drug entrapment with indomethacin and 
diclofenac sodium was good. The compatibility between SAPD and various NSAIDs has also 
been investigated. NSAIDs were chosen because it could act locally and it has high potency. 
= polyaniline 
= indomethacin 
118 
 
The difference in this drug behaviour may be due to factors such as charge, molecular size 
and solubility of the drugs. It was important to ensure that the drug with the most appropriate 
characteristics was chosen. From this study, indomethacin has shown the best compatibility 
with the SAPD and was the drug of choice for this system. The major problem presented 
with several other NSAIDs was the leakage observed from the SAPD. In order to allow 
optimization and modification, it was important to assess the drug release mechanism and 
physicomechanical behaviour of the SAPD. In this Chapter, the SAPD was constructed 
through a crosslinked hydrogel by employing various polymers. After the crosslinked 
hydrogel was synthesized, drugs were entrapped and DEE was used to assess the amount 
of the drug within the SAPD. Certain drugs were not retainable by the SAPD and drug 
leakage occurred, thereby rendering it unsuitable for the SAPD. Entrapped drugs were 
liberated when the SAPD underwent erosion. The erosion occurred may be attributed to the 
breakage of crosslinks between the PVA and DAA. Breaking a crosslink has been achieved 
by other researches and is a possible mechanism of release (Tezel, 2005; Susic, 2004; 
Conway, 1983). One reason for elucidation of the drug release mechanism of the SAPD was 
that it allowed the optimization of the SAPD. By understanding the factors such as the 
degree of polymerization, PANi distribution and drug entrapment, we could understand how 
these factors influenced drug release, which in turn allowed modifications to these factors as 
to allow optimum drug release profile. 
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CHAPTER 5 
OPTIMIZATION AND ELUCIDATION OF THE RELEASE MECHANISM OF THE STIMULI-
ACTUATED POLYMERIC DEVICE  
 
 
5.1 Introduction 
 
Once a design of the SAPD was achieved, the following step was the optimization of the 
various factors which affected the SAPD. These factors included internal factors such as the 
ratio of the constituents and external factors such electrical current. These factors may or 
may not affect the physicochemical and the physicomechanical properties of the SAPD, but 
the establishment of these parameters was important.  
 
In order to determine the optimum working range of the SAPD, it was important to start with 
internal factors such as the ratio of constituents and the amount of drugs used. By varying 
the ration of constituents, the rate of drug release may be altered and the physicomechanical 
properties of the SAPD. The crosslinking should be adequate in order to provide good 
structural integrity but does not significantly hinder drug release. The amount of drug loaded 
should be maximized so that more drug release may be achieved and therefore prolonging 
the release cycle of the SAPD. In Chapter 4 Section 4.7.4, the erosion rate of various 
SAPDs under different ratio of constituents was investigated. In this Chapter, we have 
further tested the amount of drug release under various potential differences. Our current 
model suggested that the higher the erosion rate, the higher the drug release. A good 
starting point was to begin with a SAPD which contained a SAPD with high PANi 
concentration, high drug loading and intermediate volume. This should yield a high erosion 
rate while maintaining the structural integrity of the system. In order to ensure the SAPD 
synthesized was appropriate, computer simulation would be done to ensure that the 
optimum ratio was chosen.  
 
Once the internal factors were established, the SAPD would be characterized for its drug 
release rate under different environmental factors. Environmental factors such as 
temperature and current strength was investigated in order to determine what affect these 
factors have on drug release. A change in temperature may affect the visco-elastic property 
of the SAPD. This change in physicomechanical property may determine the storage 
conditions and stability of the SAPD. Other characterization may have included properties 
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such as melting points, glass transition temperature and thermal degradation. Both 
characterization and optimization would be important in order to establish a foundation for in 
vivo experimentation.  
 
5.2. Materials and Methods 
 
5.2.1. Materials 
The conductivity tester used was the TDSTestTM Kit Model WD-35661-70 (Oakton® 
instruments, Vernon Hills, IL, USA). The Box-Behnken quadratic design was performed by 
the use of a Minitab Statistical Software, Version 14 (Minitab Inc., State College, PA, USA) 
The potentiostat/galvanostat used for the cyclic voltammetry was the PGSTAT302N 
(Autolab, Utrecht, Netherland). Molecular Mechanics (MM) Computations in solvated system 
with water as solvent were performed using the HyperChemTM 8.0.8 Molecular Modeling 
System (Hypercube Inc., Gainesville, Florida, USA) and ChemBio3D Ultra 11.0 
(CambridgeSoft Corporation, Cambridge, UK) on an HP Pavilion dv5 Pentium Dual CPU 
T3200 workstation. The rheometer used was the Haake Modular Advanced Rheometer 
System (Thermo Electron Corporation, Waltham, MA, USA). Arthrexin® 25mg capsule was 
used for comparative dissolution study. The dissolution machine used was Calev® Model 
7ST (Techne, Cambridge, England). The software used for blood-drug concentration 
simulation was the Vensim PLE. 
 
5.2.2. Optimization of external and internal factors of the Stimuli-Actuated Polymeric 
 Device 
 
5.2.2.1. The optimization of the constituent ratio in order to achieve rapid drug release 
upon activation. 
The role that various polymers have contributed to the SAPD was previously assessed. 
Taking these factors into consideration, a SAPD with minimal crosslinking, intermediate 
volume and high PANi concentration should be a favourable starting point for further 
optimization of the SAPD. An experiment was conducted by immersing SAPD in 20mL of 
PBS followed by exposure to electric current for 45 seconds. The SAPD was left in the PBS 
for an hour prior to actuation with electrical stimulation. Samples were taken before and after 
actuation in order to assess the amount of drug released and if there was any drug leakage 
during the absence of electric current. This experiment was conducted over a three hour 
period. The SAPD was synthesized using 0.5g PVA, 0.5g, 2%w/w PANi and 100mg 
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indomethacin. The DEE for this device was 70.25%. The results may be presented by Figure 
5.1. 
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Figure 5.1. The fractional drug release profile of the stimuli-actuated polymeric device over a 
three hour period with 45 seconds of electric current at an hourly interval. 
 
Based on results from Figure 5.1, the SAPD was capable of controlled release of drug in the 
presence of an electric current, although the initial release cycle was higher than the 
subsequent cycles. The stepwise increase in drug was an indication of a favourable drug 
release profile because it demonstrated significant increase in drug release when the SAPD 
was exposed to electric current for the short amount of time. It was important to determine 
the effects that various potential difference has on the SAPD. In order to standardize the 
potential difference applied, SAPDs were synthesized and exposed to varying potential 
differences of 0.3V, 1.2V, 2V, 3V, 4V and 5V. The drug release profiles were assessed and 
compared to the drug release profile of the SAPD under 1.2V. This would allow 
determination of any difference in terms of drug release behaviour and response caused by 
a difference in the voltage applied. The results may be summarized by Figure 5.2 which 
depicts fractional drug release against time when the SAPD was exposed to various 
potential differences.  
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Figure 5.2. The fractional drug release from the stimuli-actuated polymeric device when 
exposed to various potential differences. 
 
The results obtained from Figure 5.2 indicated that the drug release increased with an 
increase in the applied potential difference. By analyzing this result, it was possible to 
achieve a release of a therapeutic dose of indomethacin based on an ‘ON-OFF’ drug release 
profile. A high fractional drug release from the SAPD meant that the implant would have to 
be replaced frequently and is unfavourable.   
By using the fractional drug release obtained after 4 release cycles, it enabled us to 
calculate the maximum amount of drug release possible under varying voltages. Figure 5.3 
depicted the number release cycle possible when varying potential differences were used. 
The number of drug release achievable was constant between potential differences of 1.5V 
to 3.5V, as the fractional drug release did not differ significantly. However, the number of 
release cycle seemed to change drastically when the potential difference was shifted outside 
this range. 
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Figure 5.3. The quantity of drug release cycles achievable when various voltages were 
applied. 
 
From Figure 5.3, we could determine the quantity of drug releases from the SAPD when 
various voltages were applied. Based on the results obtained from Figure 5.2 and Figure 5.3, 
it seemed feasible to use 1V as the optimum potential difference for the actuation of the 
SAPD. By using 1V as the standardized potential difference, it offered a release cycle of 
approximately 60 and provided adequate drug release of approximately 0.7mg into the 
surrounding area. This study was important as the optimization of the actuation voltage 
greatly affected the number of release cycles and the amount of drug released from the 
SAPD. 
 
5.2.2.2. The optimization of the Stimuli-Actuated Polymeric Device with the use of a 3 
Factor Box-Behnken Design 
Once the actuation voltage was determined, the next step of optimization was to determine 
the ratio of the optimum constituents before further analysis can be performed. This study 
was guided through a three factor, three centre points Box-Behnken quadratic design. In 
order to form an optimized SAPD with high drug entrapment and minimum erosion, fifteen 
SAPDs with various combinations of the independent variables were synthesized and tested 
in accordance to their drug release profile, drug entrapment efficiency and rate of erosion. 
The three independent variables employed for the synthesis of SAPD included the hydrogel 
component formed by polyvinyl alcohol, the crosslinker DAA used to increase the structural 
integrity of the hydrogel and the EAP, namely PANi, to enhance the conductivity of the 
N = 3 
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SAPD. Table 5.1 represents the upper and lower limits for each of the variables. The limits 
for these variables were based on its ability to form a stable SAPD with optimal percentage 
drug release (maximum amount of drug release before depletion) with a minimal erosion rate 
and the 15 combinations for the SAPD.  
Table 5.1. The upper and lower limit levels used for the Box-Behnken template. 
Independent 
variables 
Levels  Units 
Low High 
PVA 0.5 0.8 Grams 
DAA 0.0 0.3 Grams 
PANi 1.0 4.0 %w/w 
Formulation  Composition   
PANi (%w/w) PVA (g) DAA (g) 
1 1.00 0.80 0.15 
2 4.00 0.65 0.30 
3 1.00 0.65 0.30 
4a 2.50 0.65 0.15 
5 2.50 0.80 0.00 
6 4.00 0.80 0.15 
7 1.00 0.65 0.00 
8a 2.50 0.65 0.15 
9 2.50 0.50 0.00 
10 4.00 0.50 0.15 
11 2.50 0.50 0.30 
12a 2.50 0.65 0.15 
13 2.50 0.80 0.30 
14 1.00 0.50 0.15 
15 4.00 0.65 0.00 
 
Note: a The centre points for experimental design template 
 
The 15 SAPDs were made as according to the combination depicted in Table 5.1. Each 
SAPD was given a constant dosing of 100mg indomethacin and the SAPDs were assessed 
for its drug release profile, drug entrapment efficiency (DEE) and the rate of erosion.  
The preparation of the SAPD was based on the optimized values obtained from the Box-
Behnken Design. The optimized value was obtained through a three factor, three centre 
point Box-Behnken quadratic design by measuring the drug release profile, the drug 
entrapment efficiency and the erosion rate of the SAPD. The aim of this design was to obtain 
a SAPD with drug release of approximately 1.7% of the total drug per release, with a 
maximum DEE and minimum erosion. The effects of the PVA, DAA and PANi on the SAPD 
was depicted in Figure 5.4 and the results of the optimization obtained from the Minitab® 
software are depicted in Table 5.2. 
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Figure 5.4. Optimization plots showing the effects of polyvinyl alcohol (PAA), polyaniline 
(PA) and DAA on the Drug release profile, DEE and the Erosion of the stimuli-actuated 
polymeric device. 
 
Table 5.2. The results obtained from Minitab® for the optimization of the stimuli-actuated 
polymeric device. 
Formulation Drug Release after 
8 cycles (%) 
DEE (%) Erosion (% of 
original weight) 
1 1.90 89.44 5.50 
2 12.00 37.89 17.32 
3 18.00 43.18 10.43 
4 24.00 36.62 14.16 
5 16.00 39.74 8.97 
6 11.00 59.22 7.36 
7 5.90 73.67 5.67 
8 57.00 23.87 4.28 
9 12.00 82.02 15.91 
10 7.70 82.43 23.39 
11 15.80 41.95 8.77 
12 24.40 36.07 24.36 
13 42.00 34.25 9.05 
14 41.00 25.07 15.31 
15 34.00 26.63 10.16 
d = The probability of obtaining the yield value with the optimized values 
D = The probability of the SAPD having the indicated yield value for drug release, DEE and 
erosion rate  
 
Table 5.3 The probablility of achieving each of the ideal characteristics when employing the 
yielded optimal value 
Drug Release  
Target = 1.7% 
Yield =  1.9040 
d = 0.99993 
 
 
DEE 
Target = Maximum 
Yield = 80.5381 
d = 0.87179  
Erosion rate 
Target = Minimum 
Yield = 6.3201 
d = 0.93052 
 
D = 0.93261 
Optimal = PANi (1.3418%w/w), PVA (0.8g), DAA (0.0689g) 
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The result depicted by Figure 5.4 demonstrated the effects of various components on the 
SAPD. An increase in PANi tended to increase drug release, due to the increase in erosion 
and interaction with the electrode. The DEE was, however, decreased with an increase in 
PANi. Both the PANi and indomethacin were incorporated into the SAPD via entrapment 
during the crosslinking of the hydrogel system. With the PANi and indomethacin competing 
with each other for entrapment, an increase of PANi in the hydrogel would mean a decrease 
in indomethacin. The erosion rate of the SAPD increased with an increase in the PANi 
concentration, although this increase reached a plateau with only a minute increase in PANi. 
The next constituent tested was the PVA. An increase in PVA decreased the erosion rate 
and ultimately the drug release rate. This decrease in erosion was attributed to the decrease 
in the PANi concentration caused by the increase in the volume of the hydrogel. The DEE 
was increased overall due to increased hydrogel volume which allowed more entrapment of 
the drug during the crosslinking. The last constituent used was the DAA. Results indicated 
by the Box-Behnken Design has indicated an overall increase in erosion and drug release 
rate, which was contradictory to our previous study done in Chapter 4 Section 4.7.4. An 
increase in DAA increased the crosslinking and thus the structural integrity of the SAPD. 
However, the results from this test indicated that DAA could have played a more significant 
role in the drug release mechanism of the PANi hydrogel system other than the crosslinker. 
These results may be depicted as Figure 5.5 which shows the effect of DAA, PANi and PVA 
on the drug release and the erosion of the SAPD. 
 
Figure 5.5. The surface area plot depicting the effect of a) DAA b) PANi and c) PVA on the 
SAPD 
 
An optimized SAPD may be synthesized by employing 0.8g PVA crosslinked with 0.0689g of 
DAA with 1.3418%w/w PANi incorporated within has a probability of 0.93261 of achieving the 
desired yield value as indicated by Table 5.2. The amount of indomethacin used for the 
formulation remained 100mg. The DEE should be approximately 80%, as indicated by the 
software, when used in these combinations. 
 
 
a) b) 
c) 
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5.3. Results and Discussion 
 
5.3.1 The characterization and evaluation of the optimized Stimuli-Actuated Polymeric 
Device  
Following the optimization of the SAPD with the use of the Minitab® software, the SAPD was 
synthesized according to the optimized value and evaluated in terms of its drug release 
profile, the DEE and the erosion rate. The quantity of the constituents used was the 
optimized value of 0.8g PVA crosslinked with 0.0689g DAA and a PANi concentration of 
1.3418%w/w. The amount of indomethacin used for this study remains 100mg. This optimized 
SAPD was tested for its drug release profile, DEE and erosion. The results obtained were 
compared against the target value obtained by the Box-Behnken Design. The results 
obtained for the drug release profile after 4 release cycles is depicted as Figure 5.6.  
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Figure 5.6. The drug release profile of the optimized stimuli-actuated polymeric device after 
4 release cycles. 
 
The results obtained were satisfactory when compared to the target values determined by 
the Box-Behnken design. The values for drug release profile, DEE and erosion rate were 
1.622%±0.1857% (target 1.7%), 76.32±10.46% (target 80.5381%) and 5.73%±1.26% (target 
6.3201%) respectively. Once these values were confirmed, the SAPD would be synthesized 
in accordance with these optimized values. The SAPD was further characterized in terms of 
its electroactivity and other properties. 
 
n = 3 
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5.3.2. Cyclic voltammetry of the the Stimuli-Actuated Polymeric Device 
Cyclic voltammetry was performed on the SAPD in order to assess its electroactivity. The 
cyclic voltammetry was performed using PBS (pH 7.4) as the conducting solvent (Raoof, 
2009; Zeng, 2002). The SAPD were homogenized into the PBS via a homogenizer for a 
period of 5 minutes followed by sonication at amplitude of 70% for a period of 3 minutes. The 
sonicator used was the Vibra-CellTM (Sonics® Sonics & Material Inc., Newtown, CT, USA). 
The resultant solution was purged with nitrogen gas for 3 minutes prior to the cyclic 
voltammetry. The cyclic voltammetry was performed with the conventional three-electrode 
system with a saturate Ag/AgCl (3.0M KCl) as the reference electrode, a platinum wire as 
the auxiliary electrode and a 5mm glassy carbon electrode as the working electrode (Le, 
2009). The scan rate of this cyclic voltammetry was 0.1V/second. 
Cyclic voltammetry was performed in the SAPD in order to assess its electroactivity. The 
cyclic voltammetry showed the presence of two reduction wave and one oxidation wave. The 
range of the scan was from 2V to -2V with a scan rate of 100mV/second. The voltammogram 
was depicted in Figure 5.7. 
 
Figure 5.7. Cyclic voltammetry of the stimuli-actuated polymeric device in PBS. 
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The cyclic voltammetry of SAPD confirmed the presence of charge capacity (area under CV 
curve) for the SAPD. The curve indicated the presence of an intrinsic redox reaction 
between the electrode and the SAPD at the potential applied between 2V and -2V resulted 
from ion exchange between the electrodes and the electrolytes in the solvents carrying the 
mobile charge carrier to and from the SAPD. Under normal circumstances, PANi exhibited 
two pairs of redox peaks, one at 350mV and the other at 800mV (Wang, 1999). The 
voltammogram depicted in Figure 5.7 also exhibited two pairs of redox waves, however, 
these peaks have shifted to the right. These redox potentials shift may be due to more 
intricate reactions occur between the PANi, the hydrogel matrix, the electrolytes and the 
electrode. The result obtained from Figure 5.7 had indicated an oxidation peak occuring at 
approximately 0.6V and 1.4V and a reduction peak occuring around 1.5V and -1V. Since the 
PANi used for the synthesis of the SAPD was PANi emeraldine base, the first oxidation peak 
may be attributed to the transition of the first emeraldine oxidation state to the second 
emeraldine oxidation state. The second oxidation wave may be attributed to the transition of 
the second emeraldine oxidation state to the pernigraniline oxidation state (Chao, 2006). The 
change in the curve obtained in Figure 5.7 as compared to a standard voltammogram of 
PANi most likely resulted from ionic interactions occuring at the various interfaces between 
the PANi, hydrogel matrix, electrode and the electrolyte. 
 
5.3.3. Conductivity measurement of the Stimuli-Actuated Polymeric Device 
The SAPD was assessed for its conductivity in order to determine the role of the PANi in the 
SAPD. SAPDs with PANi concentrations of 1%, 2.5% and 4% w/w were synthesized. The 
results obtained are summarized in Table 5.3. 
Table 5.4. The conductivity obtained from the SAPD containing various concentrations of 
PANi. Six readings were obtained for each concentration and an average was recorded as 
the result. 
PANi concentration (%w/w) Conductivity (µS) 
 
1 
 
97.45 ± 7.00 
2.5 108.20 ± 4.52 
4 
 
130.30 ± 11.99 
 
The results from Table 5.3 indicated a linear increase in the conductivity of the SAPD with an 
increase in the PANi concentration. This increase may be contributed to the possibility that 
an increase in the PANi concentration within the hydrogel will result in a denser network 
structure of PANi and allowed more pathway for the electric current to travel between the 
two electrodes.  
 
130 
 
5.3.4.  Molecular mechanics simulations of the Stimuli-Actuated Polymeric Device 
The octamer of PANi and hexadecamer of polyvinyl alcohol was generated from standard 
bond lengths and angles employing polymer builder tools using ChemBio3D Ultra in its 
syndiotactic stereochemistry as 3D model. The individual polymer models were initially 
energy-minimized using MM+ force field and the resulting structures were again energy-
minimized using the Amber 3 (Assisted Model Building and Energy Refinements) force field. 
The conformers having the lowest energy were used to create the polymer-polymer 
complexes (PVA-PANi). All MM simulations were performed under the influence of an 
external electric field ranging from 0.00a.u. to 0.05a.u. for cubic periodic boxes with 
dimensions of 25×12×25Å3 containing one centred PVA-PANi complex with the centre of the 
cubic box and the remaining free space filled with water molecules and the same procedure 
of energy-minimization was repeated to generate the final models: PVA-PANi-0.01 to PVA-
PANi-0.05. Full geometry optimizations were carried out in solvated system employing the 
Polak–Ribiere conjugate gradient method until an RMS gradient of 0.001kcal/mol was 
reached. Force field options in the AMBER (with explicit solvent) were extended to 
incorporate cut-offs to Inner and Outer options with the nearest-image periodic boundary 
conditions. The outer cut-off was set to 6.46Ångstroms and the inner cut-off was set to 2.46 
Ångstroms to ensure that there were no discontinuities in the potential surface. 
 
The environment surrounding the molecules of interest in molecular mechanics was defined 
in terms of a solvated system to prevent artefacts that arise from vacuum simulations and to 
reproduce bulk solvent properties well. Although the system could also be simulated in 
vacuum, but it may introduce artefacts in the molecular geometry due to surface charges of 
the charged molecules interacting with each other (as opposed to interaction with the solvent 
in a solvated system), producing molecular conformations that are unlikely to be present in 
any other environment. The system in present research was solvated by placing explicit 
water molecules in the simulation box with PVA-PANi complex and an external electric field 
in the direction of x-axis and of magnitude of 0.00a.u. to 0.05a.u. was applied to corroborate 
the electro-liberation of indomethacin form the SAPDs under the influence of applied 
potential. The calculated values for the various energies for the PVA-PANi MM simulations 
under the external electric field are illustrated separately as bond, angle (torsion) and van 
der Waals energies in Table 5.4. The total steric energy of the PVA-PAVi complex increased 
with an increase in the electric field magnitude from 0.01au to 0.05au indicating the 
instability caused by the applied external electric field (Figure 5.8). This instability in majority 
was caused by bond torsion (82.93-335.47 kcal/mol) stretching followed by bond angle 
(44.67-141.34 kcal/mol) and minimally by van der Waals interactions (71.56-9857 kcal/mol). 
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Table 5.5. Calculated energy parameters (kcal/mol) of the PVA-PANi complex in a solvated 
system under the influence of electric field. 
Structure Energy (kcal/mol) 
Total ∆E stimulation Bond Angle vdW 
 
PVA-PANi-0.00 
 
-3115.92 
 
- 
 
33.4948 
 
56.3898 
 
71.5598 
PVA-PANi-0.01 -2826.36 +289.56 44.6791 82.9305    72.6148 
PVA-PANi-0.02 -2643.41 +472.51 61.2286 129.845    76.1276 
PVA-PANi-0.03 -2213.01 +902.91 86.1102 184.596    82.4647 
PVA-PANi-0.04 -1982.23 +1133.69 111.422 255.45    91.9177 
PVA-PANi-0.05 -1772.02 
 
+1343.9 141.338 335.476 98.5723 
vdW: van der Waals energy 
 
 
Figure 5.8. Variation in total steric energy as a function of applied external electric field. 
 
The two strands of polymers were tightly bonded in a helical model, as shown by the 
plausible molecular model of the complex (Figure 5.9). This coiled coil state may be 
responsible for the non-decomposition, non-unwinding or non-eroding of the complex on its 
own in solvent. External electric fields may change the neutral arrangement of electrons on 
the surface of SAPDs and produce electrical forces that change the mechanical behaviour 
causing the adduct to form a coiled coil rather than an extended chain and resulted in the 
formation of globular aniline-vinyl complex. The MM simulations estimated the energy 
associated with vibration about the equilibrium bond length and the models tend to break 
down as a bond was stretched toward the point of dissociation. Further, the charge 
distribution affected the external electric field and made a new net field causing the outer 
shell of gel to reach the critical concentration for erosion and flake off. The increase in 
energy levels of hormonic oscillators, bond and angle terms, may have resulted in instability 
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which in turn caused complex dissociation followed by conversion of polymers into 
respective monomer units to stabilize the steric energy as electric field was increased in 
magnitude. These energy variations and subsequent erosion can be quantified in terms of 
amount of indomethacin released after the respective applied electric potential.   
 
Figure 5.9. Visualization of geometrical preferences of PVA-PANi molecule after molecular 
simulation in a solvated system under external electric field. Colour codes- PANi (yellow), 
PVA (red) and water molecule (blue). 
133 
 
5.3.5. Rheological study of the Stimuli-Actuated Polymeric Device 
The importance of rheological study in a hydrogel system is fundamental as the behaviour of 
the SAPD may vary between different temperatures (Carvalho, 2010). Rheology is the study 
of the flow of a matter. This study of flow is not particularly important in a solid as it did not 
exhibit much flow. In the case of a semi-solid and liquid, the stress and strain may affect the 
character of the substance, such as the case of a thixiotropic flow. In this case, the system 
exhibited solid properties when left alone, but shifts to liquid properties when force was 
exerted onto the system (Donald, 1971). The study of rheology extends deeply into a wide 
variety of fields. Semi-solids which are mixed, sprayed, pumped, moulded, cooled, heated or 
rubbed have to undergo the rheological testing in order to test the stability of the system 
under various factors. Rheology has been mainly utilized in the pharmaceutical field as a 
polymer science.  The characterization of the viscoelasticity behaviours of the polymers was 
an important factor, as it determined how the polymers behaved under mechanical stress. 
These properties may be affected by variables such as temperature, pressure, aging and the 
molecular weight of the polymer used. The testing of rheological properties is important in 
the field of pharmaceuticals in terms of tablet coating, spray coating, electrophoresis and roll 
coating (Honary, 2003). For the rheological study of the SAPD, the SAPD was initially 
dissolved into water by heating, upon which a gel was formed. This gel was tested by the 
use of a rheometer in order to assess the rheological property of the SAPD. The SAPD was 
dissolved by immersing 3.2g of SAPD into 10mL of water. The water was heated to boiling 
point and cooled to room temperature, which resulted in the gel formation.  This gel was 
subjected to rheological study under specific test conditions. With the use of the rheometer, 
it was possible to determine the yield value and the storage and loss modulus of the SAPD 
in the semi-solid state. For a rheological study, there are several setups which may be 
utilized. These setups are shown in Figure 5.10. 
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Figure 5.10. The possible setup of the rheometers which can be used. Each setup is 
suitable depending on the characteristic of the material being tested. 
 
Since the SAPD formed a gel with an intermediate viscosity after it was dissolved, a parallel 
plate setup was chosen for thus rheological assessment. The first test performed was the 
determination of yield value of the SAPD in the semi-solid form. This was done by plotting a 
stress-strain graph of the SAPD. The strain, which was the percentage displacement of the 
SAPD, was plotted against the stress, which was the pressure exerted upon the hydrogel. 
The determination of yield value was tested for the amount of force required before 
deformation occurred on the SAPD. The result may be depicted as Figure 5.11. 
 
Figure 5.11. The yield value of the stimuli-actuated polymeric device. 
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The yield value indicated by the rheometer suggested that 1.295 Pa was required in order to 
deform the SAPD from its elastic state. This data demonstrated that the SAPD is capable of 
withstanding 1.295 Pa of force before permanently deformation occurs. The determination of 
the yield value was important as it allowed assessment of the pressure that the SAPD was 
able to withstand before in undergoes deformation. However, it did not assess the 
viscoelastic behaviour of the polymer system. For this purpose, the oscillatory rheology was 
used in order to assess the mechanical behaviours of the SAPD. 
 
Oscillatory rheometry exerts a sinusoidal shear deformation to the specimen held between 
the two plates. The bottom plate exerts a strain on the sample via rotation, while the top 
plate remains stationary. A sinusoidal strain deformation was exerted to the sample, and the 
resultant torque exerted by the sample onto the upper plate was recorded as stress. The lag 
between these stress-strain relationships would demonstrate whether the sample exhibited 
predominantly plastic, viscous or viscoelastic properties. This relationship may be presented 
in Figure 5.12.  
 
 
 
Figure 5.12. The lag between the stress-strain which may be used to determine whether the 
material under analysis exhibits predominantly liquid or solid properties (Weitz, 2007). 
 
This information allowed us to determine the storage modulus (G’), loss modulus (G”) and 
the dynamic viscosity. The measurement of these factors assisted with evaluation in regards 
to solid or liquid behaviour of the SAPD at any time when the sinusoidal shear was exerted. 
In order to determine the modulus characteristic of the SAPD, oscillatory frequency sweep 
δ = 0 δ = π/2 
0 < δ < π/2 
Elastic solids Viscous fluid 
Visco-elastic materials 
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was performed. The aim of this test was to start from a low frequency and end up with a high 
frequency while measuring the storage and loss modulus of the SAPD on the same set of 
axis. The result would be the crossover frequency and the modulus characteristic of the 
SAPD under different forces. This study started from a frequency of 0.5Hz and was 
continued until the loss modulus and the storage modulus crossover. The results obtained 
would allow determination of the sheer when the liquid characteristics of the SAPD were 
equal to that of the solid characteristics. The result obtained was depicted as Figure 5.13.  
 
Figure 5.13. The results obtained by oscillatory frequency sweep showing both the storage 
modulus and the loss modulus of the stimuli-actuated polymeric device. 
 
The results obtained from Figure 5.13 have shown that the crossover frequency occurred at 
approximately 70Hz. Equation 5.1 was used in order to convert the frequency into cycles per 
second. 
 
  	
                  Equation 5.1 
 
Where ω = angular speed measured in radians per second. 
  f = ordinary frequency measured in Hertz 
 
Based on the crossover frequency of 70Hz, the angular frequency may be calculated 
as       giving an angular speed of 439.6 radians per second. In order to convert the 
radians per second into cycles per second, we divided the 439.6 by 6.283, giving a value of 
69.97 cycles per second. This indicated that the SAPD was able to withstand a high amount 
of stress before the solid property was lost under room temperature.  
 
G’ = f (t) 
G” = f (t) 
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The next part of the study was to assess the temperature stability of the SAPD. In this study, 
the angular speed was kept at a constant of 10Hz, while the temperature was increased 
gradually from 20ºC to 50ºC. The storage and loss modulus was recorded and the 
temperature where the crossover occurred was recorded. The results may be depicted in 
Figure 5.14. 
       
Figure 5.14. The effect of temperature on the storage and loss modulus of the stimuli-
actuated polymeric device. 
 
As with all semi-solids or viscous fluids, the higher the temperature, the more liquid 
properties it exhibits and the less viscous it becomes. Based on Figure 5.14, the SAPD 
exhibited primarily solid state behaviours until the crossover temperature was reached at 
approximately 43ºC. At this point, the liquid state properties were almost equivalent to that of 
the solid state properties. Therefore, at a temperature of 43ºC or higher, the SAPD would 
behave in a semi-solid manner, with liquid properties dominating at higher temperature. As 
indicated, the SAPD should be stable if stored below 40ºC. By measuring these properties, it 
would allow the determination of the storage conditions of the SAPD in order to preserve its 
potency and efficacy. As indicated by the results obtained from this study, the SAPD offered 
good stability and handling under room temperature.  
 
 
 
G’ = f (t) 
G” = f (t) 
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5.3.6. The comparison of the in vitro drug release profile between the Stimuli-Actuated 
Polymeric Device and the conventional oral system of indomethacin 
This study aimed to compare the drug release profile of the SAPD as opposed to the 
conventional oral drug delivery system. The controlled release of SAPD should offer better 
targeted drug release with reduced side effects due to decreased systemic circulation of the 
indomethacin. The drug release profile of the optimized SAPD was compared against the 
drug release profile obtained from a 25mg indomethacin capsule. The capsules used for this 
study was the Arthrexin® 25mg capsule. The drug release profile was obtained by immersing 
the capsule in a buffer of pH1.2 and 6.4 respectively. The temperature of the buffer was kept 
at a constant of 37ºC. The capsule was kept under a mesh positioned 2cm under the rotor in 
order to prevent the capsules from floating. The speed of the rotor was set to 50RPM as in 
accordance with the USP. Samples of 5mL were taken at an interval of 10 minutes and 
analyzed with the UV/visible spectroscopy. Five mL of fresh buffer was replaced after each 
sample was taken and the dilution factor was taken into account. The drug release from the 
indomethacin was expected to be higher in the pH 6.4 medium as it exhibited higher 
solubility in basic pH. The results obtained from the UV/visible spectroscopy may be 
depicted by Figure 5.15.  
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Figure 5.15. The drug release profile of the conventional oral system compared to the 
stimuli-actuated polymeric device. 
 
The drug release profile from the oral indomethacin system was done with a gastric retention 
time of 70 minutes. The oral system was left in the pH1.2 buffer for 70 minutes, after which 
the system was transferred into the pH6.8 buffer. The drug release profile has indicated that 
drug release by the oral system in the stomach was minimal as compared to the intestinal 
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release. This may be attributed to the poor dissolution of indomethacin in the presence of an 
acidic environment as opposed to the basic environment of the intestine (Nokhodchi, 2005). 
The results obtained in Figure 5.15 showed that as opposed to the oral system, the SAPD 
was capable of controlled and prolonged release over a longer period of time with an “ON-
OFF” mechanism. In addition, this would limit the amount of indomethacin in the systemic 
circulation and thus targeted release with minimal side effects. Another way to describe the 
advantage of this system over the conventional system may be shown by a computer 
generated simulation. This simulation depicted the conventional dose-related problem 
associated with oral system. The software simulation was performed with an eight hourly 
dosing of indomethacin. The results may be shown as Figure 5.16. 
 
Figure 5.16. The computer generated simulation of an eight hourly dose of 25mg 
indomethacin. 
 
Suppose the therapeutic window of indomethacin is between 30mg to 40mg of 
indomethacin, the drawback of a conventional oral dose becomes apparent. After the 
administration of the first dose, the patient would experience no effect since the drug had not 
reached the therapeutic windows. Following subsequent dosing, the patient did indeed reach 
therapeutic dose, but further dosing would result in peaks of toxicity whereby the patient 
would experience side-effects. The patient would also experience subsequent inefficacy 
where the drug diminishes below the therapeutic window some time before the next dose. 
This problem was commonly seen with oral dosing of drugs. With the use of targeted and 
controlled release of drug at the local site, it was possible to overcome these problems. 
 
5.4. Concluding remarks 
 
The use of HyperChemTM 8.0.8 Molecular Modeling System, ChemBio3D Ultra 11.0 and 
various other equipments allowed us to analyze and characterize the SAPD at a molecular 
Inefficacy 
Therapeutic 
Toxicity 
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level. The use of these tools proved to be invaluable for the elucidation of the mechanism of 
drug release and erosion of the SAPD. The mechanism of erosion was indicated as the 
conversion of the polymer into the monomer and flaking of the outer crust of the gel due to 
charge distribution. The electroactivity of the SAPD was further assessed by the use of a 
cyclic voltammetry, which confirmed the presence of an oxidation-reduction reaction 
occurring when the SAPD was actuated. In addition, cyclic voltammetry has shown a shift of 
the redox peaks, thus suggesting an interaction of the PANi with one of the components of 
the SAPD. The optimization of the SAPD with the use of a 3 factor Box-Behnken Design 
allowed us to establish a relationship between the DAA, PANi and PVA with drug release, 
drug entrapment and erosion rate. The conductivity of the SAPD was further assessed and 
found to be directly proportional with the concentration of PANi in the hydrogel. This was 
further substantiated by the 3 factor Box-Behnken Design as an increase in the PANi has 
indicated an increase in erosion rate. This may be attributed to the increased conductivity of 
the PANi which resulted in an increased electrical flow through the SAPD and ultimately 
increased flaking and erosion. Lastly, the drug release profile of the optimized SAPD was 
compared against the conventional oral system. Results have indicated that indomethacin 
has a low dissolution rate in an acidic environment and drug release from the oral system 
was slow in the first few hours due to gastric retention. This may be attributed to the acidic 
nature of indomethacin which renders it insoluble in acidic environments. The dissolution 
rate did increase drastically when exposed to basic medium.  This is also due to the 
increased solubility of indomethacin in a basic environment. The advantage of the SAPD 
would be the immediate availability of the drug at the target site whenever it was required by 
the patient. Factors effecting drug availability such as dissolution, first-pass metabolism and 
protein binding could be avoided. Since the drug release from the SAPD could be changed 
by varying the various components, it was also possible to synthesize SAPD ranging from 
slow release to fast release in order to treat different patients suffering from varying degrees 
of chronic pain.  
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CHAPTER 6 
IN VIVO EVALUATION OF THE STIMULI-ACTUATED POLYMERIC DEVICE UPON 
SUBCUTANEOUS IMPLANTATION INTO A RAT MODEL 
 
 
6.1 Introduction 
 
The drug release profiles obtained from the SAPD has thus far been in vitro. Most of these in 
vitro studies have been, as much as possible, to simulate an in vivo environment. However, 
several factors such as extracellular fluids and skin conductivity were still difficult to replicate 
and the use of electric current through an in vitro approach may not provide an accurate 
drug release profile of the SAPD when implanted subcutaneously. The use of an animal 
model would provide a more accurate pharmacokinetic and pharmacodynamic profile of the 
SAPD.  
 
The difference between in vivo and in vitro studies may be demonstrated by a simple 
example of bacterial exposure to an anti-biotic agent in an aqueous medium. Firstly, bacteria 
needed a surface onto which it adheres before it was capable of colonization and 
establishing an infection (Ethel, 2006; Soong, 2006 and Yah, 2008). The ultra-structure of 
the bacteria in an aqueous medium was also different to that of the bacteria found in human 
body. The rate of growth of bacteria in vivo was also slower than that compared to in vitro 
(Zak, 1982). The activity of certain anti-biotics such as beta-lactam was significantly affected 
by the rate of growth. Bearing the above factors in mind, it was clear that a pure in vitro 
study regarding the effects of anti-biotics was not sufficient and there was a need for further 
elucidation which required an in vivo study.  
 
A study done on the in vitro-in vivo correlation for indomethacin has proven that blood 
samples and buffer samples did indeed show significant difference in drug concentration, 
Tmax and Cmax. This difference may range from approximately 9-74% for Area Under the 
Curve (AUC), 0-100% for Tmax and 2-89% for the Cmax based on the different apparatuses 
used (Lootvoet, 1992). Difference in data between in vitro and in vivo drug concentration 
was also observed in other drugs and correlation between the two sets of data was still 
necessary (Chen, 1995; Munday, 1955).  The difference in blood concentration of drug 
between the two sets of data was not the only discrepancy. Another example was the 
potentiating effect that indomethacin has on the medullary cyclic AMP. Indomethacin was 
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thought to potentiate the hydro-osmotic action of vasopressin. This may be attributed to the 
ability of indomethacin to suppress the prostaglandins, especially that of prostaglandins E. 
However, the quantification of this effect was difficult to establish and in vivo study was 
necessary in order to obtain these results (Lum, 1977).  
 
From an implantation point of view, drug release profile between in vivo and in vitro may 
differ greatly with just a small variant in thickness of skin, weight of animal model, drug 
concentration and particle size (Balasubramaniam, 2008). The site of implantation may also 
affect the drug release profile due to varying physiological factors present. Factors such as 
presence of inter-cellular protein would affect the interstitial colloidal pressure which would in 
turn affect drug release from the implant (Aukland, 1993). The degree of vascularisation was 
also important as the blood supply was responsible for carrying the drug away from the 
implantation site, and in certain cases, to the target site. Blood vessels also exhibited varying 
permeability in the human body, thus affecting the drug release profile further (Whang, 1989). 
Lastly, the rate of blood flow around the implantation area may vary and affect the drug 
release profile (Iyer, 2006). Blood flow may vary depending of the time of the day, exercising, 
blood pressure and various factors. These factors cannot all be accounted for by using in 
vitro study and hence an in vivo study for the SAPD was crucial in order to assess the 
pharmacokinetics and the pharmacokinetics of the SAPD as accurately as possible.  
 
The drug release from the SAPD was activated by the presence of an electric current 
through the skin. The use of electric current through an in vitro approach (e.g. electrolyte 
solution) did not provide an accurate drug release profile of the SAPD when implanted 
subcutaneously. The use of an animal model would also provide a more accurate 
pharmacokinetic and pharmacodynamic profile of the SAPD. 
 
Rats were a suitable model as it would be unethical to use human subjects as initial 
subjects. The use of animals larger than the rat would present problems as the number of 
animals required by the study was relatively large. One study conducted by Epping-Jordan 
et al. has subcutaneously implanted osmotic minipump containing nicotine using rat model 
(Epping-Jordan, 1998). Subcutaneous implant in rat model has been done on several 
studies in various fields of research (Tomilla, 2008; Russo, 2007; Macleod, 2005 and Arenaz, 
2004). The blood samples obtained would be analysed with the use of High Performance 
Liquid Chromatography and Ultra Performance Liquid Chromatography. 
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6.2. Materials and Method 
 
6.2.1. Materials 
Mobile phase used was acetonitrile (Merck, Wadeville, Gauteng, South Africa), 
orthophosphoric acid (Merck, Wadeville, Gauteng, South Africa) and double deionised water 
obtained from the Milli-Q System. Control blank rat plasma was supplied from healthy donor. 
The drug used was indomethacin (Sigma Aldrich, Steinhelm, Germany)). Healthy Sprague-
Dawly rats were used for this in vivo release study. Blood samples were analyzed with the 
High Performance Liquid Chromatography (HPLC) model Waters 1525 Binary Pump with 
2489 UV/visible detector. The column was a C18 silica gel column (4.6150mm, 5µm particle 
size, Waters) while the pre-filter used was a 0.44µm Millipore® filter. Further analysis was 
done with the Ultra Performance Liquid Chromatography model Waters Acquity Ultra 
Performance Liquid Chromatography System (Waters, Milford, MA, USA). The column used 
in the UPLC was a C18 column (2.150mm, 1.7µm particle size, Waters). Tissue samples 
were sent to the IDEXX Laboratories for histological analysis. 
 
6.2.2. Animal ethics clearance 
This is to certify that this animal study has obtained clearance to use rats as an experimental 
model via the Animal Ethics Screening Comittee (AESC) of the University of the 
Witwatersrand (As per Appendix). 
 
6.2.3. In vivo studies to assess the biocompatibility and drug release kinetics from the 
Stimuli-Actuated Polymeric Device 
Studies were conducted on Sprague-Dawley rats in order to assess the drug release profile 
of the SAPD. The SAPD was implanted subcutaneously, blood samples were taken at pre-
determined time intervals and the results of the Control Group were compared to that of the 
Placebo Group. This would allow the quantification of the drug release from the SAPD in 
vivo in the rat. The blood samples were assessed for any presence of drug which would 
indicate drug release from the SAPD. In addition, tissue samples were harvested from the 
implantation site and histological examinations were performed in order to assess for any 
long-term inflammations or tumor formations. 
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6.2.4. Method and approach for the in vivo study of the Stimuli-Actuated Polymeric 
Device 
All animal study procedures and surgeries were performed in collaboration with the Central 
Animal Service (CAS) of the University of Witwatersrand. The number and characteristics of 
animals required for this study was shown in Table 6.1 
Table 6.1. The amount and species of animals required for this animal study. 
Species Strain Sex Age/Body 
Mass 
Number 
required 
Location 
 
Rat 
 
Sprague-
Dawley 
 
M/F 
 
200-250g 
 
18 
 
Central 
Animal 
Service 
 
 
This study was an interventional study. 18 rats with an initial weight of 200-250g were 
randomly assigned to 3 groups (n=6 in each group). 
 
1. Test group 1 (n=6): SAPD was subcutaneously implanted into the flank (abdominal area) 
of each animal in this group. This group received a SAPD containing approximately 16mg/kg 
of indomethacin (van Kolfschoten, 1985). 
 
2. Placebo group 2 (n=6): SAPD was subcutaneously implanted into the flank (abdominal 
area) of each animal in this group. This group received a drug-free SAPD. 
 
3. Comparison group 3 (n=6): The rat in this group would receive intravenous administration 
of indomethacin (0.8mg/100g body weight) 15 minutes prior to their blood sample taken 
(Lacroix, 1996).  
 
All the groups were provided with water and food ad libitum. The rats was caged in groups of 
fifteen and maintained on a 12hour light/12hour dark cycle. They were weighed daily so as 
to indicate their general state of well being. Cage activity by means of observation for 1 hour 
periods daily was in order to use to assess state of well being. At the final sampling point, 
rats from Group 1, 2 and 3 were sacrificed. The procedure of this animal study may be 
summarized by Figure 6.1. 
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Figure 6.1. Schematic showing the design of the in vivo studies model for each time period. 
 
 
 
Group 3 (6 Rats): 
Comparison group 
for intravenous 
administration of 
indomethacin 
Group 1 (6Rats): 
Test group for 
subcutaneous 
implantation of the 
drug-loaded SAPD. 
Group 2 (6 Rats): 
Placebo group for 
subcutaneous 
implantation of non-
drug-loaded SAPD. 
Anesthesia – Xylazine IM 40mg/ and Ketamine IM 80mg/kg for implantation of 
SAPD. The same amount of anesthesia will also be used during sampling. 
Sampling will be conducted at fixed time intervals: 7, 14, 21 days post implantation 
of the SAPD. At these time points, blood samples were gathered using tail vein 
technique. Healthy control rats who only received iv dose of indomethacin will be 
returned to stock.  
At day 0, Group 1 and 2 was implanted with SAPD. Group 1 had the drug-loaded SAPD while Group 
2 had the SAPD without any drugs. Group 3 was injected with indomethacin on day 7, 14 and 21 
when samplings are due to take place. 
Blood samples will be 
collected via cardiac 
puncture from the rats in 
group 1, 2 and 3. 
Implantation site will be assessed 
for any inflammation and tumour 
via tissue samples from rats in 
Group 1 and 2. 
Blood samples will be 
stored at -70 oC until 
UPLC can be performed 
to determine the 
concentration of 
indomethacin in the 
Rats were euthanized on day 21. Tissue samples were taken for histopathological studies. 
18 Rats 
 6.2.5. Implantation of the Stimuli
Six Experimental Group rats and the 
in the flank (abdominal area), as shown in F
fully hydrated). This was performed 
(5mg/kg) and ketamine (100mg/kg). 
implantation and closed with a surgical wound clip. An injection of buprenophrine 0.
subcutaneous injection was administered for 3 days after the surgery (Sweet, 2007).
Figure 6.2. Sketch of the rat showing the site of implantation of the
polymeric device into the flank
 
The SAPD was synthesized
Kolfschoten, 1985). The dimension of the 
fully hydrated. The SAPD was sterilized
and 2 would receive the 
subcutaneously respectively. Animals 
and Ketamine (100mg/kg i.m.). The 
procedure.  
 
The rat may develop an inflammatory response due to the presence of
would be treated with appropriate anti
order to prevent any possible interference with the study
results in severe distress to the rats, those rats w
experiment would also be terminated if the rats experience severe side effects such as 
gastrointestinal haemorrhage. Considering that the rats 
indications of the animal being in distress such as a 15% reduction in weight or animals 
displaying sickness behaviour or showing deteriorating body condition 
the rats being removed from the experiment.
 
Once the SAPD was implanted, a potential difference of 
implantation site. By applying the potential differ
prevent the current from flowing through the heart, 
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SAPD for implantation was 1 x 1 x 0.3
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injury in the rats. Currently, no study has been done on the safety potential difference which 
could be applied to the rat. A potential difference of 1V was chosen because it was 
considered relatively safe. Commercial electronic rat traps such as Victor M240 Electronic 
Rat Trap® utilizes 8500V in order to kill a large rodent. Two electrodes was placed on the 
lower flank of the rat and a controlled voltage was applied by the use of a potentiostat 
(PGSTAT302N, Autolab, Utrecht, Netherland) in order to monitor the voltage going through 
the rat at any time. PGSTAT302N was utilized as it allowed the potential difference to be 
monitored at all time as well as safety termination of this study should a fluctuation occur. 
The experiment would be cut off at anytime should the voltage exceed 1.5V or the current 
exceed 200mA. The duration of the electric current during the sampling was 1.5 minutes. 
This sampling procedure would take place on day 7, 14 and 21. 
 
6.2.6. Electrical actuation and safety procedures  
The rat was placed on an insulating material and conductive gel was applied onto the two 
electrodes in order to enhance the current flow in order to ensure a conductive 
skin/electrode interface. The two electrodes were placed next to each other at the lower left 
flank. This setup was important as it directed the pathway of the current away from the heart 
and prevented any fatalities in the rat model. Under conventional circumstances in an 
electrical mat, the pathway of the current enters the rat from one of its legs and exits from 
another. This pathway would direct the current to pass through the heart of the rat and 
results in death. However, by placing the electrodes next to each other on the lower flank, 
the pathway of the current is cut short in order to prevent fatalities of the rats. This may be 
explained further in Figure 6.3 and 6.4. 
 
Figure 6.3. The pathway of a conventional electric shock. 
 
a) b) 
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From Figure 6.3, one can see that during an electrical shock, the current enters from the 
source and exits to the ground. In Figure 6.3 a), the electrical mat induced a current entering 
form the one leg of the rat and exits from the other, while in Figure 6.3 b), the man may have 
touched a bare wire with his right hand and as a result the current flowed through him to the 
ground. In both cases, there was a chance that the current would flow through the heart, 
leading to fatality. In Figure 6.4, we can demonstrate how this can be avoided.   
 
 
Figure 6.4. The setup to be used for the actuation of SAPD via electrical stimulation from the 
PGSTAT. 
 
In Figure 6.4, the rat was placed on an insulating mat, thus preventing the electrical current 
from been grounded. The current entered the rat from the working electrode. Since there are 
no other pathways for the current to travel, the only option was to exit via the counter 
electrode placed adjacent to the working electrode. The electrode would be placed so that 
the SAPD was between the two electrodes and in the pathway of the electrical current, 
allowing actuation to occur. This setup would restrict the electric current locally and prevents 
the risk of injury or fatality to the rats. 
 
Another safety measure may be attributed to the low voltage used with a DC setup for the 
testing of the SAPD. The threshold for rat muscle contraction to occur is measured to be 
approximately 0.03mA with maximum contraction occurring at approximately 0.2mA 
(Sobotka, 2010). In order to determine the quantity of current flowing between the two 
electrodes, Equation 6.1 was used. 
 
I=V/R                                                                                                                  Equation 6.1 
 
Insulating mat 
Electrodes 
+ - 
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Where I = current flowing in Amperes, V = the potential difference applied in Volts and R = 
the resistance of the conductor in Ohms. The electrical resistance of the rat skin is currently 
unknown, however, research done on human skin has indicated an electrical resistance of 
approximately 100000Ω on a dry skin (Fish, 1993). Therefore, application of 1V on a dry skin 
would yield 1/100000 = 0.01mA which is below the threshold for any form of muscle 
contraction to occur. A local application of 1V of potential difference should be, in this 
instance, adequate for the actuation of the SAPD without causing any injuries or fatalities to 
the rat model. 
 
During the experimentation, the rat may experience discomfort such as stress, anxiety and 
fear. The use of electric current should not cause pain as electrical stimulation does not 
activate the nociceptors. Furthermore, the mammalian somatosensory system appears to 
lack receptors which are dedicated especially for electrical stimulation (Lindsay, 2005). The 
passing of electrical stimulation may induce involuntary muscle contraction (Bradford, 1985). 
Electrical stimulation therapy used to stimulate muscles generally used between 100-500V 
of potential difference, therefore the application of 1V should be sufficiently safe so as to 
avoid any discomfort caused from involuntary contraction of the muscle (Wong, 1986). The 
last possible discomfort may be the heat build-up when electric current is passed for a 
prolonged period. This heat build-up is dependent on the resistance of the conductor, the 
potential difference and the current. This may be calculated by Equation 6.2, where P = 
power in watt, I = current in ampere and R = resistance in Ohm. 
 
P=I2R                                                                                       Equation 6.2 
 
The current flowing through the skin was approximately 0.01mA and a resistance of 100000 
Ohm. Therefore, the power generated by 1V would equate to 0.00001W. This meant that the 
energy delivered between the two electrodes equates to 0.00001J/second (1W = 1 
J/second). If the placement of the electrode was 90 seconds, the total energy delivered to 
the rat was 0.0009J. This may then be converted into 0.000215cal (1cal = 4.184J). In order 
to increase the temperature of 1 gram of water by 1ºC, 1cal was required. Therefore, the use 
of the PGSTAT over a period of 90 seconds would only increase the surface temperature by 
a maximum of 0.000215ºC. This amount of power is inadequate to produce any burn or 
discomfort onto the skin of the rats. 
During this period, the animal may be restrained by either placing it in a modified conical 
plastic bottle, or it may be wrapped in a linen cloth (Preedy, 1988 and Omaye et al., 1987). 
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The conical plastic bottles may be setup in accordance to the one setup by Omaye and co-
workers (1987). This restraint device allowed minimal movements from the rat while inflicting 
no pain. This device may be depicted as in Figure 6.5. The device was mainly composed of 
two plastic bottles and a restraining clamp. A hole on the side of the flank allowed electrode 
placement for one and a half minutes, after which the rat may be returned and blood 
samples drawn. In order to decrease the anxiety of the rat, the rat should not be picked up 
by its tail at all time (Hurst, 2010). This sampling procedure would take place on day 7, 14 
and 21. 
 
Figure 6.5. The setup of the rat restraint device during the drug release testing. 
 
The animals were inspected around the implantation site for any signs of inflammation, 
infection on day 7, 14 and 21. This was also essential in determining the biocompatibility of 
the SAPD. Blood was drawn on day 7, 14 and 21 following the exposure of the SAPD to 1V. 
On average, the total blood volume of the rat is around 6-8% of total body weight. For non-
terminal blood collection, 0.2-0.3mL of blood may be obtained from the tail vein, which was 
performed on day 7, 14 and 21 (Hoff, 2000). 
 
The blood samples obtained from the rats were assessed for the presence of indomethacin by the 
use of HPLC. Initial blood samples obtained would be centrifuged at 3000G and the plasma was 
mixed with a solvent and injected into the HPLC in order to determine if there was any 
indomethacin present. 
500mL plastic 
bottle 
Holes for 
electrode 
placement 
1L plastic bottle 
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Anaesthesia was induced before the implantation and sampling of the SAPD. The anaesthesia 
was achieved with xylazine (5mg/kg) and ketamine (100mg/kg) prior to the procedure. This also 
ensured that the rat was in the correct position when the blood was drawn and prevented any 
possible injury which could be done to the rats (Hoff, 2000) 
6.2.7. Drugs and medicinal substances to be used for this animal study 
The drugs used for this study has to be dosed according to the amount required for 
therapeutic effects in a rat model. This included any drugs used for anaesthesia, the model 
drug used in the SAPD and the drug used for euthanasia. These drugs were administered by 
a veterinarian at the Central Animal Service (CAS) of the University of Witwatersrand. These 
drugs may be summarized in Table 6.2. 
Table 6.2. The amount of drugs to be used for the animal study. 
Drug/Substance Route  Dose Frequency 
 
Indomethacin* 
 
i.v. 
 
 
 
0.8mg/100g  
 
i.v. administration of 
the drug will be 
done weekly 
 contained in the 
SAPD 
16mg/kg  A once-off 
implantation of 
SAPD and weekly 
sampling 
Xylazine** Intramuscular 
injection 
5mg/kg Administered before 
implantation of 
SAPD and prior to 
euthanasia.  
Ketamine*** Intramuscular 
injection 
100mg/kg Administered before 
implantation of 
SAPD and prior to 
euthanasia. 
Sodium Pentobarbitone**** Intracardiac 
injection 
200mg/kg Administered once 
off for euthanasia. 
 
* (van Kolfschoten, 1985) 
** (Lacroix, 1996) 
*** (Koshikawa, 1988) 
**** (Kirschvink, 2005) 
 
The i.v. administration of indomethacin would allow comparison between the i.v. dose, which 
was an instantaneous drug delivery form, against the SAPD and gave us an indication of the 
quantity of drugs entering the systemic circulation at any given time. Ideally, the drugs 
should be entrapped within the intercellular space at the site of inflammation as to permit 
entry of the drug into the cell membrane. Once into the cell membrane, the drug inhibits 
COX II enzyme, therefore preventing the conversion of arachidonic acid into prostaglandins 
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(Cheng, 2007). The amount of drug which entered the systemic circulation should be 
traceable in order to confirm the release of drug from the SAPD. 
 
The drug was administered via the femoral vein of the rats (Wang 2010 and Mok, 1992). The 
dosage used is 0.8mg/100g (Lacroix, 1996) for this i.v. injection. An i.v. administration of 
1.5mL has been done on rats weighing as little as 150g (Khong, 2000). For our purpose, 
1.5mL injection will be sufficient. The rat in the comparison group should be weighed and the 
dosage calculated at 0.8mg/100g. The required amount should be dissolved in 1.5mL of 
sterile saline solution using aseptic technique following disinfection by UV light before it was 
given as an i.v. dose. 
 
6.2.8. Plasma sampling from the rat model after the experimental procedure 
Plasma levels of indomethacin were measured via blood samples obtained around the 
SAPD implantation site and would be analyzed using the High-Performance Liquid 
Chromatography (HPLC). The blood sample was obtained by the tail vein technique. This 
was performed by two people. One person restrained the rats by the use of a tightly-fitting, 
homemade bag of towelling while exposing the tail. The tail was held with one hand while an 
incision is made with the other hand. The tail was gently stroked and a blood drop formed at 
the site of incision. The blood drop may be collected for analysis (Fluttert, 2000). The tail 
vein technique was advantageous as the animal need not be anesthetized and it was not a 
terminal procedure (Oliveira, 2009; Beeton, 2007). The animal was returned to CAS until the 
next sampling was due to take place. The blood sample was stored in heparinised tube and 
centrifuge at 3000G for 15 minutes. The plasma sample was stored at -70ºC until HPLC 
analysis (Sweet, 2007). 
 
6.2.9. Liquid-liquid extraction technique for the separation of drug bound in plasma 
Once the blood samples have been extracted from the rat model, the drug would have to be 
separated from the plasma sample before it was available for analysis via the HPLC. In 
order to achieve this, liquid-liquid extraction technique was used. The liquid-liquid extraction 
technique was used in cases where a solution contained two or more solutes. The solutes 
may be separated from each other by making use of the individual solubility of each solute. 
By placing the solution in the extraction fluid, the solutes would separate out from the 
solution into the extraction fluid based on its affinity for the extraction fluid. The extraction 
fluid typically contained an organic and inorganic phase and allowed the separation of non-
polar solutes into the organic phase and the polar solutes into the inorganic phase. The two 
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The addition of a non-
polar solvent into the 
mixture. 
solutes may be extracted following the evaporation of the respective solvents. This 
mechanism may be depicted in Figure 6.6. 
 
 
 
Figure 6.6. Depiction of a liquid-liquid extraction. 
 
Based on Figure 6.6 above, the two different solvents may be separated when solutions 
were left to evaporate. By using this technique, it was possible to separate a drug from a 
blood sample collected from the rat model. The blood was centrifuged and the plasma was 
collected. The processed plasma sample may be mixed with another solvent in order to 
extract the drug out of the plasma. In the case of indomethacin, an organic solvent should be 
used since indomethacin exhibits high solubility in organic solvents as compared to other 
solvents (Yadav, 2009).   
 
This method was initially tested by dissolving 100mg of indomethacin into a pH11.5 NaOH 
solution. After the indomethacin was dissolved, 350mg of sucrose was added into the 
indomethacin solution as a mixture. This mixture was poured into a liquid extraction phase 
consisted of 40mL water and 40mL chloroform. This mixture was vortexed at high speed for 
1 minute before it was allowed to stand for solvent separation. The top layer consists of the 
polar solvent and was extracted with the use of a 5mL syringe. This polar solvent was left to 
dry overnight and the dried extract was analyzed with FTIR. The result obtained has 
A polar solution containing 
highly soluble solute A and a 
partially soluble solute B. 
Mixing the two 
solvents. 
Upon separation of the two 
solvents, solute A will 
dissolve into the preferred 
non-polar solvent while 
solvent B will remain in the 
preferred polar solvent. 
a) 
b) 
c) 
d) 
e) 
f) 
Solute B Solute A 
Polar solvent 
Non-polar solvent 
154 
 
indicated a successful extraction of the sucrose from the indomethacin/sucrose solution. The 
FTIR spectra may be depicted as Figure 6.7. 
 
Figure 6.7. The FTIR spectrum obtained from the sucrose obtained via the liquid-liquid 
extraction technique is depicted as blue, while the FTIR spectrum of pure sucrose is 
depicted in black.  
 
It was possible to determine that the dried extract obtained from the polar solvent was 
sucrose based on the comparison of the FTIR spectrum obtained against that of pure 
sucrose. This may be further confirmed by the corresponding spectra within the fingerprint 
region of this FTIR spectrum (1500-400 wave numbers). The dried extract from the non-
polar phase also depicted a similar result for indomethacin. Therefore, by using the liquid-
liquid separation technique, it was possible to separate the drug component from the plasma 
component, thus allowing analysis of the drug concentration in plasma via the use of the 
HPLC. 
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6.2.10. Subcutaneous implantation of the device into the rat  
The first step of this in vivo study was the subcutaneous implantation of the device into the 
rats. Eighteen rats were used for this study, with 3 rats housed per cage. The rats were 
caged one week prior to implantation to allow time for acclimatization. They were also 
weighed and checked on a frequent basis to ensure their health was in good condition prior 
to the implantation. Rats 1-6 received an implant which contained the active drug 
indomethacin, while rats 7-12 received a placebo device which contained no drug. The rats 
were numbered by the use of a permanent marker on the tail and were labelled 1-18 
numerically. 
. 
Following the acclimatization of the rats, the devices were implanted subcutaneously while 
under general anaesthesia. The pulse during this time was monitored by the senior 
veterinary nurse, while the implantation was performed by the veterinary surgeon. The entire 
procedure was simple and quick, with each implantation taking 5-10 minutes. The devices 
were disinfected with Hibiscrub prior to implantation. Figure 6.8-6.13 summarizes the entire 
subcutaneous implantation procedure. 
 
Figure 6.8. The rats were shaved on the left flank after general anaesthesia. Oxygen was 
given and pulse was monitored at all times. 
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a b 
 
Figure 6.9. The animals were draped and the surface was cleaned with Hibiscrub. 
        
Figure 6.10. a) and b) A 1cm incision was made on the left flank of the rat. 
 
 
Figure 6.11. The implantation of the device into a pocket made under the skin of the rat. 
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Figure 6.12. The incision was closed up by the use of suture. 
 
Figure 6.13. Once the implantation was complete the rats were left in a cage where post-
operative care was given until the animals had recovered. 
 
Once the 6 active devices and the 6 placebo devices were implanted, the animals were 
given 10 days to recover and heal. Stitches were removed 5 days after the surgery. The rats 
were weighed again after ten days of recovery in order to determine their health condition. 
The implantation site was also checked for signs of swelling which indicated either 
inflammation or infection. The weight of the rats before and 10 days after the surgery are 
shown in Table 6.3. 
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Table 6.3. The difference in the weight of the rats 10 days after the implantation procedure 
was performed.  
Rat Initial Weight Post-operation 
Weight (10 days) 
 
1 
 
230 
 
250 
2 222 232 
3 238 251 
4 233 252 
5 228 241 
6 224 247 
7 224 223 
8 219 236 
9 228 237 
10 215 222 
11 214 218 
12 218 235 
13 235 246 
14 222 236 
15 234 245 
16 211 224 
17 238 242 
18 218 225 
 
 
The comparison of the weights before and after the operations has indicated that the rats 
were fit and healthy enough to proceed with the study. The rats did not show any signs of 
excessive weight loss. The post-operation weight also included the weight of the 
implantation. 
 
6.3. Results and Discussion 
 
6.3.1. High Performance Liquid Chromatographic analysis of plasma sample for the 
presence of indomethacin 
Following the implantation of the SAPD into the rat model, blood samples were drawn on 
day 7, 14 and 21. The next step was the isolation of indomethacin from the plasma sample 
and analysis of drug release by utilizing the HPLC. The blood samples were taken from the 
rats which would indicate drug release from the device at the implantation site. Some of the 
drugs from the implantation site would be absorbed into the blood and presence of drug in 
the blood sample would indicate a release of drug at local site. Interstitial fluids cannot be 
used as sample since interstitial fluids in general does not yield enough quantity for analysis. 
Before the blood sample may be processed, it was collected in a heparinised tube. The 
recommended dosage for heparin is 70 units per 10mL. The blood samples gathered was 
0.5mL, which required approximately 4 units of heparin. This equated to 4µL of the heparin 
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for the half mL blood samples. The collected blood samples were centrifuged and the 
plasma was extracted by the use of a 1mL syringe. The indomethacin was extracted from 
the plasma samples by the use of the liquid-liquid separation technique as mentioned. This 
was done by adding 100µL of phosphate buffer and 2mL of ethyl acetate into 400µL plasma 
sample. The mixture was vortexed vigorously for 10 minutes. The organic layer was 
separated and ethyl acetate was left to evaporate. The residue was re-dissolved in 200µL of 
the mobile phase and 50µL was injected for analysis by the HPLC. This method was 
adapted by a work done by Dawidowicz and co-worker (Dawidowicz et al., 2009).  
 
Before the samples could be analysed, a blank sample of indomethacin should be analysed 
for comparison purpose. This would assist us to ascertain whether the results obtained 
corresponded with that obtained by Dawidowicz and co-worker (2009). This method was 
tested by dissolving pure indomethacin into methanol at a concentration of 1mg/mL. Once 
the drug was dissolved, it was injected into the HPLC. The experiment was carried out under 
room temperature with a flow rate of 0.8mL per minute. The mobile phase consisted of 63% 
of acetonitrile and 37% of distilled water with the pH adjusted to 2 with 0.2% of 
orthophosphoric acid. The obtained result has indicated that the retention time did indeed 
correspond with previous study. This method seemed appropriate as the results had 
corresponded with that obtained from previous studies. The results may be presented as 
Figure 6.14 and 6.15. 
 
 
Figure 6.14. The HPLC chromatography obtained during the study. 
Indomethacin 
Mobile Phase 
    254nm 
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Figure 6.15. The HPLC chromatography obtained by Dawidowicz and co-workers 
(Dawidowicz et al., 2009). 
 
Based on the similarity of the two chromatography obtained, it was clear that this method 
was suitable for further analysis of the blood samples. The last part of the HPLC study was 
to assess whether heparin would be detected as a peak when injected into the HPLC under 
the same condition, since the blood samples would have contained heparin in order to 
prevent coagulation. The HPLC method was repeated identically, with the exception that the 
drug used was heparin. The results may be presented as Figure 6.16.  
 
 
Figure 6.16. The chromatogram obtained from the HPLC when heparin was injected as 
sample. 
 
As Figure 6.16 has depicted, the use of heparin did not interfere with the chromatogram at 
the wavelength of 254nm. The use of this method should prove to be appropriate for the 
sampling of blood sample for any presence of indomethacin. Once the method for HPLC 
was established, the blood samples may be further processed for injection into the HPLC to 
Indomethacin 
Retention Time (Minutes) 
R
esponse (m
V
) 
    254nm 
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a 
allow further analysis for the concentration of drugs present. In order to determine the 
concentration of the drug in the blood sample, a calibration curve of indomethacin in the 
mobile phase was constructed. This graph may be presented as Figure 6.17 and was used 
to calculate the concentration of the total drugs present inside the blood sample obtained 
from the rat model. 
Concentration (mg/mL)
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Figure 6.17. The calibration curve of the absorbance versus drug concentration in the 
mobile phase which may be used for determination of drug concentrations gathered from the 
rat model. 
 
With the use of Figure 6.17, we would be able to work out the concentration of drugs in the 
blood sample based on the absorbance. The results obtained were depicted in Figure 6.18 
a) to l) which depicted the blood sample obtained from rats in the Test Group and the 
Placebo Group. 
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Figure 6.18. a) to f) indicated the blood samples obtained from rats in the test group, g) to l) 
indicates blood samples obtained from the placebo group. 
 
b) a) 
c) d) 
e) f) 
g) h) 
i) j) 
l) k) 
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a 
As seen from the blood samples obtained from the test group, the presence of drug may be 
seen as a peak appearing around the 6th minute of the chromatogram. This peak was 
absent in the Placebo Group, which was used as a comparison for the Test Group. This 
absence of peak confirmed the release of drug in the test group. One set of blood sample 
taken between the 7 day release cycles has confirmed that, as indicated by the in vitro test, 
there was no drug leakage during each actuation. These results may be compared against 
the blood samples obtained from the comparison group in order to confirm that the 
degradation of the SAPD did not produce any possible untoward reaction during the release. 
The blood samples from the rats in comparison group may be presented as Figure 6.19. 
 
Figure 6.19. a)-f) The chromatogram of the 6 blood samples obtained when indomethacin 
were administered intravenously into the rats in the comparison group. 
 
By using the data from Figure 6.17 and 6.18, one could see the chromatogram produced has 
indicated only the presence of indomethacin alone in the blood samples without any other 
possible metabolites which may occur during the release.  
 
6.3.2. Further analysis of blood sample with the use of Ultra Performance Liquid 
Chromatography 
The presence of drug in the rat plasma sample was further ascertained use the use of Ultra 
Performance Liquid Chromatography (UPLC). UPLC offered higher sensitivity and resolution 
with decreased retention time. Methods used on the HPLC may be incorporated onto the 
a) b) 
c) d) 
e) f) 
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UPLC, although several adjustments were required. The first adjustment required was the 
target injection volume. Since the column used in UPLC was much lower in dimension than 
the HPLC, volume adjustment was required in order to allow optimal analysis from the 
UPLC. The volume adjustment was done based on Equation 6.3. 
 
Target Injection Volume=Original Volume × Target Colum Volume
Original Colum Volume
                      Equation 6.3 
 
By using Equation 6.3, the quantity of sample required for injection may be calculated as 
follows: 
Target Injection Volume=50µL ×
3.14×1.12×50
3.14×2.32×150
 =3.81µL 
 
Besides from the quantity of the samples injected, the run time was also reduced due to the 
shorter column found in the UPLC. In order to determine the required run time for the UPLC, 
gradient duration from the original HPLC should be determined. The equation used for the 
calculation of gradient duration may be depicted as Equation 6.4. 
 
Gradient Duration  Gradient Volume
Colum Volume
                Equation 6.4 
 
Gradient Volume=Flow Rate ×Time= 0.8mL
min
×10min=8mL     
Colum Volume= π×r2×Length=3.14×0.232×15=2.49mL 
Therefore, Gradient Duration= 8mL
2.49mL
=3.21  
 
The gradient duration of the HPLC column with a flow rate of 0.8mL/min for 15minutes was 
3.21. The next part of the adjustment was the scaling of flow rate from the HPLC column to 
the UPLC column. This was done as using Equation 6.5. 
 
Target Flow Rate= Original Flow Rate× π×r
2 of target
π×r2 of original
=Original Flow Rate× π×r
2 of target
π×r2 of original
                  Equation 6.5 
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The last step was to calculate the gradient step time for the UPLC. This adjustment was 
necessary as the run time of the UPLC would be shorter than the HPLC and needed to be 
scaled down. This was calculated using Equation 6.6.  
 
Gradient Step Time= Gradient Step Volume
Target Flow Rate
               Equation 6.6 
 
UPLC Colum Volume= π×r2×Length=3.14×0.1052×5=0.17mL 
Gradient Step Volume of HPLC=Gradient Duration×UPLC Colum Volume =3.21×0.17   
                                                               =0.546mL  
Gradient Step Time of HPLC=
0.546mL
0.17mL
=3.21 minutes 
 
Step 2 of the calculation required the calculation of gradient step time of the UPLC using 
Equation 6.7. 
 
Gradient Step Volume of UPLC= Gradient Step Volume of UPLC
Target Flow Rate
                                     Equation 6.7 
 
Gradient Step Volume of UPLC =  Gradient Duration×Target Colum Volume 
                                                                =3.21×0.17=0.5457mL 
Gradient Step Volume of UPLC= 
0.5457mL
0.167mL/min
=3.27 minutes 
 
Using the results obtained, we could then modify the HPLC method for the UPLC by keeping 
the same mobile phase, with an injection volume of 3.81µL, a flow rate of 0.167mL/min and 
a run time of 3.27 minutes. One set of blood sample from the placebo group and testing 
group were processed and injected into the UPLC. The results may be depicted as Figure 
6.20 and Figure 6.21. 
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Figure 6.20. The UPLC chromatogram obtained for the rat blood sample in the placebo 
group. 
 
Figure 6.21. The UPLC chromatogram obtained for the rat blood sample in the test group. 
 
Blood samples injected into the UPLC from the placebo group did not exhibit a peak at 
approximately 3.5 minutes of the run time. This peak was observed in the blood sample 
obtained from the Test Group and corresponded with the results obtained from the HPLC. 
The use of the UPLC has also confirmed the peak of indomethacin in the rat blood sample at 
a higher absorbance and a shorter run time. The retention time for the indomethacin in the 
UPLC was 3.62 minutes. 
 
Blood samples were gathered for duration of 21 days with a release cycle every 7 days. The 
drug release over these 3 cycles was determined by the amount of drug present in the 
blood. Although the blood concentration of the drug did not necessarily represent that of the 
drugs present at the local site, it was an indication of the drug release which has occurred 
locally and entered the systemic circulation. This was due to the drawback that attempts to 
extract interstitial fluids from rat models do not yield sufficient quantities for analysis 
purposes. However, by looking at the drug concentrations in the blood samples, it would 
Indomethacin 
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demonstrate the consistency of drug release from each cycle. The drug-blood 
concentrations on the three release cycles may be presented as Figure 6.22. 
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Figure 6.22. The drug release profile of the SAPD from the in vivo rat model. 
 
The release cycle over the 21 day period has indicated a fairly consistent release and a 
favourable drug release profile. The large standard deviation exhibited in the first release 
cycle may be attributed to the increased drug release experienced with the first release cycle 
of the SAPD.  
 
6.3.3. Histopathological sampling of the tissues obtained from the site of implantation 
The final assessment for the biocompatibility of the SAPD was the histological examinations 
at the site of implant at the end of the in vivo study. This was done by taking samples from 
random rat models. These samples were compared against the samples taken from the rats 
in the Comparison Group in order to determine if there was any significant change in tissue 
morphology followed by the implantation of the SAPD. Six samples were taken for 
histological evaluation, with two samples from each group. The sample details were as 
follows: 
Rat 1 & 2:  Test Group (SAPD with indomethacin) 
Rat 7 & 9:  Placebo Group (SAPD without any drugs) 
Rat 14 & 15: Control (healthy rats without any implantation) 
N = 6 
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c 
The tissue samples around the SAPD implantation site underwent histological examination 
in order to determine the effect that SAPD has on the tissue morphology of the rat. The 
presence of any inflammatory infiltration, foreign body giant cells and hyalinization 
associated with tissue inflammation will be noted in order to determine the biocompatibility of 
the SAPD. These samples were sent off to the IDEXX Laboratories (IDEXX Laboratories, 
19B Morris Street, East Woodmead, Willows Off Park, Johannesburg, Gauteng) in order to 
be assessed. 
 
Once the tissue samples were submitted, these sections were processed overnight in an 
automated tissue processor according to the standard operating procedure of the IDEXX 
Laboratory. (PTA-his-SOP-27). Following the routine histological processing, wax blocks 
were produced in paraffin wax and sections of about 6µm cut according to IDEXX 
Laboratory SOP (PTA-his-SOP-30). 
 
The slides were stained with Haematoxylin and Eosin according to the SOP. The results on 
the histological findings which show tissue morphology of rats in test group and placebo 
group may be presented as Figure 6.23-6.26. 
 
              
 
Figure 6.23. a), b) and c) The histological sample of rat 1 obtained from different areas of 
the implantation site. 
a b 
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a 
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The skin section revealed an implanted basophilic mass with black irregular granules 
embedded in the basophilic stained implant in the subcutaneous tissue. There were mild 
granulomatous inflammations observed surrounding the implant where macrophages and 
multinucleated giant cells are surrounding small fragments of the implant material in a 
foreign body granulomatous inflammatory process. Mild lymphocytic infiltrates and 
fibroplasia with encapsulation could be demonstrated. 
                  
 
Figure 6.24. a), b) and c) The histological samples of rat 2 obtained from different areas of 
the implantation site. 
 
The subcutaneous implant could be identified and was similar to that reported for rat 1, and 
again small areas of foreign body inflammation as well as fibrous capsule were observed 
encapsulating the SAPD. 
b 
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a b 
 
Figure 6.25. The histological sample of rat 7. 
 
From the results obtained from rat 7, a mild foreign body granulomatous inflammation could 
be demonstrated with islands of fragment implant entrapped in the foreign body 
inflammation. Macrophages with epitheloid transformation as well as multinucleated giant 
cells are present. There was a well-developed fibrous capsule which was visible.  
 
       
Figure 6.26. a) and b) The histological sample of rat 9 obtained from two different areas of 
the implantation site. 
 
Lastly, the tissue samples obtained from rat 9 showed a basophilic implant can be identified 
in the subcutis with a mild peripheral foreign body granulomatous inflammation and 
fibroplasia to form a fibrous capsule on the periphery, encapsulating the transplant 
completely. The inflammatory reaction was mild. No morphological differences could be 
recorded and the transplant was surrounded by a mild foreign body inflammatory reaction, 
and was well-encapsulated in all of the abovementioned implantation sites. The control 
specimens were morphologically normal.  
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6.4. Concluding remarks 
 
The use of an in vivo study has allowed us to determine the biocompatibility and the drug 
release profile when the SAPD was implanted subcutaneously. The SAPD was implanted 
subcutaneously into the rat model, and found to release drugs in the presence of electrical 
stimulation. This was done by sampling blood obtained from the rats at weekly interval. The 
results obtained from the HPLC and UPLC have indicated the presence of minute 
concentrations of drug in the blood, which ascertained the release of indomethacin from the 
SAPD into the surrounding tissue.   
 
Results were also compared against the control group and interval blood samples obtained 
has shown that leakage of the drug has not occurred. This result also corresponds with that 
obtained from the in vitro study. The drug release from the SAPD over the 3 release cycles 
also seemed to be consistent. 
The biocompatibility of the SAPD was determined accurately via histopathological analysis. 
The rats were checked daily after the implantation procedures were performed and showed 
no signs of illness. The site of implantation did not show any signs of swelling, which 
indicated the absence of inflammation or infection. The rats weighed during the implantation 
period have also shown a steady increase in body weight and growth. Histological results 
have shown that although mild inflammatory process was present, the overall 
biocompatibility of the SAPD remained fairly good. No tumor or signs of significant tissue 
changes were discovered. This was further substantiated by the general well-being of the 
rats during the duration of this study.  
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
7.1 Conclusions 
 
Worldwide, many patients suffering from chronic pain relied on chronic medication for their 
treatment. Those conventional treatments usually included oral drugs such as NSAIDs or 
opioids. However, long term use of these drugs may lead to side effects and, in the case of 
opioids, addiction and abuse which is great concern to the health care professionals 
(Carinci, 2010 and McCabe, 2008). Current researches into chronic pain have managed to 
produce COX II-selective NSAIDs which reduced the incident of gastric ulcer related with 
chronic NSAID use, but problems such as renal or hepatic toxicity still occurred with the use 
of the COX II-selective NSAIDs. 
 
The development of SAPD allowed this device to be employed as an implantable controlled 
drug delivery system. By implanting the SAPD directly at the target site, it allowed the 
delivery of drug directly into its surrounding environment. SAPD observed during drug 
release study has indicated that erosion was primarily the mechanism of release and was 
confirmed with the use of a chemometric and molecular modelling approach. The erosion 
phenomenon would occur at the proximity of the electrode and happened at approximately 
15 seconds of actuation. This was beneficial as it meant rapid drug delivery once the SAPD 
was actuated. 
 
The SAPD should be implanted subcutaneously at the target site. Subcutaneous 
implantation is a simple and efficient procedure which is used frequently, as in the case of 
implantable contraceptives. The entire implantation procedure of the SAPD should take ±10 
minutes and was well tolerated in the rats during the in vivo study. 
 
A stable HPLC method was adopted and further conversion of this method was done to 
allow more accurate assay of the blood sample on the UPLC. The use of these assays has 
demonstrated that drug release was achieved in the rat model and SAPD may be further 
developed for human implantation. The biocompatibility and potential toxicity has indicated 
no untoward effect and the SAPD have exhibited good biocompatibility. 
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7.2 Recommendations 
 
Several controlled-release implantable devices were developed and tested with many more 
still underway. However, few of these systems were tested for their biocompatibility, and 
even fewer were tested for its drug release profile in vivo. This is due to the lack of animal 
studies in these stimuli-actuated implants. As mentioned, the use of the SAPD allowed direct 
drug release at the target site when required. This concept may be further developed so that 
in future other drugs may be incorporated. Extensive research needed to be conducted in 
order to develop alternative devices capable of controlled release of other drug substances 
using similar concepts. This may be useful for conditions which required a ‘when necessary’ 
drug dosing.  
 
The results obtained from in vivo study using rat models have shown promising results. 
While the use of a rat model allowed assessment of the biocompatibility and drug release 
profile to a certain extent, further research using larger mammals such as apes may be 
beneficial as the results obtained may relate closer to that of humans. Extracellular fluid may 
be extracted with fewer difficulties and produced a more accurate result of the in vivo drug 
release of the SAPD.  
 
Another importance of the primate study would be the further study on the erosion study of 
the SAPD in an in vivo setting. Current study suggested that eroded materials would be 
disintegrated by the macrophages in the body. Future study using in vivo models should also 
include erosion studies as to determine the fate of the eroded hydrogels.  
 
External devices for the actuation of the SAPD should be developed. The actuation device 
should be portable, capable of varied electrical stimulation and affordable. Currently, a 
proposed method was to design the portable device as a watch which could then be 
actuated by the patient at the required time. The SAPD may also be stored as cartridges in 
the watch and implanted when required. The ease of implantation meant that it may be done 
at any clinic, hospital or pharmacy within 10-15 minutes. The ease of this process would 
offer great flexibility and convenience to the patients. 
 
7.3. Future Outlook 
 
The development of the novel SAPD would open up certain new opportunities in the field of 
stimuli-actuated controlled drug delivery device. This device may be modified to produce 
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SAPD with varying physicomechanical properties and drug release profiles. The device may 
also be modified to incorporate various drugs which may be used for a wide range of health 
conditions over a period of one to two months. The patency of the SAPD was filed in South 
Africa, but further patent filing is in progress to ensure SAPD receives international patency. 
The development of such technology in South Africa would ensure that we compete with the 
pharmaceutical industries at an international level. Due to the flexibility of the SAPD, further 
development may include the incorporation of colchicines for gout, the release of ergotamine 
for patients suffering from frequent migraine, or any condition which requires infrequent 
dosing of drug. 
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